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Oral squamous cell carcinomas (OSCC) appear to contain a sub-population of cells endowed 
with indefinite self-renewal capacity, usually referred to as cancer stem cells (CSCs). These 
cells are clonogenic and are responsible, in all probability, for tumour initiation and 
propagation. Cancer cell lines consistently show morphological patterns similar to normal 
keratinocytes (holoclones, meroclones and paraclones) reflecting a hierarchical organization 
associated with stem, amplifying and differentiated cells. In-vitro studies of OSCC cell lines 
have revealed further phenotypic differences in colony formation between the stem and non-
stem fractions and have identified cell surface proteins such as CD44, E-Cadherin, ß-catenin 
and Vimentin which are differentially expressed in association with stemness. Recent studies 
suggest tumour progression to be associated with Epithelial Mesenchymal Transition (EMT), 
a process occurring in SCCs which confers invasiveness and motility to CSCs and also suggests 
a strong involvement of external factors such as those present within the tumour-host 
microenvironment. Analysis of these properties may provide insight into mechanisms of stem 
cell fate determination and provide mechanisms for therapeutic targeting of CSCs.  
Methods and Materials: Immunocytochemistry was used to analyze differential expression 
of cell surface and internal markers for their role in stemness and EMT, FACS was used to 
isolate and analyze sub-fractions of cells for clonal studies. Real time videos of cell lines were 
used to examine cell movement in colonies and cell acquisition of a fibroblastic phenotype. As 
a test of whether this process is actually EMT, cells were exposed to TGF-ß, a known inducer 
of EMT, to determine whether this enhanced the formation of the mesenchymal-looking cells 
at colony margins. 
Results and Conclusions: Video images showed cells at the margins of holoclones acquiring 
a motile phenotype. Immunohistochemical analysis revealed that certain stem-cell-related cell 
surface molecules were expressed at higher levels in holoclones than paraclones and at different 
levels within holoclones. Expression of CD44 was stronger in the center than at the edge of 
holoclones suggesting that this molecule plays a role in maintaining a stem-like state. Some 
images indicated nuclear translocation of CD44 and ß-catenin at colony margins. TGF-ß 
increased the incidence of mesenchymal-like cells at the edges of colonies and seemed to 
scatter and mobilize these cells with loss of the normal colony architecture. Further, TNF-α 
alsogreatly enhanced this effect by working synergistically with TGF-β suggestingthe 
involvement of external factors such as inflammatory cytokines and other cells present within 
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The word cancer is used to describe a particular class of diseases in which cells making up 
tissues and organs display uncontrolled growth and invasion into surrounding stroma.It often 
culminates in metastasis where the cancerous cells spread through the bloodstream or the 
lymphatic system to colonize secondary sites as new tumours. As early as 370 BC, Hippocrates 
described several types of cancers, referring to them with the Greek word ‘carcinos’ (The 
history of cancer, 2009). Carcinos was later translated into the Latin word ‘cancer’ also 
meaning crab. The oldest references to surgical treatment for cancers are from Egypt and date 
back to 1600BC. With development of the microscope in the 1800s it was recognized that the 
body is made up of tissues that, in turn are made up of millions of cells. Genetic patterns were 
later recognized to contribute to cancer initiation and the accidental discovery of the effects of 
radiation on bone marrow was instrumental in the development of marrow transplants for 
leukaemia.Benign tumours resemble the 
tissue of origin and grow locally but do not 
invade into surrounding tissue and are 
usually walled off by a capsule of 
connective tissue. They can arise in most 
organs and may generate all the cells 
concerned within the organ or just some 
components within it, patterns apparent 
with tumour formation in organs with 
tubular structures like the breast and kidneys. Benign tumours may grow to press on 
surrounding structures such as nervous tissue or, if they are in secretory tissues such as the 
pituitary, may cause symptoms due to excessive production of hormones. Malignant tumours 
lack a fibrous capsule, invade into the surrounding tissues or even manage to gain access to the 
bloodstream and lymphatic systems to travel to distant sites which they colonize as new 
tumours. Cancers are also classified on the basis of the type of cell that the tumour resembles 
which, as discussed later, is usually also assumed to act as the cell of origin of the tumour. The 
causes of cancer appear to relate to both environmental and genetic influences which lead to 
failure of regulation of tissue growth (Mehanna et al, 2010). This process is normally very 
tightly controlled in all cells, but especially so in those which are responsible for the lifetime 
renewal of organs (discussed later in the chapter). Growth is usually under the command of 
tumour suppressor genes and oncogenes. Oncogenes are of a class of genes that promote cell 
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growth and reproduction, whereas tumour suppressor genes usually inhibit cell division and 
survival. Mutations in these genes have been linked to aberrations in cell proliferation in many 
organ systems. The transformation of a normal cell to a cancer cell appears akin to a chain 
reaction where an initial event causes errors, which are progressively compounded into 
cumulative errors allowing the cell to escape normal growth limits. Cancers also evolve as they 
grow becoming progressively more aggressive through clonal evolution, the process usually 
responsible for the progressive change of cancers into more invasive subtypes (Hanahan, 2000, 
2011). 
1.2 Head and Neck Cancer and Oral cancer 
The term head and neck cancer encompasses a group of biologically similar cancers that 
commonly originate and occur in the upper aerodigestive tract. Their location can be the nasal 
cavity, lip, oral cavity, the larynx, pharynx and even the paranasal sinuses (Cancer, 2009; 
ISBN: 14392-6386-8). Almost ninety percent of these tumours are squamous cell carcinomas 
(HNSCC) and originate from the epithelia of these regions. HNSCC commonly spread to the 
lymphatics of the neck and this may be the first and sometimes the only manifestation of the 
disease. Smoking and alcohol are amongst the major risk factors for HNSCCs (Murata et al, 
1996) and account for about 75% of cases discovered. Viral infections such as Epstein Barr 
virus (EBV) and human papilloma virus (HPV) have been strongly correlated with HNSCCs 
and genetic tendencies are also recognized as significant risk factors for oral cancer (Hirsch et 
al, 2010). Oral cancers are the 10th most common cancers occurring worldwide and the seventh 
most common cause of cancer induced deaths in the world (Mehanna et al, 2010).   
Oral SCCs, a subtype of HNSCC, are usually highly aggressive and arise as primary lesions 
from within oral epithelium, most commonly of the tongue, but also of the floor of the mouth, 
cheek, lips and the palate (Rogers et al, 2010). When precursor lesions for these tumours exist 
they are referred to as leukoplakias (adherent white patches on the mucous membranes) and 
erythroplakias (red patch or lesion). The latter are less common but more highly correlated with 
future transformation into malignancy (Bouquot, 1995). The progression pathways for OSCCs 
are well established and premalignant lesions present themselves histologically as squamous 
dysplasia, usually graded as mild, moderate or severe (Anneroth et al, 1986), previously also 
termed carcinoma in situ, based on structural differences and cellular atypia. This grading is 
dependent on the thickness of the epithelium affected and if the full thickness of the epithelium 
is altered it is considered severe dysplasia, moderate if the middle third or prickle layer is 
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affected and mild if only the lower layers are involved. Tumours invading through the basement 
membrane are described as invasive squamous carcinomas. These gradings, although usually 
reflective of the severity of the lesion, can be misleading as they cannot consistently predict 
malignant potential (Hunt, 2011).  
Histologically, lesions are associated with hyperplastic (excessive cell proliferation) or 
dysplastic (abnormal cell maturation) cellular changes or a combination of both (Jon and 
Albrecht, 2003). Dysplastic lesions are characterized by loss of the organization and maturation 
patterns typical of squamous epithelia and dysplastic cells show aberrant features ranging from 
nuclear enlargement, irregularities in the nuclear membrane and hyperchromatism. Squamous 
carcinomas typically show some degree of keratinization and, when it is marked, the tumour is 
termed well differentiated whereas those tumours showing little evidence of keratin formation 
are considered poorly differentiated. Histological evaluation distinguishes between different 
variants of SCCs such as verrucous carcinoma, papillary SCC, basaloid SCC, spindle cell, 
acantholytic and undifferentiated carcinoma. HNSCCs can present with many symptoms 
depending on where they originate. Laryngeal cancers cause hoarseness of the voice while 
pharyngeal cancers present with dysphagia and sore throat. Many patients only have a painless 
lymph node. One of the common presentations of tongue carcinomas at the time of diagnosis 
is the presence of a non-healing ulcer on the lateral aspect of the tongue (Mehanna et al, 2010). 
Other signs and symptoms are listed in the figure below. 
 
Figure 1.0: Signs and symptoms commonly associated with head and neck cancers 
(adapted from Mehanna et al, 2010) 
Worldwide almost 500,000 new cases of head and neck cancer are diagnosed annually (Pisani 
et al, 2002). Patients with malignant cancers of the oral cavity and oropharynx have a 5-year 
survival rate of 56% which has not reduced over the last few years (Joshua et al, 2010). These 
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tumours have poor prognosis as most patients present with advanced stage disease many of 
whom are diagnosed incidentally by dental practitioners by which time the disease has spread 
to the regional neck lymph nodes (Lee and Moon, 2011). The percentage of oral and 
oropharyngeal cancers diagnosed early stands at 64% and 16% respectively. Males are affected 
more than females and this ratio varies from 2:1 to 15:1 depending on the epidemiological area 
examined (Mehanna et al, 2010). 
The treatment of early stage head and neck cancers centres on surgery, to produce healthy 
margins, or radiotherapy.The choice between the two depends on preservation of function. 
Although radiotherapy is the preferred method in tongue carcinomas allowing the preservation 
of speech and swallowing, recent advances like the carbon dioxide laser have reduced 
morbidity by increasing organ preservation compared to open surgery (Mehanna et al, 2010). 
In advanced head and neck malignancies, single modality treatment alone has proved 
ineffectual and studies have proved that surgery coupled with radiotherapy or chemotherapy 
provides a better chance of a cure. Although advancements in molecular science have made 
different and new chemotherapeutic agents available, most of them are still associated with 
high morbidity owing to adverse side effects. 
1.3 Stem Cells 
Adult tissues maintain their structure and function through cell division patterns that are 
associated with cyclical renewal or tissue repair (Mackenzie et al, 2006). Cell loss is delicately 
balanced by cell renewal and normal epithelial function requires cell loss to be balanced 





Figure 1.1: Figure showing hierarchy of cells present within the epidermis. A stem cell 
is shown which divides relatively infrequently to produce proliferative transient cells 
which lack extensive self-renewal capacity. These in turn divide to form the differentiated 
cells for tissue function and leave the basal layer. (Adapted from Alonso and Fuchs, 2003)  
The maintenance of this delicate balance ensures effective homeostasis and overall control of 
this process depends on relatively small populations of cells within a tissue that possess the 
ability both to self-renew and to give rise to a cellular hierarchy within tissues (Lavker et al, 
2000). They are known as somaticstem cells. When stem cells divide, they typically give rise 
to a cell that retains stem cell properties, thus ensuring that there is a continuous supply of these 
long-lived cells, together with a cell committed to differentiation, providing cells for tissue 
function and ensuring that cell loss balances cell turnover. Stem cells are often slow cycling in 
vivo (Mackenzie et al, 2006) and divide relatively infrequently as compared to other cells. 
Earlier views stating the equal potential of all proliferatively active cells in tissues are 
incompatible with the results of later studies which make it clear that cells within a tissue are 
heterogeneous with regard to their proliferative capacities (Tudor et al, 2004). A slow cell cycle 
may make stem cells less prone to the adverse effects of mutations which are most likely to 
occur at the time of division. Understanding stem cell and progenitor cell behaviour and its 
relationship to pathways involved in homeostasis is one of the main foci of current stem cell 
research. For the majority of adult tissues the mechanisms by which stem cells maintain a 
balance between proliferation and differentiation remain unclear.  
An asymmetry model is the basis of the hypothesis that tissue homeostasis is maintained by 
stem cells which divide to give rise to a daughter stem cell and a committed cell which 
eventually differentiates. With the invariant asymmetry/division asymmetry model cell loss is 
balanced by the asymmetry of division at the single cell level, where slow cycling stem cells 
give rise to daughter stem cells and cells that continue to differentiate (Potten and Loeffler, 
1990; Klein et al, 2011). This has been welldocumented in Drosophila (Knoblich, 2008). It is 
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thought that this type of division takes place either through polarization of stem cells prior to 
division or owing to external signals from the microenvironment (Voog and Jones, 2010). An 
alternate mechanism, called the population asymmetry model, proposes that there is a pool of 
stem cells that divides to produce either two stem cells, two differentiating cells, or one of each 
and it is by the overall balance within these probabilities that homeostasis is achieved (Jones, 
2010). Earlier studies on intestinal epithelium and murine oesophageal cells are also in line 
with the idea of population asymmetry (Cheng and LeBlond, 1974; Marques-Pereira, and 
LeBlond, 1965).  
Figure 1.2: Tissue self-renewal models. In (A) a stem cell divides to produce a stem 
(green) and a differentiating (red) 
cell. In (B) half the stem cells 
divide to self-renew while the 
other half differentiates (Jones, 
2010).  
 
Stem cells are thought to reside in 
restrictive environments called ‘niches’ (Alison et al, 2002; Burkert et al, 2006) that are 
involved in generating signals that collectively control stem cell fate (Watt and Hogan, 2000). 
These dynamic microenvironments within tissues balance stem cell activity, maintaining 
homeostasis during normal physiological development and in disease. Schofield (1978) 
proposed the existence of a niche, or specialized location, for hematopoietic stem cells (HSCs) 
and showed that hemopoeitic cells from the spleen are more proliferatively active than cells 
isolated from within bone marrow and suggested that this was because the cells in the spleen 
were not associated with niches. This was the first suggestion of a stem cell niche as a 
physiological microenvironment consisting of specialized cells that physically anchor the stem 
cell and provide factors necessary to maintain its ‘stemness’ and prevent maturation of these 
cells. Stem cell interactions with the niche microenvironment may actually control many facets 
of stem cell behaviour, including self-renewal and clonogenicity (Sneddon et al, 2007). Niches 
have been identified for mammalian stem cells in the neural, epidermal, and hematopoietic 
systems (Li and Xie,2005;Weissman et al, 2001; Palmer et al, 2000). The figure below shows 





Figure 1.3: Proposed stem cell niches in different tissues and assays used for their 
identification (Voog, Jones,2010). 
Studies of hematopoietic systems in vitro have shown the survival of progenitor cells to be 
dependent on factors produced by other cells (Watt and Hogan, 2000; Quesenberry and Becker, 
1998). Secreted factors such as TGF-β have been shown to be important in the maintenance of 
neural crest stem cells through both paracrine and autocrine mechanisms (Shah, et al, 1996; 
Watt and Hogan, 2000). Interaction between epidermal stem cells and extracellular matrix 
through integrins and similar adhesion proteins are thought to be crucial for maintaining a stem-
like state (Zhu and Watt, 1999). 
1.3.1 Classification of Stem cells 
The criteria used to define a stem cell vary quite widely but, stem cells are usually classified 
on the basis of their origin as embryonic, germinal or somatic.  
Embryonic stem (ES) cells are derived from the inner cell mass of the blastocyst and during 
normal development give rise to all the tissues of the body. They hold great potential for 
regenerative medicine but they require very sensitive culture conditions. ES cell research is 
considered unethical by some people as they believe that human embryos have full 
developmental potential and destroying them to harvest cells is morally unjustifiable. In some 
places ES cell research is considered illegal (Alison et al, 2002). Somatic stem cells are cells 
present in adult tissues that are responsible for the maintenance of these tissues throughout the 
life of the organism, whereasgerminal stem cells are responsible for gamete production. 
Stem cells can also be classified largely on the basis of potency. Cells derived from the early 
blastocyst are said to be totipotent as they can give rise to all the tissues of the body and also 
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the placenta; hence they are the most versatile and the least committed. These cells, on further 
division, give rise to pluripotent cells of the three germ layers of the body, namely the 
ectoderm, the mesoderm and the endoderm (Smith, 2001). Subsequently, these cells, whilst 
still capable of long-term self-renewal, become committed to certain lineages, are responsible 
for the maintenance of specific tissues, and can be termed multipotent. Multipotent cells are 
more committed than pluripotent cells and give rise to lineage restricted progenitor cells which 
in turn can generate specific tissue systems. For example, in the hemopoeitic system 
hemopoeitic stem cells (HSCs) give rise to relatively undifferentiated progenitor cells that 
divide in turn to generate the various haematopoietic lineages (Priddle, et al, 2006). Although 
immature epithelial cells can be stimulated experimentally to form morphologically and 
phenotypically distinct types of cells, they are normally lineage specific (Mackenzie et al, 
1983). 
Forced lineage specification studies carried out by Weintraub et al (1989) demonstrated that 
fibroblasts could be converted to skeletal muscle cells by the forced expression of a 
transcription factor MyoD. Since then fibroblasts have been shown to convert into neurons, 
cardiac cells and blood-cell progenitors (Chambers et al, 2011). In the early 1960s Gurdon and 
colleagues found that a nucleus from a differentiated frog cell, when transplanted into an 
enucleated germ cell could give rise to a new frog, indicating that a differentiated cell retains 
the same genetic information as an early embryonic cell (Hochedlinger and Stadtfeld, 2010). 
The potential applications of this were unveiled with the cloning of Dolly the sheep in 1996 
from a differentiated cell. These applications gave rise to the induced Pluripotent Stem Cell 
(iPSC) technology, when it was shown that transcription factor based programming of cells 
could also yield cells with stem like capabilities (Takahashi and Yamanaka, 2006) and this has 
now revolutionized the field of regenerative medicine. 
1.4 Proliferative patterns of normal stem cells 
As described, stem cells in the hematopoietic system divide relatively infrequently to give rise 
to a hierarchical pattern in which immature progenitor cells eventually differentiate to form all 
the cells derived from the bone marrow (Morrison et al, 1995; Reya et al, 2003). Stratified 
squamous epithelia have also been shown to follow a similar pattern of division where 
undifferentiated cells in the basal layer divide to form transient amplifying cells that divide to 
give differentiated cells which move up through the epithelium to be shed. 
1.5.1  Asymmetric Division 
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Although asymmetric division patterns have been established for many tissues, it is still 
uncertain how and when asymmetric cell fate is determined; i.e., at the time of division or by 
events taking place after the cell has divided. However, either pattern provides a means for the 
balanced homeostatic turnover required for a tissue to function normally in a steady state. 
Typically, three cell compartments are present in a tissue, a stem cell compartment, a transient 
amplifying compartment and a differentiated one. It has been estimated that for the epidermis, 
a stem cell has to divide only once to generate a stem daughter and 8 differentiated cells (Potten, 
1997; Tudor et al, 2004). Watt et al (2000), demonstrated that asymmetric divisions define the 
architecture of human oesophageal epithelium. In developing mammalian skin, cells in the 
basal layer were shown to undergo two types of divisions (Lechler and Fuchs, 2005). The first 
type of division was seen frequently in early embryonic skin (up to day 12) and took place with 
the mitotic spindles of cells aligned parallel to the basement membrane where cells divided 
laterally to form a single layer of cells (Figure 1.4a). A few cells, however, showed a second 
pattern where the mitotic spindles were arranged at right angles to the basement membrane 
(Figure 1.4b). The mechanisms by which mammalian skin undergoes stratification are still 
poorly understood but it was proposed that the cells dividing at right angles to the basement 
membrane resulted in the production of a cell which lost contact with the basal layer thus 
inducing its exit from this layer and commitment to differentiation. (Lechler and Fuchs, 2005). 
The figure below shows the two types of divisions discussed. 
Figure 1.4:The 
parallel (a) and 
perpendicular 
(b) orientation 
of the mitotic 
spindles during 
cell division. The 




Later in development, once stratification began, most of the spindles were oriented at ninety 
degrees to the basement membrane (Figure 1.4b). Thus it was inferred that most of the late 
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divisions occurring in the basal layer were asymmetrical, giving rise to a stem cell compartment 
and a transient amplifying compartment. The cells leaving the basal layer migrate towards the 
surface showing expression of differentiation markers such as keratins and 
involucrinsuggesting again, that loss of contact of basal cells with the basement membrane 
initiates a differentiation stimulus (Seery et al, 2000).  
1.5.2  Symmetric division (1) 
It is also possible for a stem cell to divide to produce 2 cells, both of which enter the 
differentiation pathway. This pattern, which leads to depletion of the stem cell population, 
could result from a depleted number of niches available to support stem cell survival e.g. after 
irradiation therapy (Costea et al, 2006) or from a change in the signalling pathways associated 
with stem cell maintenance. Inducing such a division pattern could also be of potential value 
in the removal of cancer stem cells. Gupta and co-workers demonstrated this through the use 
of a screening process and identified small molecule inhibitors that induce differentiation of 
CSCs in breast cancer cell lines(2009). 
1.5.3  Symmetric division (2) 
In an third pattern of division, a stem cell can divide to give rise to two stem cells, a pattern 
expected when stem cells have been lost through wounding and new stem cells need to be 
generated. Time lapse video of cancer cells suggest that this sort of division occurs in-vitro in 
cultures of cell lines derived from tumour tissue (Mackenzie lab, 2006). It is thought that 
murine cells in culture divide symmetrically, as suggested by the continuously expanding 
central zone of cells in murine cultures (Tudor et al, 2006), a pattern described in more detail 
in section 1.5. As described below, colonies formed by oral cancer cell lines show a similar 
pattern in which cells around the edges of colonies look and behave differently from cells 




1.5.4  De-Differentiation 
Once a transient amplifying cell has been formed, it is expected to continue down the 
differentiation pathway. However, Potten and Grant (1998) suggested that if stem cell survival 
is disturbed (i.e. the self-renewing cell dies or is lost) then a transient amplifying cell may stop 
differentiating and revert back to a stem cell state. Barrandon and Green (1980) showed that if 
paraclones, representing late amplifying cells, are transfected with a viral oncogene, they can 
revert back to a stem cell state with full restoration of growth potential. This suggests that the 
transition from stem to amplifying to differentiated cells may not be irreversible although the 
mechanism by which this happens still remains unclear. Stem cell divisions and their various 
outcomes are illustrated in Figure 1.5, which has been adapted from Costea et al, 2006. 
Figure 1.5: Hierarchical stem cell concept in human oral mucosa. Stem cells (red) with 
a low proliferative rate but high self-
renewal capacity, undergo a 
symmetric division to generate two 
new stem cells (left), an asymmetric 
division (centre) to produce a new stem 
cell and a more differentiated transit 
amplifying cell (pink), or a symmetric 
division to give two cells committed to 
differentiation (right). TA cells 
differentiate into specialized cells that 
maintain the tissue (blue round cells), 
and finally desquamate from the epithelial surface (blue flattened cells) (Costea et al, 
2006). 
1.5 In vitro behaviour of Epithelial Stem cells 
Hemopoeitic stem cells (HSCs), known to be responsible for the generation of all cell types in 
the blood in mice and humans, have been positively identified and successfully isolated 
(Weissman et al, 2001). As this system is the most widely studied of all adult tissues, and hence 
the best characterized, information generated from it has been used as a basic conceptual 
guideline for other systems studied, particularly the adult epidermis (Mackenzie, 2006). The 
existence of epithelial stem cells was proposed as early as 1970 by Mackenzie when small 
proliferative units were discovered in mouse epidermis. It was also hypothesized that cells at 
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the center of this unit had the ability to remain quiescent. Localization of slowly-cycling cells 
in murine epithelia was examined through a process called ‘label retention’. The epithelium 
was labelled with titrated thymidine, which is taken up by DNA during the S-phase of cell 
division and the tissues were sampled a month or later (Bickenbach, 1981). This method relied 
on the concept that stem cells, being slow cycling, would be the only cells retaining the label 
at the end of the month, while, the cycling cells, would have diluted the label through cell 
division (Mackenzie and Bickenbach, 1985).  
 
Figure 1.6: The ‘immortal strand’ hypothesis; a possible way for stem cells to maintain 
the integrity of their genome. (Adapted from Burkert et al, 2007) 
This interpretation is complicated somewhat by the ‘immortal strand hypothesis’, in which 
Cairns (1975) gives another potential mechanism for label retention. As depicted in the figure 
above, he suggested that stem cells have evolved protective mechanisms to help conserve the 
integrity of the genome. A cell is most prone to carcinogenic mutations generated through 
copying errors at the time of cell division and one way to protect against this would be to 
segregate newly synthesized, potentially error prone strands from pre-existing parent strands. 
In this way, a distinct set of strands (immortal strands) would be retained at every division,with 
a pre-existing DNA strand in each chromosome selected as the strand destined to remain with 
the stem cell. The newly synthesized strand incorporates label and this is given off to the 
daughter cell, destined for differentiation and loss from tissue. The original strand (unlabelled) 
will be kept by the stem cell and theoretically preserved indefinitely. This also means that 
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potentially there would be two types of labelled stem cells formed. The first type would lose 
the label by the time it has divided twice as the younger strand would have been segregated to 
the differentiating daughter. However, in conditions where stem cells are being actively 
recruited at times of injury it would become possible to label the immortal strand at the time 
when the new stem cell is created. This cell, according to the hypothesis should reduce the 
label at the first division and then remain labelled indefinitely. This was demonstrated by Potten 
and co-workers in 1978 where labelled cells were shown to halve the label at the first division 
and then maintain what was left for up to four weeks (Cairns et al, 2006). Experiments carried 
out on this phenomenon have largely been inconclusive as results indicate that DNA 
segregation is largely random. Nevertheless people have also shown that a small number of 
cells may selectively segregate their DNA strands. Experiments performed by Potten’s group 
on small intestinal crypt cells demonstrated the presence of both types of cells, those which 
lost the label after about two divisions and those which retained the label for up to four weeks. 
In each case, cells either retaining or losing the label were demonstrated close to regions where 
stem cells were thought to reside that is support for Cairns hypothesis has been found in 
experiments carried out by Potten’s group (Potten et al, 2002). Clevers demonstrated 
asymmetric division in Drosophila and showed that disruption of this balance led to cells 
acquiring cancer like states (2005). A small subset of breast cancer cells were shown to possess 
slower cell cycle kinetics in culture where these cells retained their label longer than the bulk 
of the population, a larger proportion of which were also shown to be positive for proliferation 
markers suggesting that these cells had a slower cell cycle (Fillmore and Kuperwasser, 2008). 
The presence of stem cells has since been demonstrated in most epithelial tissues that have 
been carefully studied, for example, the skin (Janes, 2002), the liver (Cantz et al, 2007), 
pancreas (Bonner-Weir, 2002) andbreast (Stingl, 2009). The majority of cells with high 
clonogenic potential in the skin are present in the bulge region of the hair follicle (Alonso et 
al, 2006) and label retaining cells (LRCs), isolated from the bulge region are not only slow 
cycling but can be cultured extensively over many passages, one of the properties of stem cells. 
Other studies have also shown that interfollicular epidermal stem cells retain the ability to be 
reprogrammed and have the potential to give rise to multiple lineages (Liangand Bickhenbach, 
2002). This concept is a main focus of biomedicine, where research has made it possible to 
generate new skin in vitro for grafting onto burns victims (Alonso and Fuchs, 2002). 
Further information about human stem cells has been obtained from both in-vitro studies and 
from those involving NOD/SCID mice where the property of clonogenicity has largely been 
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used to assess stem-potential. As already mentioned, epithelial tissues contain cells with a range 
of growth potentials, i.e. the cell population is heterogeneous. In vitro this was first shown by 
Barrandon and Green in 1987, who plated human keratinocytes isolated from normal human 
epithelia, at clonal density, and found that three types of colony patterns were consistently 
generated. Some cells gave rise to round, tightly packed colonies of relatively small cells with 
a high nuclear to cytoplasmic ratio. These were termed holoclones (Figure 1.7a) and, as they 
contained cells which could be extensively replated to generate similar colony patterns, they 
were thought to contain stem cells. These cells could also regenerate a functional epithelium 
when transplanted onto mice (Fuchs and Blanpain, 2009). Other cells generated colonies 
consisting of loosely packed cells with an irregular outline, which were less capable of 
extensive growth and were termed meroclones (Figure 1.7b). The proliferative behaviour of 
these cells suggested an intermediate stage between stem and committed cells corresponding 
to transient amplifying cells. Some cells generated only small, abortive colonies which were 
not capable of much growth, corresponding to late transient amplifying cells, and were termed 
paraclones (Figure 1.7c). Such colony morphologies can be repeatedly generated in culture 
under a wide variety of culture conditions thus supporting the hierarchical concept of 
heterogeneity of epithelial cell behaviour while suggesting that the mechanisms by which these 
colony patterns are generated reside autonomously within the cells. (Tudor et al, 2004). 
 
Figure 1.7: Cellular heterogeneity of oral keratinocytes when cultured. Holoclones are 
formed from small tightly packed cells (a). Meroclones are made up larger, loosely 
arranged cells (b). Paraclones contain large irregular shaped cells and show little 
growth(c).  
Studies involving murine keratinocytes reveal similar patterns of cell behaviour although the 
morphology of the colonies formed differs from human keratinocytes (Tudor et al, 2007). 
Murine keratinocytes plated at clonal density form three distinct types of colonies, termed Type 




Figure 1.8: Different colony morphologies generated by murine skin keratinocytes. 
Panels (a-c) show type 1, type 2 and type 3 colonies. The central zone (3) (c) is thought to 
contain the stem cells as cells in this zone are highly clonogenic and can also give rise to 
the other zones. Zones marked 2 and 3 contain early and late transient amplifying cells 
respectively. Panels (d-e) show similar patterns obtained when cells from murine tongue 
were cultured (Adapted from Tudor et al, 2007). 
Type 1 colonies contain loosely packed and scattered cells that cannot be maintained in 
subsequent passages (panel a). Type 2 colonies consist of type 1 cells at the periphery with an 
additional inner zone of smaller more closely packed type 2 cells (panel b). Type 3 colonies 
(panel c) are similar to Type 2 colonies but contain a central zone of even smaller and more 
tightly packed Type 3 cells. Replating cells from type 2 colonies generated both type 1 and 2 
morphologies but only the central cells from type 3 colonies were able to be passaged for longer 
periods of time and reconstitute all three colony morphologies. It was hypothesized that these 
cells have stem cell capabilities whereas type 2 and 1 colonies represented committed transient 
amplifying and differentiated cells respectively (Tudor et al, 2007).  
Generally, however, human and murine keratinocytes lack the ability to grow indefinitely in 
culture and after repeated passages all cells eventually give rise to paraclones or Type 1 
colonies, reflecting the depletion of stem cells. It is therefore interesting that epithelial cells 
that are expanded in vitro and then reintroduced into in vivo conditions (human and murine) 
(Compton, 1998; De Luca, 1990) are able to support a functional epithelium indefinitely. One 
can infer from this that although some aspects of the generation of hierarchical colony patterns 
are epithelium-autonomous, the in vivo maintenance of stem cells is also dependant on 
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interactions between epithelium and connective tissue (Mackenzie, 1994). Work done by 
Maas-Szabowski and co-workers on compound cultures has reinforced this observation by 
showing that fibroblasts release keratinocyte growth factor (KGF) in response to interleukin-1 
(IL-1) produced by epithelial cells (Maas-Szabowski N et al, 1996). 
1.6 Stem cells, cancer and cancer stem cells (CSCs) 
A solid tumour is like an organ that has developed in an aberrant way but still contains a 
heterogeneous mixture of cells and tissues (Wei et al, 2006). Malignant tumours and their 
metastases remain one of the leading causes of death in developed countries. Hanahan and 
Weinberg (2011) have described certain traits which a cell must have in order to become a 
cancer cell, suggesting that tumourigenesis is a multistep process where each step represents a 
progressive change resulting from genetic alterations which eventually lead to the 
transformation of a normal cell into its malignant derivative. They list six essential alterations 
dictating malignant change:  
 Self sufficiency of growth signals 
 Insensitivity to anti-growth signals 
 Invasion of apoptosis or programmed cell death 
 Limitless replicative potential 
 Sustained Angiogenesis 
 Invasion and metastasis 
Figure 1.9: Sequelae of events required for 
carcinogenesis (Hanahan and Weinberg, 2009). 
Most cancers share all these characteristics with 
each of these acquired changes representing a 
breach in the normal anti-cancer protective 
mechanisms which cells have evolved. Self 
sufficiency of growth signals allows a cell to divide 
without being dependant on external signals which 
maintain a normal steady state. Anti-growth signals work by keeping cells either quiescent in 
a non-proliferative state or by forcing them into differentiation allowing cells to remain 
quiescent when they fail. Programmed cell death ensures that cell death balances cell turnover 
through mechanisms hardwired within cells, disruption of which allows cells to survive for 
prolonged time periods. Limitless replicative potential, a hallmark of normal stem cells, when 
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acquired by cancer cells allows them to multiply and eventually replace normal cells through 
a process of clonal expansion (Mackenzie, 2006). Angiogenesis is the process by which cells 
within tissues generate blood vessels to satisfy the demand for oxygen and nutrients and is very 
tightly regulated in normal tissues. Dysregulation of this process ensures a constant supply of 
nutrients for the cancer cells to survive indefinitely. Finally, the ability of cells to invade 
surrounding tissues provides a means for them to escape the primary tumour mass and colonize 
distant sites where nutrients and space to divide are available. 
It is now generally accepted that, like normal epithelium and most other tissues, the growth of 
cancers, including oral cancers, is driven by a small population of self-renewing stem cells 
within the bulk of the tumour that allows the malignancy to be capable of extensive growth. 
This was first suggested as early as 1979 by Minden and co-workers and was demonstrated by 
Griffin and Lowenberg (1986) whose work with hematologic malignancies showed that only a 
small population of leukemic cells was clonogenic in culture. More conclusively, Bonnet and 
Dick (1997), by transplantation of acute myeloid leukemia (AML) cells into immunodeficient 
mice, showed that only cells with a CD34+/CD38- phenotype were able to form tumours. Since 
then CSCs have been identified in breast cancers (Al Hajj et al, 2003) where cells with CD24-
/CD44+/ESA+ phenotype were shown to be related to tumour initiation when transplanted into 
mice. A study involving neuroblastomas identified cells expressing higher levels of CD133 as 
malignant progenitors (Jeanette et al, 2004). More recently malignant stem cells have been 
shown to exist in lung cancers (Kim et al, 2005), oral squamous cell carcinomas (Prince et al, 
2007) and a range of other cancers. The finding that cancers are heterogeneous in both their 
cellular content and tumourigenic potential has led to ‘the cancer stem cell’ hypothesis (Clarke 
et al, 2006; Reya et al, 2001) which states that only a few subsets of cells within tumours have 
stem cell capabilities and that these are responsible for the long term growth and survival of 
cancers. 
Experiments carried out by Locke and co-workers (2005), using cell lines derived primarily 
from oral cancers, have shown that stem cell patterns are also retained in OSCC cell lines. They 
showed that the in-vitro colony patterns of holoclones, meroclones and paraclones displayed 
by malignant cell lines are similar to those of normal keratinocytes. Further, one can predict 
not only the growth potential of these cells but also their surface molecular expression by the 
colony morphologies they give rise to. Malignant holoclones were comprised of small, rapidly 
adherent and highly clonogenic cells (Figure 1.10a) which show high surface expression of 
molecules such as CD44, β-integrin and β-Catenin, which are also highly expressed by normal 
33 
 
epithelial stem cells (Cotsarelis et al, 1999; Tudor et al, 2004). Correspondingly, paraclones 
expressed markers of differentiation, showed lower levels of expression of putative stem cell 
markers, and formed loose irregular colonies of flattened and less rapidly adherent cells which 
showed little growth potential. Meroclones had intermediate features with ovoid cells that were 
found to survive five or six passages. It was concluded that paraclones and meroclones 
represent populations of late and early transient amplifying cells respectively.  
 
Figure 1.10: Ca1 cells plated at clonal density generate holoclones (H), meroclones (M) 
and paraclones (P). 
Tumour cells cannot be easily studied in vivo and standard in vitro cultures fail to generate 
conditions present in vivo including cell to cell interaction patterns of normal epithelia. 
Although organotypic cultures do not fully correspond to in vivo conditions (Parenteau et al, 
1992), they do provide a more normal environment with regard to cellular interactions and 
normal epithelial growth patterns seem to occur. The use of organotypic cultures with 
malignant oral cell lines has indicated a small population of cells with regenerative capabilities 
(Mackenzie, 2004). 
Tumour cell populations, grown on a collagen matrix populated with fibroblasts form a 
stratified structure similar to that formed by normal keratinocytes. However, examination of a 
range of cell lines indicated that they all failed to form a well-organized epithelium and none 
generated a cornified layer. When tumour cells were incorporated into cultures of normal 
keratinocytes, they tended to remain in the basal layer and failed to differentiate normally 
(Mackenzie, 2004). With time, some tumour cells expanded to form clusters or islands of 
tumour cells growing at the expense of the surrounding normal epithelium (Mackenzie, 2004). 
The growth patterns of these clusters suggested a clonal origin and, as the number of clusters 
formed was less than the number of tumour cells initially seeded, that only a sub-fraction of 
cells was clonogenic. 
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1.7 The origin of the cancer stem cell 
1.8.1 Malignant Transformation of normal stem cells 
Maintenance of tissues by a small population of stem cells retained in the tissues throughout 
life suggests that they are likely to be the functional targets of carcinogens and acquire the 
deleterious mutations leading to cancer (Wei et al, 2006). Other epithelial cells, having a finite, 
and relatively short, life span, are unlikely to be retained in the tissue long enough to 
accumulate all the mutations necessary for carcinogenesis. However, there is some evidence 
that transient amplifying cells may be affected by such mutations and the in-vitro growth 
potential of human keratinocyte paraclones can be restored by transfection with viral 
oncogenes (Barrandon et al, 1989). 
From review of the literature, it seems most likely cancer stem cells arise as a result of the 
accumulation of mutations in a normal stem cell which already possesses the properties of self-
renewal and clonogenicity. As cancer stem cells lack pluripotency, it is likely that these cells 
are formed from adult stem cells (Biddle and Mackenzie, 2012). It seems reasonable to assume 
that mutations occur in genes controlling the genetic and epigenetic pathways linked to self-
renewal mechanisms. Disruptions in this pathway could result in the maturation arrest of 
normal stem cells, thus reducing the normal proportion of asymmetric divisions and eventually 
leading to an increase in the number of altered stem cells. The two stage model of mouse skin 
carcinogenesis supports this observation as the interval between tumour initiation with 
dimethylbenzanthracene (DMBA) and the application of tumour promotion factors, such as 
phorbol esters, can be delayed with little reduction in tumour yield (Pardal et al, 2003), an 




1.8.2 Epithelial Mesenchymal Transition 
Epithelial Mesenchymal Transition (EMT) is a biologic process that allows epithelial cells to 
assume mesenchymal traits such as increased motility, invasiveness, resistance to apoptosis 
and survival in anchorage independent conditions (Thiery et al, 2009). Epithelial cells are 
arranged in a polarized pattern and maintain tight junctions with each other and with the 
substratum. They are separated from the surrounding stroma by a basement membrane that 
controls apico-basal polarity, distribution of adhesion molecules such as cadherins, and prevent 
changes in cell shape by controlling the cellular cytoskeleton (Gjorevski et al, 2011). All these 
ensure that epithelial cells are kept tightly in check and unable to migrate from their immediate 
environment (Mani et al, 2009).Many adult tissues are formed either by conversion of epithelial 
cells into mesenchymal cells or by the reverse process of mesenchymal to epithelial transition 
(MET) (Chaffer et al, 2006). EMT programs are activated in three biological settings and have 
been classified as Type 1, Type2 and Type3.  
Type 1 EMT encompasses all EMTs occurring during gastrulation and early embryogenesis 
where epithelial cells generate mesenchymal cells which have the potential to undergo a MET 
to form secondary epithelia and initiate organogenesis. (Thiery, 2006; Sleeman, 2011; Kalluri, 
2009). 
Type 2 EMTs are activated during wound healing and tissue regeneration. They differ from 
Type 1 in that they are physiologically activated under inflammatory stress and stop once 
healing and repair is complete. Such EMTs are induced in response to growth factors and 
inflammatory cytokines produced as a consequence of the injury. Prolonged activation of these 
programs can result in fibrosis, for example renal fibrosis, where fibroblasts accumulating 
within the lesion are derived from epithelial cells undergoing EMT (Kalluri et al, 2003).   
Type 3 EMTs refer to aberrant EMT programmes that are activated in cancer cells and produce 
changes favouring the uncontrolled growth that allows them to acquire invasive traits.As 
discussed later in this section, this enhances their metastatic potential and also allows them to 




1.8 Epithelial Mesenchymal Transition and Cancer 
The role of EMT in tumour progression is not completely understood (Tarin et al., 2005) but it 
has been proposed that EMT is a cyclic process that occurs initially at the primary tumour site 
to induce transformation and invasion. Later, as a reverse process, “mesenchymal–epithelial–
transition” (MET), occurs to re-establish secondary tumours with epithelial properties similar 
to the primary tumour (Thiery, 2002). As discussed earlier, EMT is related to CSC behaviour 
and has been shown to play a role in the progression of many tumours. Cancer cells appear able 
to take control of existing EMT cellular machinery transforming themselves into invasive 
mesenchymal-like cells which have the ability to metastasize (Chaffer et al, 2006). 
Mani and co-workers (2008) have suggested that EMT may contribute to the generation of 
stem-like properties of cancer cells. Induction of EMT in mammary epithelial cells enabled 
them to acquire mesenchymal traits, to express higher levels of stem cell markers and, 
additionally, an increased tendency to form spheres in culture, another property of self-
renewing stem cells. Consequently, EMT cancer cells with stem cell characteristics have the 
ability to invade the adjacent stroma and to escape to distant sites and colonize new tumours.  
In addition to acquisition of invasive abilities, metastasizing cancer cells need to complete a 
series of steps, referred to as the invasion-metastasis cascade (Mani et al, 2009). These are:  
a) Invasion: Epithelial cells undergo EMT to become mesenchymal-like and breach the 
basement membrane. 
b) Intravasation: The transformed cell moves into a blood vessel or into lymphatics, as 
is usually the case for HNSCCs. 
c) Extravasation: On reaching a distant organ the cells leave the blood vessel and 
extravasate into the surrounding tissue to establish micro-metastases. 
d) Colonization: This final step involves the growth of the micrometastases to form a 
macroscopic tumour. 





Figure 1.11: Schematic representation of tumour metastasis (Thiery, 2002). 
As secondary tumours typically reconstitute the epithelial differentiation patterns present in the 
primary tumour, it appears that EMT, by a reverse process of mesenchymal to epithelial 
transition (MET) is necessary during secondary tumour formation (Chaffer et al, 2006). The 
implications of EMT in cancer have led to the mobile cancer stem cell model (MCSC). This 
model is important as it integrates both current cancer stem cell and EMT concepts. Tumour 
cells within the bulk of the tumour are relatively stationary and cannot disseminate but tumour 
cells at the tumour/host interface would be the ones most likely to undergo EMT in order to 
escape the primary tumour and these are termed migrating stem cells (MSCs). Understanding 
the biology of a tumour cell which can combine the traits of stemness and mobility is important 
in understanding malignant progression (Brabletz et al, 2005). This paradigm has led to studies 
of the tumour/host interface, also known as the “invasive front”. It has also been shown that 
the tumour microenvironment contains inflammatory cells which produce cytokines such as 
epidermal growth factor (EGF), and transforming growth factor-β (TGF-β) and these have been 
shown to induce EMT (Eger, et al, 2004).Experimental studies into the pathways and signalling 
regulators of EMT have implicated the aberrant activation of the WNT programme which has 
been shown to be important in the development of stem cells and in the initiation of the EMT 
programme (Brabletz et al, 2005; Grunert et al, 2003). In colorectal cancer, the presence of 
cells expressing high levels of nuclear β-catenin at the tumour host interface is strongly 
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correlated with poor prognosis (Bankfalvi et al, 2002). 
1.9 Stem cell markers. 
Currently, there is an absence of reliable markers for stem cells in various types of solid cancers 
but the expectation is that they may exist and that molecules expressed by normal stem cells 
will also be found in their malignant counterparts. If reliable markers for tumour stem cells can 
be found they are expected to provide target-oriented approaches that might be effective in 
tumour eradication and in prevention of recurrence and spread. In leukemias, rare cells with 
the CD34+/CD38- molecular phenotype are able to initiate tumours in mice(Bonnet et al, 
1997).Breast cells enriched for CD24-/CD44+ form tumours in mice and also regenerate 
cellular heterogeneity in vivo and in vitro. (Al-Hajj et al, 2003). Functionally adequate markers 
have now similarly been identified for lung and brain cancers and, recently, for oral carcinomas 
(Prince et al, 2007). The figure below lists some of the known markers for normal and 
malignant stemcells. 
 
Figure 1.12: Proposed markers for normal and malignant stem cells (Burkert. J et al, 
2006). 
Several cell surface molecules have been associated with stemness and tumourigenicity. In 
brain tumours, cells enriched for CD133 and Nestin (Uchida et al, 2000; Jeanette et al, 2004) 
were shown to form tumours in mice. Only CD133 positive cells were reported to form 
neurospheres, a hallmark for neuronal stem cells (Al-Hajj and Clarke, 2004). Interestingly 
CD133 has also been reported as a marker for lung cancers when it was found that CD133 
positive cells were able to asymmetrically segregate their DNA strands. It was also found that 
this subpopulation was able to repopulate the entire tumour population under in vivo and in 
vitro (Pine et al, 2010).  
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A small population of cells within tumours cell lines has also been shown to possess the ability 
to efflux Hoechst dye and are termed the side population (SP).These cells were also shown to 
have stem cell characteristics of high self-renewal and clonogenicity (Ho et al, 2007). This 
ability was later attributed to these cells expressing high levels of ABC transporter proteins. 
They were first described by Goodall and co-workers (1996) in the bone marrow as cells 
expressing high levels of hematopoietic stem cell markers but since then they have been 
characterized in human cancers of many origins including leukemias, neuroblastomas, gliomas, 
lung and breast cancers (Ho. et al, 1996; Goodall et al, 2004). Further, SP cells have been 
shown to be resistant to standard chemotherapy and radiotherapy regimes (Moserle et al, 2009), 
this having been first demonstrated by Hirshmann-Jax and colleagues who showed that 
neuroblastomas were resistant to the drug mitoxantrone (2004). Experimental data from breast 
and brain models suggest that SP cells within many tumours may be resistant to radiation and 
this was shown to be connected to the aberrant activation of the Wnt/β-catenin pathway (Chen 
et al, 2007). However, concerning HNSCC, breast and prostate cancers, CD44 is one of the 
most extensively studied stem cell markers (Al-Hajj et al, 2002; Wang et al, 2006; Prince et al, 
2008, Harper et al, 2007). 
The designation CD44 encompasses a group of multifunctional, mostly cell surface, proteins 
existing as about nine or more isoforms. Different isoforms are generated by complex splicing 
of mRNA transcripts of the CD44 gene, and undergo post-transcriptional modification, leading 
to potentially complex functions (Bankfalvi et al, 2002). The smallest of these isoforms is the 
standard form of CD44 (CD44s) which is the most common member of this family (Mack and 
Gires, 2008) and is present on most vertebrate cells (Marhaba, 2003). CD44 is one of the main 
cell surface receptors for hyaluronic acid present within the extracellular matrix and probably 
plays a major role in cell adhesion (Gunthert et al, 2005). However, CD44 also possesses a 
range of signalling functions that include control of lymphocyte activation and homing 
(Gunthert et al, 1998), cell migration (Estess et al, 1999) and metastasis (Oliveira and Odell, 
1997; Herrlich et al, 1993; Zoller, 2011). Deranged patterns of CD44 expression have been 
reported in bladder cancers (Matsumura et al, 1995), lymphomas (Koopman et al, 1993) and 
breast cancers (Ponta et al, 1995). In the 1990s it was recognized that CD44 isoforms, 
particularly CD44v6 might play a major role in tumour invasion and metastasis (Gunthert et 
al, 1991) through studies on a rat model. CD44 variants 4-7 were shown to play a vital role in 
the metastasis of pancreatic cancers in a rat model and it is interesting to note that blocking the 
function of v6 inhibited lymph node and lung metastases (Gunthert. et al, 1998). Since then 
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numerous reports have been published which implicate CD44 and its exons in the behaviour 
of many human tumours (Rousseau, 2010). In colorectal cancers CD44s, v3, v6 and v8-10 were 
shown to correlate with poor prognosis whereas in breast and ovarian cancers, CD44v3, 
CD44v6 and CD44v7/8 were related to more invasive disease (Kainz et al, 1995; Gotte et al, 
2006).  
Cells positive for CD44 in oral cancers have been shown to be more clonogenic than the rest 
of the cell population and are also able to instigate tumour formation in immune deficient 
(NOD/SCID) mice. (Prince et al, 2007). This was better demonstrated by Biddle et al (2011) 
who showed that transplantation of CD44 high cells rather than CD44 positive cells into the 
tongue of mice correlated with tumour yield and further showed that selection of CD44high cells 
with those expressing low levels of ESA (epithelium specific antigen, EpCAM) also resulted 
in lymph node infiltration. Harper et al (2007) demonstrated the clonogenicity of CD44high cells 
obtained from fresh cell lines generated from HNSCC tumour biopsies. Recently HNSCCs 
derived from Fanconi anaemia patients were also shown to have a subpopulation of clonogenic 
cells expressing high levels of CD44 (Gammon et al, 2011). These cells were also more 
resistant to apoptosis and spent an extended time in the G2 phase of the cell cycle which has 
been associated with DNA repair (Harper et al, 2011). Normal oral epithelia also express CD44 
with basal cells generally staining stronger than the other layers (Oliviera and Odell, 1997). 
The expression patterns of CD44 and its variant v6 were evaluated by Mack and Gires (2008), 
who found the CD44s form to be abundantly expressed in all the normal and cancerous tissues 
examined. They also found no differential expression of v6 between normal and cancerous 
sectionsand question the validity of CD44 as a stem cell marker. Their findings are somewhat 
in contrast to those by Prince (2007) who stated that only a minority of cells (<10%) 
represented the CD44positive, and hence the tumour initiating population  
Based on the information present in the literature which implicates CD44 in initiation and 
progression of OSCC and other tumours, it would be a logical target for the development of 
therapy aimed at successful HNSCC treatment. Phase I clinical trials against v6 were developed 
and looked promising as they successfully blocked major aspects of tumourigenesis in vitro, 
but resulted in the death of a patient owing to adverse side effects on skin and have largely 
been abandoned. The efficacy of these peptides is currently being tested in xenograft models 
using breast and oesophagus cancer cells (Orian-Rousseau, 2010).Aldehyde Dehydrogenase 
(ALDH) is one of the recently implicated markers for head and neck cancers and ALDH 
positive cells were found to form tumours with greater efficiency in mice as compared to 
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ALDH low cells (Prince et al, 2010). High ALDH activity has also been used to characterize 
murine hemopoeitic stem cells (Armstrong et al, 2004), CNS stem cells (Pearce et al, 2005) 
and colonic cancers (Huang et al, 2009). Biddle and co-workers have shown that bi-potent stem 
like cells within oral cancer cell lines also express high ALDH1 activity (2011). 
 
Figure 1.13: Known pathways of stem cell self-renewal and results of 
dysregulation(Pardal et al, 2003). 
1.10 EMT pathways and the molecular mediators involved in this 
transition 
Studies of pathways involved with ‘stemness’ have shown that the same pathways may be 
closely related to EMT. The Wnt pathway is one which is thought to activate some or all aspects 
of EMT and has also been shown to have a role in maintaining stem cell self-renewal (Wei et 
al, 2002) when its inhibition successfully blocked epidermal squamous cell carcinoma 
development. The loss of membranous E-Cadherin is crucial in the development of carcinomas 
from benign tumours (Hollier et al, 2009) and this cell adhesion protein is linked to EMT with 
its loss appearing to be a rate limiting step in this process. EMT is also characterized by a 
change in -catenin location and this protein is also a central mediator of EMT. Brabletz et al 
(2009) have shown that where loss of E-cadherin characterizes EMT it is accompanied by 
dysregulation of -catenin. There is evidence that accumulation of nuclear -catenin increases 
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as E-cadherin is downregulated. In normal epithelial cells, membrane localized β-catenin exists 
in a junctional complex with E-cadherin but once this complex is inactivated, free -catenin 
translocates to the nucleus where it activates target genes involved in oncogenesis and tumour 
progression (Kim, 2001). The integrity of the E-cadherin and β-catenin complex is thus vital 
for cell adhesion and disruptions of this adhesion complex are pivotal in the development of 
metastatic potential and the acquisition of invasive potential (Brabletz et al, 2009). 
Transforming growth factor-β (TGF-β) is a member of a large family of cytokines that are 
involved in many processes, including growth, differentiation, migration, cell survival and 
adhesion. Its role as an inducer of EMT is also well documented. Excessive TGF-signalling 
has been implicated in many pathological conditions such as fibrosis and cancer (Hill et al, 
1999) and loss of TGF- activity has been linked to compromised wound healing (Roberts and 
Sporn, 1993). This family of growth factors works through Type I and Type II receptor 
serine/threonine kinases, activation of which causes the two receptors to come together to form 
a complex. These signal the nucleus through the SMAD family of proteins that are categorized 
into three functional classes as receptor activated, co-mediator and inhibitory SMADS. Once 
activated, receptor and co-mediator SMAD proteins form complexes in the nucleus that are 
directly involved in the transcription of target genes. The inhibitory SMADs negatively 
regulate TGF-signalling by competing for receptor sites and preventing phosphorylation of 
Type I and Type II receptors (Shi and Massague, 2003). TGF- super family members have 
also been shown to activate the MAP-kinase pathways which control morphogenesis and 
growth, although the mechanisms underlying this are poorly understood (Massague and Chen, 
2000). 
TGF- was first described as an EMT inducer for normal mammary epithelial cells by Duband 
(1994) but human alveolar epithelial cells have also been shown to undergo EMT under the 
influence of TGF- (Zhang et al, 2005). Murine epithelial cells change morphology and acquire 
EMT characteristics when stimulated by low doses of TGF- (Thiery, 2002). Similarly human 
keratinocytes show an E-Cadherin response to TGF- (Zavadil et al, 2004). Other studies show 
that TGF- may also be able to cause alterations in cell morphology directly through receptor 
activation without nuclear regulation (Perrez-Plasencia et al, 2007; Ozdamar et al, 2005). A 
large body of evidence strongly linking TGF-β mediated EMT to tumour progression, and 
particularly invasiveness, has now accumulated (Border and Noble, 1994). In breast cancer, 
colon cancer and squamous cell carcinomas, treatment with exogenous TGF- leads to 
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increased invasiveness and metastasis (Massague, 2008; Bates and Mercurio, 2005; Cano et al, 
2009). 
1.11 Patterns of local invasion of HNSCC: the invasive margin. 
At the time of starting the work for this thesis the questions thought to be of particular interest 
were a) how the apparently immortal CSC fraction of tumour cell lines was maintained in a 
self-renewing state and b) how changes occurred in a fraction of cells that resulted in them 
losing self-renewal and becoming identified as founders of meroclones and paraclones. The 
initial idea was that cells at the margins of holoclones were in less tight contact with other 
epithelial cells and might be subject to lesser levels of paracrine factors maintaining their 
“stemness”. This concept was supported by the lesser staining of peripheral cells for markers 
such as CD44, e-cadherin, and ESA that are found at high levels on clonogenic cells. The figure 
below shows a colony of the CA1 cell line viewed in phase contrast microscopy and by 
fluorescence to show the pattern of staining for CD44.  
Figure 1.14: Culture of CA1 cells stained with anti-CD44 antibody. 
Cells in the centre of the colony show strong staining for CD44 but this is reduced in peripheral 
cells and in the scattered isolated cells. However, some of the motile cells at the edge stain 
strongly for CD44. Our initial approach was therefore to search for markers that indicated 
further differentiation-related differences between centre and edge cells. 
During the progress of work for this thesis, one of our research group members made the 
observation that the EMT detectable in cancer cell lines arose as a result of changes in the stem 
cell fraction and was able to further characterize various events associated with this process 
(Biddle et al, 2011). Phase contrast microscopy indicated the presence of elongated fibroblast-
like cells in cultures of all cell lines and time-lapse video indicated that these cells appear highly 
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motile and seemed to be generated from cells at the colony periphery. As discussed below, it 
appeared that this phenomenon was potentially related to the in vivo invasion of cancers, and 
the focus of the research of the thesis therefore shifted towards mechanisms of EMT. 
Concerning cellular changes potentially associated with invasion of HNSCC into the adjacent 
tissues, there have been reports of a range of factors associated with local invasion and 
metastasis (Finger and Giaccia, 2010). These are the growth factors, proteins and enzymes 
produced by the tumour cells and the cells present in the adjacent stroma, or tumour 
microenvironment. In normal conditions the cellular microenvironment keeps malignant 
growth in check through induction of control mechanisms discussed earlier (Figure 1.9), but 
tumour cells can modulate this to enhance their own survival, adhesion and motility (Scheel et 
al, 2011). The tumour’s environment is made up of endothelial cells, fibroblasts, perivascular 
cells and inflammatory cells supported by an extracellular matrix or basement membrane and 
these components are thought to play critical roles in various processes involved during tumour 
progression including inflammation and angiogenesis. Inflammatory cytokines have been 
implicated in HNSCC tumour progression where their prolonged activation promotes an 
environment favouring invasion and migration (Mariotti et al, 2009). Tumour cells are also 
able to secrete cytokines which attract inflammatory cells and tumour associated macrophages 
that have been shown to produce pro-angiogenic factors (Schoppmann et al, 2002). TGF-β is 
one of the major mediators of this process and has been shown to aid the spread of cancer cells 
to lymph nodes (Coussens and Werb, 2002; Finger and Giaccia 2010). The region of interface 
between the tumour and the stroma, (variously referred to as the tumour front, invasive front, 
or invasive margin) is an area of particular prognostic importance (Bankfalvi and Piffko, 
2000;Bryne et al., 1998). It is thought that disturbances in mechanisms controlling 
proliferation, differentiation and epithelial mesenchymal interactions at the tumour-host 
interface govern malignant progression of carcinomas. The evidence also strongly suggests that 
fibroblasts in the vicinity of the tumour cells undergo activation becoming ‘cancer associated 
fibroblasts’ (CAFs) and promote the spread of tumours by creating an environment favouring 
inflammation (Cirri and Chiarugi, 2011) through the production of inflammatory cytokines 
(Gerber et al, 2009). They also induce EMT in cancer cells that allows them to become more 
migratory and invasive (Kalluri, 2009; Thiery et al, 2009). The role of CAFs in promoting 
tumour progression has been documented in prostate (Gianonni et al, 2010), colon (De Wever 
et al, 2004), and breast cancers (Orimo et al, 2009). An increasing body of evidence suggests 
that the most aggressive cells within cancers are present at this invasive front. The significance 
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of the invasive front has also been demonstrated in squamous carcinomas occurring in the 
larynx, uterine cervix and the breast (Bryne et al, 2005; Zhang et al, 2005; Bankfalvi and Piffko, 
2000). Elucidation of events involved in the molecular interactions occurring at the invasive 
front appears to be the key to understanding malignant progression,but few have been 
characterized. The Ki-67 protein is a marker of proliferation and it has been proposed that 
increased proliferative activity is in direct relation to dysplastic severity (Kearsley et al, 1990; 
Papadimitrakopoulou et al, 2002). Another widely studied protein is p53 and the p53 tumour 
suppressor gene (or guardian of the genome) that mediates cell cycle arrest and apoptosis in 
cells after DNA damage, mutations in which have been reported in many cancers (Vogelstein 
et al, 2000). Histologically-detected changes of prognostic significance in this region include 
increased expression of CD44v5 and v6 isoforms (Herold-Mende et al, 1996; Piffko et al, 
1996). Immunochemistry of OSCCs showed a reduction of membranous E-cadherin, β-catenin 
and desmosomal proteins (Bankfalvi and Piffko, 2000). A wide range of molecular changes 
has also been reported in the expression levels of proteins such as vimentin, e-cad, b-cat, 
MMP9, -SMA, snail and laminin-5 (Marsh et al, 2011; Franz et al, 2009; Berndt et al, 2001; 
Berndt et al, 1997; Lewis et al, 2004;Kristensen et al, 1999; Liu et al, 2009; Sterz et al, 2010; 
Wang et al, 2009). It is of interest that changes in most of these molecules have also been 
reported to be associated with EMT (Brabletz et al, 2009). These observations indicated that 
while, as we had initially considered, some holoclone cells have patterns of programmed cell 
division that lead to generation of differentiating cells, others are at the same time undergoing 
a process similar to EMT.  
In some respects, therefore, a holoclone colony can be likened to a tumour with the center of 
the colony representing the bulk of the tumour and the edge representing the invasive front. 
Considering such parallels between the in vivo and in vitro conditions, it was thought that the 
behaviour of cell colonies in vitro might form an interesting model for study of the events 
associated with tumour growth and invasion in vivo. 
1.12 Hypotheses 
It is now generally accepted that cancer growth is ultimately driven by a sub-population of 
highly-clonogenic, long lived stem cells which generate the cells present within the bulk of a 
tumour. Experimental studies have established that these cells differ from the rest of the tumour 
cells in terms of their cell surface markers and gene expression patterns. Concerning the 
behaviour of cells in cancer cell lines, it was hypothesized that: 
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a) The changes associated with transition from holoclone to paraclone cells can be 
identified using immunocytochemistry and FACS analysis for key markers.  
b) In-situ hybridization using radioactively labelled mRNAs for putative stem cell markers 
may identify stem cells in sections of biopsies of oral cancers 
c) cell lines growing in vitro can be used as a model to study EMT processes related to the 
invasion and spread of tumours 
 
1.13 Aims 
a) To identify and isolate enriched stem cell populations from oral cancer cell lines. 
b) To identify key proteins that are differentially expressed in holoclones, meroclones and 
paraclones. 
c) To identify and localize stem cells in wax-embedded sections of oral squamous cell 
carcinomas and normal adult and foetal skin. 

















2.1 Analysis of the distribution of putative stem-cell-related molecules in 
wax-embedded sections of OSCC using in situ hybridization. 
2.1.1  Introduction: 
Holoclone colonies are thought to be largely composed of stem cells as these cells can be 
passaged over a long period of time and display robust colony formation when isolated and 
plated out again. Paraclone cells on the other hand, express little in the way of stem cell markers 
and show little growth, an indication of their being formed from late transient amplifying cells. 
Affymetrix analysis of OSCC cell lines (Locke et al, 2005) showed a number of molecules to 
be differentially expressed in holoclones compared to paraclones. These differentially 
regulated markers were deemed suitable as possible stem cell markers and selected for in-situ 
probe design. It was hypothesized that these markers might better serve as stem cell markers 
and could reveal stem cells or stem cell zones within wax-embedded sections of OSCC and 
might identify changes of cellular expression in colonies invitro. 
Proposed markers included CEBP-, DKK3, Pirin, Hurpin7, IGFB3, RDHL, PSCA, Erb-b3, 
Notch3 and Vimentin. B-Actin was selected as a control to demonstrate the presence of 
hybridisable mRNA in the tissue sections studied which included foetal skin, lung tissue, heart 
musculature, adult skin and two blocks of HNSCC.  
2.1.2  Materials and Methods 
In Situ Hybridization 
a) Tissue Preparation and Handling 
Blocks of formalin-fixed and paraffin embedded tissues were obtained from the archives of 
Prof. Gareth Thomas at the University College Hospital for which ethics approval had already 
been obtained and a range of these was selected to analyse the specificity of the probes designed 
on different tissues. A microtome was used to cut 4-5μ thick sections which were floated on 
DEPC-treated Milli-Q (Sigma, 5758) water collected on pre-coated glass slides (Shandon, 
9991002), and left to dry overnight in a 40ºC oven protected from dust. Next, the sections were 
de-waxed in Xylene for 5 minutes followed by rehydration washes with 100%, 80%, 60% and 
30% ethanol containing 0.1% DEPC. The slides were washed in PBS followed by 
permeabilization with Proteinase K (Gibco) (20ug/ml) for 5 minutes. Washes in PBS/0.2% 
Tween 20 (Sigma, UK) were followed by two washes in PBS followed by post fixation in 4% 
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paraformaldehyde for 10 minutes and further rinsing. The tissue on the slides was acetylated 
with 0.1M Triethanolamine (Sigma, 1502) and 1.25 ml of acetic acid (Sigma, 6404), washed 
with PBS/0.2% Tween 20 followed by dehydration with alcohol in increasing concentrations 
from 30% to 100%,containing 0.1% DEPC, after which they were air dried.  
Specific localization of probe mRNA was accomplished by in situ hybridization using an 
antisense riboprobe synthesized with T7 RNA polymerase (Amersham, UK).  
b) Production of Riboprobes Labelled with 35S 
The mastermix components used the invitro transcription procedure for generation of the 
riboprobes are listed in the table below. 
Mastermix Component Volume for 4 reactions Final concentration 
5 X Transcription Buffer 10μl 1X 
Rnasin 4 μl ~1.5U/μl 
DTT 2.8μl 11.2mM 
ATP, GTP, CTP mix 8  μl 1mM each 
35S-UTP 14μl 14μM and 5.6mM 
Table 2.0 - Mastermix constituents for production of riboprobes 
The constituents of individual reactions for the generation of probes are listed in the table 
below. 
Ingredient Full reaction Half Reaction 
Mastermix 9.7μl 4.85μl 
Probe 2.4μl 1.2μl 
Appropriate polymerase 0.4μl 0.2μl 
Table 2.1 - The constituents of an individual reaction 
Using separate Eppendorf tubes, the constituents for each probe were mixed well, spun down 
at maximum speed for 10 seconds, and left to incubate for 60 seconds at 37-40ºC. The template 
DNA was destroyed by adding 1μl DNAseI to each reaction tube, mixing the constituents well 
and spinning them down for a few seconds. The tubes were incubated at 37ºC for 15 minutes. 
The Chromaspin column was inverted several times to ensure proper mixing of the gel, the top 
and bottom cap were removed and the column placed in a micro-centrifuge tube and spun down 
at 700g for 3 minutes at 15ºC. The eluate and the first collection tube were discarded. 4μl 
RNAsin plus and 6μl 100mM DTT were added to a new collection tube. At the end of the 
incubation period, the bulk of the reaction mix in the Eppendorf tubes was added to the gel in 
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the column and the assembly spun down again. The eluate was collected and used for 
hybridization procedure or stored at -20ºC. 
c) Hybridization and post hybridization washes 
For the hybridization procedure, 50% dextran sulphate solution was heated to 80ºC in a water 
bath to reduce its viscosity. The total volume of the hybridization buffer was calculated based 
on the number of slides being processed (1x106cpm/section). The constituents of the 
hybridization buffer are listed below and were added in the following order: 
Ingredient Quantity/ml 
10X salts mixed in Denhardt's solution 100μl 
Formamide 500μl 
rRNA 30μl 
Dextran Sulphate 200μl 
1M DTT 10μl 
DEPC-treated Milli-Q water 16μl 
Probe 144μl 
Table 2.2 - The constituents of the hybridization buffer 
The hybridization buffer was heated to 80ºC for 1 minute and then spun down to reduce 
aerosols. 15μl of the buffer was pippetted onto each section after which a cover-slip was 
lowered down onto the slide until the whole section was covered. The slides were stored in a 
humidified box lined with blotting paper soaked in 50% formamide (Biorad AG-501), the box 
was sealed with PVC tape, and left overnight at 55ºC.The slides were placed in a clean rack, 
immersed in 1000ml of 50% formamide buffer at 55ºC, and placed on a rocking incubator. The 
buffer was changed thrice over a period of 3 hours. The slides were washed in 1000ml 
TNEbuffer(Tris/HCl-Sigma T3253, EDTA-Sigma E5134) at least 9 times to wash out traces 
of formamide. The constituents of TNE buffer were as follows. 
Ingredient Quantity/ml 
3M Nacl 176.2g 
100nM  Na2HPO4 14.2g 
100mM Tris/HCl 100ml 
50mM EDTA 250ml 
Milli-q water 650ml 
Table 2.3 -TNE buffer constituents 
Slides were then incubated in 100μg/ml RNAse A (Sigma R-5503) in TNE buffer for 1 hour at 
37ºC after which the slides were washed in 2x standard saline citrate buffer (Sigma S-6689) 
for 30 minutes at 65ºC to wash off unbound probe fragments. The slides then passed through 
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graded ethanol (30% to absolute) containing 0.3M ammonium acetate (Sigma A-1542) to 
ensure fixation of labelled hybrids. The slides were covered and left to dry overnight.  
d) Autoradiography 
This procedure was carried out in a darkroom using a 902 filter and a 15W bulb. A water bath 
containing 25ml Milli-Q (Sigma W-4582) water was heated to 45ºC. Ilford K5 solution was 
added to make up volume to 45ml and left for 5-10 minutes for emulsion to melt. The slides 
were dipped into the stirred emulsion, placed flat on a cool metal surface to dry for 1 hour, 
placed in a black plastic bag, sealed with tape and left at 4ºC for 7 days to expose emulsion to 
the radioactive probe. 
e) Developing, Counterstaining and Examination of slides 
The slides were immersed in pre-prepared D-19 developer (KODAK) for 4 minutes at 18ºC, 
followed by 1% acetic acid (Sigma A-6604) for 30 seconds, tap water for 30 seconds and 30% 
Sodium Thiosulphate (Sigma S-7026) for two changes of 4 minutes each. Giemsa counterstain 
(BDH, 35086) was used to discriminate epithelial structures and appendages.The sections were 
examined under conventional or reflected light and dark field conditions on an Olympus BH2 
epi-illumination microscope and photographed using a camera that allowed individual 
autoradiographic silver grains to be seen as bright objects on a dark background. Pictures were 
saved on an Apple Mac (Apple Inc) and viewed using Adobe Photoshop CS2 (Adobe Systems).  
f) Technical help 
The experimental work was carried out at Cancer Research United Kingdom (CRUK), (London 
Research Institute, Cancer Research UK, Lincoln's Inn Fields Laboratories, 4 Lincoln's Inn 
Fields, London, WC2A 3LY, United Kingdom), in collaboration with Richard Poulsom’s lab 





(I) Wax-embedded tissue sections 
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a) β-Actin: (Control tissues) 
 
Figure 2.0: The expression of β-Actin mRNA in foetal skin (a, d), ventricular musculature 
(b, e) and alveolar epithelium (c, f).Panels a-c show brightfield views of histological sections 
of the tissues examined. Panels (d-f) show the same views photographed using epi-illumination 
to visualize the silver grains generated by the radioactive probe. β-actin is expressed strongly 
in foetal skin and is restricted mainly to the epithelium with only slight expression in the 
connective tissue (d). It is also strongly expressed in heart musculature (e), in lung alveolar 




b) B-Actin: (Adult skin and OSCC) 
 
Figure 2.1: The expression of β-actin mRNA in adult skin and OSCC sections.Histological 
sections of adult skin (a) and OSCC blocks examined are shown (b, c). Panels (d-f) show the 
same views photographed using epi-illumination to visualize the expression of β-Actin mRNA 
in adult skin (d) and OSCC sections (e, f). Strong expression of β-actin is evident in adult skin, 
restricted mainly to the epithelium with only weak expression in connective tissues. β-Actin 
expression was present in both epithelium and connective tissue of the cancer sections 




c) CEBP-α: (Control tissues) 
 
Figure 2.2: The expression of CEBP-α mRNA in foetal skin (a), heart musculature (b) 
and alveolar tissue (c). CEBP-α mRNA is strongly expressed in foetal skin (d), localized 
mainly to the basal layers of the epithelium. Weak expression is seen in heart musculature (e) 




d) CEBP-α (adult skin and OSCC) 
 
Figure 2.3: Expression of CEBP-α mRNA in adult skin (a), and OSCC sections (e, f). 
Moderate expression of CEBP-α was seen in adult skin mainly in the epithelium (d). Moderate 
expression in seen in OSCC sections examined (e, f) and was restricted to epithelial structures 




e) Vimentin: (Control Tissues) 
 
Figure 2.4: Expression of Vimentin mRNA in foetal skin (a), heart musculature (b) and 
lung tissue (f). Very strong expression of Vimentin is seen in foetal skin (d), localized mainly 
to the epithelium but with moderate to high expression seen in connective tissue. Heart tissue 
shows moderate expression throughout (e). Strong expression is evident in alveolar epithelia 




f) Vimentin (Adult skin and OSCC) 
 
Figure 2.5: Expression of Vimentin mRNA in adult skin (a) and OSCC sections 
(b,c).Weak expression of vimentin is seen in adult skin in both epithelium and connective tissue 
(d). Both OSCC sections (e, f) show moderate to high levels of vimentin expressed in both 
connective tissue and epithelium with highest levels in the basal epithelium. The levels detected 




g) Notch3: (Control tissues) 
 
Figure 2.6: Expression of Notch3 in foetal skin (a), heart musculature (b) and lung 
tissue (c). Moderate expression of Notch3 is seen in foetal skin, localized mainly to the 
epithelium (d). Heart tissue shows very low expression throughout (e). Strong expression is 




h) Notch3 in adult skin and OSCC 
 
Figure 2.7: Expression of Notch3 mRNA in adult skin (a) and OSCC sections (b, c).Low 
expression of Notch3 is seen in adult skin (d) and is scattered throughout the epithelium and 
connective tissue. Strong expression of Notch3 was present in both epithelium and connective 
tissue of OSCC sections (e, f) in both superficial and deep layers of the tumours. The Notch3 




i) DKK3: (Control tissues) 
 
 
Figure2.8: Expression of DKK3 mRNA in foetal skin (a), heart musculature (b) and 
lung tissue (c). DKK3 mRNA is strongly expressed in the epithelium of foetal skin (d). Heart 
muscle shows moderate expression (e) whereas moderate poorly-localised expression is seen 
in lung tissue (f). The tumour sections probed for DKK3 were of questionable quality and were 




j) PSCA (Control tissues)
 
 
Figure 2.9: Expression of PSCA mRNA in foetal skin (a), heart musculature (b) and 
lung tissue (c). PSCA mRNA is moderately expressed in sections of foetal skin (d) and is 
present in both epithelium and connective tissue. However the quality of the slides is poor 
because of the background. Heart muscle (e) and lung tissue (f) show little or no expression 
and background staining remains a problem. The OSCC sections were again of questionable 





Probes for in-situ hybridization were designed based on Affymetrix data obtained through 
experiments carried out with Locke and co-workers in 2005. Markers that showed differential 
expression in holoclones and paraclones were selected for in-situ probe design and it was 
hypothesized that the molecules selected might serve as stem cell markers and reveal stem cell 
zones in normal tissue sections and cancer blocks. Proposed markers included CEBP-, DKK3, 
Pirin, Hurpin7, IGFB3, RDHL, PSCA, Erb-b3, Notch3 and Vimentin. B-Actin was selected as 
a control to confirm the presence of hybridizable mRNA in the tissue sections studied which 
included foetal skin, lung tissue, heart musculature, adult skin and cancer blocks 1 and 2.  
β-actinwas used as a control as it is known to be stably expressed in many types of tissues 
(Ruan and Lai, 2007). Strong β-Actin expression was evident in both foetal and adult skin(2.1 
a, c; 2.2 a, c)restricted mainly to the basal epithelium with a scanty signal detected in connective 
tissue. β-Actin was also detected in heart musculature and lung tissue (Figure 2.1b, e; c, f). 
Both cancer blocks showed a good signal from the β-Actin probe in epithelium and connective 
tissue(2.2 c-f). These control tissues indicated that both the probe and the vector functioned 
well to give a good signal in both the cancer blocks and the control tissues. Out of the nine 
probes examined, only CEBP-α (2.2, 2.3), Notch3 (2.6, 2.7) and Vimentin (2.4, 2.5)showed a 
good differential hybridization signal in cancer sections compared to normal adult skin. DKK3 
showed some promise as a marker but the OSCC slides did not develop cleanly and were lost 
owing to technical reasons(2.8 a-f). Although the probes for these molecules showed a higher 
signal in cancer blocks, they failed to localize stem cell zones/hot spots as had been hoped at 
the beginning of the study. This was disappointing as, in addition to date from Locke et al 
(2005), altered expression of these molecules has previously been associated with cancer and 
stem cells (Dahl and Veeck, 2012; Blanpain and Fuchs, 2006). 
Impaired function of CEBP-α contributes directly to the development of acute myeloid 
leukemia and decreasing CEBP-α function represents a promising target for novel therapeutic 
strategies in this disease (Mueller et al, 2006). CEBP-α mRNA was strongly expressed in the 
basal epithelium of foetal skin (Figure 2.2 a, c) whereas only weak expression was evident in 
adult skin (Figure 2.3 a, c). Both heart and lung tissue showed weak and diffuse hybridization 
of the probe (Figure 2.2 b-f). However both cancer blocks showed moderate to strong 
hybridization of the probe restricted to epithelial structures, namely basal epithelium and 
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keratin pearls (Figure 2.3 c-f). Although not localised to distinct zones, it was still evident that 
expression of this molecule was higher in the cancer blocks as opposed to adult skin.  
Notch proteins have been shown to be key modulators and regulators of stem cell self-renewal 
in diverse populations (Molofsky et al, 2004) including hemopoeitic and neural stem cells. 
Conversely, Notch proteins have also been linked to promoting the differentiation of glial cells 
and are known to play a key role in maintaining the stem cell niche in the drosophila (Xiaoqing 
Song et al, 2007). Similar mechanisms might exist in oral cancer cell lines and enable stem 
cellpopulations to proliferate and remain undifferentiated.Very low levels of Notch3 mRNA 
were detected in adult and foetal skin (Fig 2.4 a, d; 2.5 a, d). Similarly, hardly any signal was 
detected in lung and heart tissue (Fig 2.4 b-f). Interestingly, a very strong signal was detected 
in sections of both blocks of SCCs (Fig 2.5 b-f) and Notch3 levels appear high in cancer as 
compared to normal skin.  
Vimentin was strongly expressed in foetal skin and lung tissue (2.4 d, e), being localized to 
basal and alveolar epithelia respectively. Probe hybridization was seen in most of the muscle 
architecture of the heart (2.4c, f). Moderate to high expression was seen in SCC blocks (2.5 e, 
f), which was interesting as a low signal was detected in normal adult skin (2.4 c),where the 
probe hybridized mainly to epithelium More studies of this probe would be worthwhile as this 
protein has been linked to the metastatic spread of epithelial tumours through epithelial 
mesenchymal transition (EMT), characterized by, among other events, up regulation of 
vimentin (Eastham et al, 2007) and it could play a crucial role in controlling the invasive 
properties of malignant stem cells. Furthermore EMT cells have been shown to be associated 
with stem cell properties and are able to reconstitute tumours in vivo in mice (Weinberg et al, 
2008). As discussed later, collaborative work done in the Mackenzie lab (Biddle et al, 2011) 
has shown that Vimentin mRNA is highly expressed in CD44high cells, the potential stem cell 
fraction in oral cancer cell lines and that this fraction also generates tumours when transplanted 
into mice. 
DKK3 is one of a family of soluble dickkopf (DKK) proteins that act as Wnt regulator proteins 
and there is evidence that increased expression of DKK3 in gastrointestinal stem cells promotes 
non-canonical Wnt signalling which could have a crucial role in maintaining the 
undifferentiated state of these cells (Marsh et al, 2008). DKK3 was expressed at moderate 
levels in both adult and foetal skin (Figure 5a, 5d) where it localized strongly to the basal 
epithelium, although expression was stronger in foetal skin. Moderate expression was evident 
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throughout heart musculature) but little or no DKK3 mRNA was detected in lung Most of the 
OSCC sections had to be discarded owing to technical failure. 
The rest of the probes examined, namely Hurpin, Pirin, RDHL and Erb-b3, were similarly 
selected on the basis of their differential expression in holoclones and paraclones (Locke et al, 
2005) and suggestions in the literature of their potential differential expression in stem cells. 
However these probes (only PSCA is shown, 2.9) failed to elicit any interesting patterns of 
probe localization. Thus, although it was hoped that patterns of stem cell localization within 
oral mucosa and oral tumours might be revealed with these probes, the observed distribution 
of label did not provide such information. Vimentin and CEBP-α showed good differential 
expression patterns in the wax-embedded sections and were selected for further examination 
of OSCC lines alongwith BMI1 and Lgr5. In the intestinal epithelium, cells expressing Lgr5 
were shown to possess stem cell properties and are responsible for its maintenance, and it is 
also known that dysregulation of Lgr5 signalling leads to colon cancer (van der Flier and 
Clevers, 2009). Bmi-1is a memberof the polycomb family that represses the transcription of its 
target genes via epigeneticmechanisms (Hanson et al, 1999) and, Lessard and Sauvageau 
(2003), showed in a mouse model of leukemia that Bmi-1 is also needed for the self-renewal 
of the leukemia initiating cell (LIC). It is now known to regulate stem cell potential in a range 
of cancers (Al-Hajj and Clarke, 2004). OSCC lines showed localization of the probe in all the 
cells examined and was seen in the nucleus as well as the cytoplasm and showed very poor 
specificity. It was hoped that this study would help localize and identify stem cells in OSCC 





2.2: Identification and isolation of stem/stem-like cells in OSCC cell lines 
2.2.1   Introduction 
Studies were undertaken to confirm that malignant HNSCC cell lines, grown under similar 
culture conditions, consistently generate hierarchical colony morphology patterns 
corresponding to stem, early and late transient amplifying cells. The expression of putative 
stem cell markers within holoclones, meroclones and paraclones was examined to find out if 
they could be used to identify and isolate stem cells within our cell lines. 3 markers of potential 
interest were selected, as suggested by the literature and previous work of the Mackenzie 
laboratory (Locke et al, 2005), and immunocytochemistry was used to analyse their expression. 
The first marker studied was CD44 as the literature indicates it to be one of the pivotal stem 
markers in head and neck squamous cell carcinomas (HNSCC) (Prince et al, 2007)and breast 
(Al-Hajj et al, 2003) and prostate cancers (Zhang et al, 2012). The next marker studied was -
catenin which has not only been linked to stem cell survival/renewal but has also been 
implicated in the process of epithelial mesenchymal transition (Smalhofer et al, 2009). The 
third marker studied was E-cadherin as it is closely associated with β-catenin and normally 
forms a catenin/cadherin complex within the cell. Disruptions in this complex are strongly 
linked to stem cell survival, EMT and poor prognosis (Smalhofer et al, 2009).  
Aims:  
 To study the growth patterns and morphology of different cell lines. 
 To identify stem cells in cell lines 
 To study the expression patterns of known stem cell markers in these cell lines 
 To investigate differences in the expression patterns of these markers within the 




2.2.2   Materials and methods 
2.2.2.1 Cell Culture 
All of the cell lines examined werederived from head and neck squamous cell carcinomas 
(HNSCC). The CA1 cell line was previously derived in our laboratoryfrom a biopsy of 
OSCC of the floor of the mouth (Mackenzie, 2004). Other lines examined were UK1 
(Mackenzie lab), H357 (derived by S. Prime from sporadic OSCC), Fanconi (Zeeburg  et al, 
2005) and 5PT (derived by T. Carey, University of Michigan). Unless otherwise stated cells 
from all lines were grown in RM+ medium. This is a basal medium (DMEM-F12) 
supplemented with 10% FBS, 2ng/ml epidermal growth factor (GIBCO), 0.4ug/ml 
hydrocortisone (Sigma), 5ug/ml insulin (Sigma), 20ug/ml transferring (Sigma), 100 U/ml 
Penicillin, 100ug/ml streptomycin and 20ug/ml glutamine (PAA). These were obtained from 
CRUK central stores, collectively available as the RM+ supplement. Cells were maintained at 
37ºC in an atmosphere of 5% CO2 / 95% air and were usually cultured in 75cm² T-Flasks 
(Nunc).For experimental use, all cell lines were plated at clonal density, i.e. 1000-2000 cells 
per ml, adding 10 ml RM+ per T-75 T-flasks. Good patterns of morphologic variation 
between colonies were usually visible by day 5. For some studies, cells were also plated at 
clonal density in 6-well plates or onto 13mm sterile glass cover slips inside 6-well plates in 
3ml DMEM/ RM+ medium per well. 
 
2.2.2.2 Immunocytochemistry 
a) Cells cultured in T-75 slide flasks 
Cells were fixed as required in either 4% buffered (7.0-7.2) paraformaldehydefor 15 minutes 
at room temperature or a 1:1 solution of acetone-methanol for 15 minutes at 4ºC. The cells 
were then washed once with phosphate buffered saline (PBS) and a drill was used to cut out 
the flask base. Areas of colony growth were outlined by a hydrophobic pen 
(DakoCytomation™) and allowed to dry. The cells were rehydrated in PBS for 10 minutes. To 
visualise surface proteins, the cells were blocked using a 2% solution of BSA in PBS or 
DMEM-F12 (basal medium) for one hour. Alternatively, for nuclear or cytoplasmic proteins, 
cells were permeabilized and blocked at the same time using 0.2%TritonX/ 2%BSA (IgG free) 
(all from Sigma) in PBS for a period of one hour. Following blocking or permeabilization the 
cells were washed x3 with PBS at 10 minute intervals.The primary antibodies used are listed 
in table 2.2.1 below. All primary antibodies were made up in PBS or DMEM-F12 with 5% 
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goat serum (Sigma). Following incubation with primary antibodies in a humidified atmosphere, 
either overnight at 4ºC or for 1 hour at room temperature, cells were washed three times in PBS 
with 10% Tween20 for 30 minutes at 10 minute intervals. Cells were incubated with 
concentrations of secondary antibodies as listed in Table 2.1.2 below. DAPI (1:100) was used 
as a nuclear counter stain after which stained areas of the flasks were covered with 
Immumount-Anti Fade reagent (Thermo Scientific) and covered with glass cover slips. The 
flasks were visualized immediately or stored at 4ºC.The cells were examined with a 
NIKONmicroscope (Nikon Eclipse TE 2000-S with Super High Pressure Mercury Lamp 
Power Supply) using fluorescence and phase contrast modes. 
Antibody Company Dilution Source 
CD44 BD Biosciences 1:100/1:250 Mouse monoclonal 
-Catenin Sigma 1:100 Mouse monoclonal 
ESA Miltenyi Biotech 1:1200 Mouse Monoclonal 
E-Cadherin Santa Cruz 1:100 Mouse polyclonal 
EGF-R Zymed 1:100 Mouse Polyclonal 
Table 2.4:  Table listing primary antibodies and concentrations used. 
Antibody Company Dilution Source 
Fitc conjugated Goat-anti-mouse Alexafluor 1:500 Goat 
Fitc conjugated Goat-anti-Rabbit Alexafluor 1:500 Goat 
Fitc conjugated Goat-anti-rabbit DAKO 1:60 Goat 
Table 2.5:  Table listing secondary antibodies used for visualization 
b) Cells cultured on cover slips 
Coverslips were fixed in either 5mls of a 4% solution of paraformaldehyde/formaldehyde for 
15 minutes at room temperature or a 1:1 solution of acetone-methanol for 15 minutes at 4ºC. 
A 6 by 6 cm glass slab was covered with tightly stretched parafilm to which evenly 
spaceddrops (18μl) of primary antibodies were applied. The primary antibodies used are 
listed in table 2.1.1 and were prepared as described in section 2.2.1. Cover slips bearing cells 
were removed from the 6-well plates and inverted onto the drops of primary antibody for 1 
hour at room temperature. The cover slips were then transferred onto a 25 μl drop of PBS 
with 10% Tween20 for 5 minutes and this was repeated three times over a period of 10 
minutes..Appropriate secondary antibodies were prepared in DMEM-F12 with 5% goat 
serum (Sigma) as described in section 2.2.1 and the cover slips were inverted onto them for a 
period of 1 hour at room temperature. After further washing, coverslips were counterstained 




2.2.3  Results: 
 
A)  Cellular heterogeneity within OSCC cell lines. 
 
Figure 2.10: Colony formation by OSCC cell lines(Scale=50µm). 
The figure above shows the colony morphology generated by CA1 (a-c) and H357 (d-f) cells 
after five days. Both cell lines give rise to round colonies (H) called holoclones (a, d)made of 
small tightly adherent cells. They also form meroclones (M) made up of looser cells that are 
larger in size (b, e). In addition to this all cell lines also form small abortive colonies (c, f) that 




B)  The expression of CD44 in cell lines derived from OSCCs 
I) CA1 
 
Figure 2.11: The expression of CD44 in the CA1 cell line (Scale=50µm). A culture of CA1 
cells grown for 5 days showing a phase contrast image (a) of a holoclone colony (H) next to a 
paraclone (P), stained with DAPI (b) and anti-CD44 antibody (c).The holoclone consists of 
tightly packed cells with somewhat larger less tightly packed cells around the periphery. The 
staining for CD44 is restricted mainly to the cell surface region with little or no signal in the 
cytoplasm (c). CD44 expression also appears higher in the central cells of the holoclone than 





Figure 2.12: The expression of CD44 in H357 cells (Scale=50µm).A culture of H357 cells 
grown for 5 days showing a phase contrast image (a) and shows a holoclone (H) next to a 
paraclone (P) stained with DAPI nuclear stain (b) and anti-CD44 antibody (c). CD44 is strongly 
expressed at the surface of cells in holoclones compared to paraclones where low expression 
is seen. The central cells of the holoclone stain markedly strongly for CD44 than those at the 




III) Fanconi 1131 
 
Figure 2.13: The expression of CD44 in Fanconi VU1131 cells (Scale=50µm).A phase 
contrast image of a culture of Fanconi cells grown for 5 days (a)showing a holoclone (H) next 
to a paraclone (P) stained with DAPI nuclear stain (b) and anti-CD44 antibody (c). CD44 is 
strongly expressed at the periphery of cells in holoclones compared to paraclones where only 
low levels are detected. The holoclone appears to be made of two cell types, those that stain 
markedly strongly for CD44 and are towards the center of the colony and those which express 
lower levels which are around the edge of the colony. The edge cells show evidence of nuclear 
translocation of CD44 (c; insets) which is slightly different from what was seen for CA1. The 
paraclone next to the holoclone shows weaker expression of CD44 in the peripheries and 




C) The expression of β-catenin in cell lines derived from OSCCs. 
I) CA1 
 
Figure 2.14: The expression of β-catenin in CA1 cells(Scale=50µm). A culture of CA1 cells 
showing a phase contrast image of holoclones and a paraclone (a) stained with DAPI nuclear 
stain (b) and anti-β-Catenin-FITC antibody (c). Ca1 cells form holoclones, meroclones and 
paraclones as discussed. Again holoclone cells tend to be tightly clustered with small cells 
forming the center of colonies and larger cells arranged around the edge (a). The expression of 
β-catenin is seen in the cell surface with little or no expression in the cytoplasm. Holoclones 
stain brighter than paraclones and meroclones and the cells forming the centres of colonies 
show higher expression than those at the edge. Cells at the edge also show nuclear expression 




Figure 2.15: The expression of β-catenin in H357 cells (Scale=50µm). A phase contrast 
image of a holoclone formed from the culture of H357 cells (a) stained with DAPI nuclear stain 
and anti-β-catenin-FITC antibody (c). The cells in the center of the holoclone are tightly packed 
while those at the edge are loosely arranged and are slightly larger compared to the central 
cells. β-catenin expression is seen on the cell surface with little or no expression in the 
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cytoplasm and it appears to be higher in the central cells of the holoclone than those at the edge. 
Cells at the edge also show nuclear localization of the protein (insets; c) and reduced expression 
at the cell surface. 
 
III) VU1131 Fanconi 
 
Figure 2.16: The expression of β-catenin in Fanconi VU1131 cells (Scale=50µm). A phase 
contrast image of a holoclone formed from culture of VU1131 cells (a), stained with DAPI 
nuclear stain (b) and anti-β-catenin-FITC antibody (c). As stated before, Fanconi cells tend to 
form predominantly holoclone like colonies and the formation of meroclones and paraclones 
is scarce. Central holoclone cells express β-catenin in primarily on the cell surface and weak 
expression is also seen in the nucleus. Cells at the edge however show the opposite with very 
strong levels expressed in the nucleus and very weak levels evident in the membrane. This can 





D)  The expression of E-cadherin in OSCC cell lines. 
I) CA1 
 
Figure 2.17: The expression of E-cadherin in CA1 cells (Scale=50µm). A phase contrast 
image of a holoclone colony formed from CA1 cells (a) stained with DAPI nuclear stain (b) 
and anti-E-cadherin antibody (c). E-cadherin is localized mainly to the cell surface and appears 
stronger within central cells as compared to the edge which show weaker expression of the 




Figure 2.18: The expression of E-Cadherin in H357 cells (Scale=50µm).A phase contrast 
image of a holoclone colony formed from culture of H357 cells (a), stained with DAPI nuclear 
stain (b) and anti-E-cadherin-FITC antibody (c). E-cadherin expression is seen mainly at the 
cell surface and cells within the center of the holoclone show stronger expression as compared 
to those at the edge and on closer examination E-cadherin can be seen to be present in the 
nucleus (inset bottom right, c). The inset on the top right shows a magnified view of the center 





III) Fanconi 1131 
 
Figure 2.19: The expression of E-cadherin in Fanconi 1131 cells (scale=50µm).A phase 
contrast image of a holoclone (H) and paraclone (P) from a culture of Fanconi 1131 cells for 5 
days (a), stained with DAPI nuclear stain (b) and anti-E-cadherin antibody (c). E-cadherin is 
localized mainly to the cell surface of holoclone cells and moderate staining is seen in the 
cytoplasm. The paraclone shows lower expression of E-cadherin and cells show low membrane 
expression and peri-nuclear accumulation of E-cadherin to the nucleus. The cells at the edge 
of the colony express lower levels of E-cadherin (c) than those in the center. The insets in (c) 
show magnified images of these cells showing cells with lowered E-cadherin in the membrane 




E) Time-Lapse video analysis of OSCC cell lines. 
To study the division of cells during colony formation they were cultured in an incubator with 
a microscope and a camera, and photographed at 15 minute intervals to create time-lapse 
videos. Videos were created of cells immediately after plating and also after cells had formed 
established colonies discussed later. (i) Early cultures 
CA1Control.avi (Command Line)H357Control.avi (Command Line)
 
Note: To play files  
1. use VLC media player (VideoLAN), the installation file for which has been provided 
in the SOFTWARE folder on the CD, 
or 
2. To view in Windows media player, kindly install K-lite codec pack, also provided in 
the SOFTWARE folder on the CD. 
(The files have been checked by Kaspersky Pure Antivirus [Kaspersky Labs™] and do not 





Each of the cell lines examined consistently showed the generation of three types of colony 
morphologies, classified as holoclones meroclones and paraclones after cells were plated at 
clonal densities, as previous work with these cell lines has shown that colonies formed under 
these conditions are usually clonal in origin. It also appeared that the cells forming holoclones 
are heterogeneous. The center of the holoclone is made up of tightly packed cobblestone shaped 
cells and slightly larger cells at the edge that are arranged loosely.  
 
Figure 2.20: The centres and edges of holoclone colonies. 
When stained for CD44, holoclones show the brightest staining, with meroclones being the 
next in intensity and the weakest signal being detected in paraclones. The CD44 in holoclones 
seems to be predominantly present in the cell surface in all the cell lines examined. However 
there is some variation in the VU1131 Fanconi line in that there seems to be some nuclear 
expression of CD44 in addition to the membrane staining consistently seen. This nuclear 
localization is present in mostly all the cells making up the meroclones and paraclones and only 
weak nuclear staining of CD44 can be detected within the central cells of the holoclone (Figure 
2.13) but it seems to be more pronounced in the cells making up the edge. Also seen 
consistently was the pattern of strong CD44 expression in the central cells of the holoclones 
and weak expression in cells making up the edges of these colonies (Figure 2.20) which 
suggests that the cells are undergoing some change at the central/peripheral cell interface and 
led to the hypothesis that the cells in the center are different from those at the edge in that the 
central cells better represent the stem cell population. 
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E-cadherin was shown to be expressed at the protein level in all the cell lines examined. In 
holoclone colonies E-cadherin was shown to be present at the cell periphery with little or no 
expression in the cytoplasm. Interestingly the central cells of the holoclone were shown to 
express higher levels than those making up the edge of the colonies. The scattered fibroblast-
like cells showed reduced expression in the membrane and very weak levels within cytoplasm. 
A few cells also showed nuclear accumulation of the protein.  
-Catenin was seen to be expressed in all three cell lines examined however the patterns 
observed differed. CA1 and H357 cells showed strong expression of the protein almost 
exclusively at the cell periphery with very little being present in the cytoplasm. Cells at the 
edge showed reduced levels. In the Fanconi 1131 cell line, -catenin was expressed in the cell 
membrane and in the nucleus of all the cells in the colonies but nuclear accumulation was more 
marked in cells present at the edge. 
A recent study carried out by Xieand co-workers(2008) showed that inhibition of the CD44 
molecule by RNAi not only increased the susceptibility of hepatocellular carcinoma cells to 
apoptosis by anti-cancer drugs, but decreased tumourigenicity as well. This study supports the 
study of CD44 as a stem cell marker in oral cell lines as the same responses could help move 
us a step closer in targeting these troublesome cells therapeutically and specifically. Recent 
work done in the lab also suggests that down regulating CD44 in oral cell lines negatively 
affects clonogenicity. The fact that CD44 is lowered around the edge could mean that the cells 
at the edges of holoclone colonies are differentiating into more committed cells, but then what 
does the nuclear translocation of CD44 signify? A study on colon cancer cells has shown that 
CD44 can migrate to the nucleus where it binds to promoters of TWIST and other genes 
involved in invasion and metastasis (Su et al, 2011) and that cells with nuclear CD44 showed 
increased invasion, characteristics of EMT cells, and increased tumour initiation when 
transplanted into mice. Another study showed that nuclear translocation of CD44 is followed 
by the formation of a STAT3/CD44 complex that then binds to the cyclin D1 promoter, 
enhancing cell proliferation (Lee et al, 2009). These data suggest that the nuclear translocation 
of CD44 seen in OSCC lines in our lab could also be an indicator of cells acquiring invasive 
traits. 
The loss of membranous E-Cadherin has been shown to be important in the formation of 
carcinomas from benign tumours (Hollier et al, 2009) and this cell adhesion protein has been 
linked to EMT with its loss appearing to be a rate limiting step in this process. EMT is also 
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characterized by a change in -catenin location from the membrane to the nucleus as shown by 
Brabletz-Schmalhofer and co-workers (2009). They showed that loss of E-cadherin 
characterizedepithelial mesenchymal transition (EMT) and this was usually accompanied by 
dysregulation of -catenin. Accumulation of nuclear -catenin increases as E-cadherin is 
downregulated. In normal epithelial cells, membrane localized β-catenin exists in a junctional 
complex with E-cadherin but once this complex is inactivated, free -catenin translocates to 
the nucleus where it activates target genes involved in oncogenesis and tumour progression 
(Joo et al, 2001; Hay, et al 2002). Another study carried compared the expression of E-cadherin 
and β-catenin in normal and cancerous breast tissues and how this correlated with changes in 
CD44 expression (Bankfalvi, 1999). This comparative study showed that reductions in E-
cadherin and β-catenin were routinely seen in cancerous tissue, correlated strongly with nodal 
metastasis, and also resulted in poor survival when accompanied with a downregulation in 
CD44v6. The integrity of the E-Cadherin and β-Catenin complex is vital for cell adhesion and 
disruptions of this adhesion complex are pivotal in the development of metastatic potential and 
the acquisition of invasive potential (Brabletz et al, 2009). The results above collectively 
suggest that there is some change going on at the edge center interface of holoclones as 
indicated by the loss of cell surface CD44 and E-cadherin and the reduced expression of β-
catenin and its translocation to the nucleus. This could mean that the cells are either 
differentiating or undergoing some other change similar to EMT.On video it can be seen that 
when holoclones form, 2 types of cells exist, the ones forming the central zone and the other 
the colony periphery. The central cells appear relatively stationary and adhere tightly to other 
cells and have characteristic cobblestone morphology. These cells are also seen to divide to 
maintain the central region of the holoclone. Cells at the edge of colonies are spindle-shaped 
in appearance and appear to want to break away from the colony. There are also spindle-shaped 
cells lying outside the edges of the colonies that are highly motile and make contact with other 
cells. Further, these spindle cells appear to be generated from the colony itself. The links for 
the movies are below. 
These observations led into the next part of this study whichrevolves around Fluorescence 
Activated Cell Sorting (FACS) and analysis of subpopulations of cells within different cell 
lines. This involves the detection of CD44 at the protein level in cells present in suspension 
form. This was done to investigate whether it was possible to (a) isolate CD44high and CD44low 
cells and (b) whether this difference could be used to predict stem like potential of these cells 
and was it reflected in the colony morphology and count generated as a result. 
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The patterns of expression of CD44revealed by immunocytochemistry indicated that although 
most cells show some staining for CD44 there is a wide range of levels of CD44 expression. 
Prince and co-workers (2007) have suggested that CD44 positive cells, when isolated by FACS, 
are more tumorigenic when transplanted into NODSCID mice. Harper and co-workers (2007) 
had previously associated CD44 expression with clonogenicity in OSCC cells. Further studies 
were undertaken to see whether cells which stained brightly for CD44 (CD44high/+) were 
different from those which did not (CD44low/-). The questions asked were (a) whether it was 
possible to separate the CD44high/+ cells from CD44 low/-cells and (b) which of these 2 cell types, 
when isolated and cultured, showed the most clonogenicity. The FACS used to carry out these 
investigations, relies on a machine to analyze single cellsin suspension using a laser system 
that also enables isolationof cells with different expression levels of the proteins of interest. 
Cells were identified as a total population (a) preliminarily on the basis of forward and side 
scatter (FSC-A, SSC-A) using 2-dimentional histograms, where forward scatter is a measure 
of cell size and side scatter that of cell complexity and granularity and were gated (b) to exclude 
cell clumps and subcellular debris giving rise to the parent population (p1). Dead cells (black) 
were excluded and viable cells (red) were selected by staining cells with DAPI and gating those 
that were negative (c). The figure below explains this procedure and this was done for each of 





Figure 2.21: Selection of suitable cells from within the total population 
The cell lines chosen were stained with mouse PE-conjugated FACS anti-CD44 antibodies 
with the cells first analyzed, and then sorted into and collected as two populations one CD44high 
and the other CD44low. These two populations were plated at clonal density and the numbers 
of colonies formed by each sorted fraction counted. 
 
2.3.2 Materials and methods 
FACS: 
Cells from OSCC lines were seeded at clonal density (2000 cells/ml) in RM+ medium in T75 
cell culture flasks and grown for 5 days. 24 hours before harvesting the cells, the medium was 
changed to basal DMEM/F12 medium as it was thought that it improved the specificity of the 
staining due to the lack of EGF and other additives, normally present in the RM+ medium. The 
cells were washed once with PBS and detached using Accutase (PAA) or Trypsin-EDTA (1%) 
for 5-10 minutes. The Accutase or trypsin was neutralized with an equal amount of DMEM-
F12 with serum and the cells were transferred to a sterile Falcon tube and spun down at 
1500rpm at 4ºC. The medium was aspirated and the pellet resuspended in sterile PBS 
containing 1% FBS, again spun down, the supernatant aspirated, and the cells resuspended in 
300 l PBS containing 1% FBS. 5l of either PhycoErythrin (PE)-conjugated or FITC-
conjugated anti-CD44 antibody was added and cells were left on ice in the dark for 15-20 
minutes. Unstained control cells were used to calculate autofluorescence. After 20 minutes 1ml 
of PBS+1% FBS was added, the Eppendorf centrifuged at 4C, 1500 rpm for 5 minutes, and 
the pellet washed with PBS, again spun down and resuspended in 1 ml PBS+1%FBS and 
transferred to a sterile FACS tube. Samples were analyzed and sorted using the BD FACSARIA 
cell sorter with cells from selected gates collected and plated at clonal densities. 
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Before sorting, cells were counted and samples were normalized for similar cell numbers and 
an equal quantity of antibody was used so as to give equal levels of cells stained. Three repeats 
were plated for each of the samples collected and were used for colony counts. 
Statistical analysis was performed using Microsoft Excel and unless otherwise stated all data 
is based on at least three experimental repeats and are reported as mean (average) ± standard 
deviation (SD). The student’s t-test was used to analyze statistical significance between the 
studied samples. The table below shows the values used to assess significance, denoted ‘*’ on 
the graphs. Data that was not statistically significant was left unlabelled. 
 





A) CA1 cell line: 
 
Figure 2.23: Flowcytometric analysis of CA1 cells.Representative FACS plots obtained for 
CA1 cells. Doublets were excluded using a forward vs. side scatter profile (A) and suitable 
cells were gated (P1). Unstained control cells were analyzed (B) and compared with cells 
stained by the PhycoErythrin-conjugated anti-CD44 antibody (C). 5-6% of the cells expressing 
the highest levels of CD44 (P2) were collected as representing CD44high cells and 5-6% of cells 
showing the lowest CD44 expression were collected as representing CD44low cells. Following 
collection, cells were cultured for 5 days and the colonies formed were counted.  
 
Figure 2.24: Growth of CD44high (a) cells vs. CD44low (b) CA1 cells. Cultures of CD44high 
(a) and CD44low (b) CA1 cells shown in phase contrast. Compared to CD44low cells, CD44high 
cells show robust colony formation, forming more holoclones, consisting of tightly packed 
small cells (H) and meroclones, made from larger but cohesive cells (M). CD44low cells show 
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poor clonogenicity mainly forming paraclones that show little growth and consist of larger 









CD44high 20.89 2.34 15.78 1.35 14.56 2.50 
CD44low 6.33 0.88 12.11 2.78 23.22 2.87 
Table 2.6: Colony counts for the CA1 cell line for CD44high vs. CD44low cells. 
 
 
Figure 2.25: Comparison of colony counts obtained for CD44high vs. CD44lowCA1 cells. 
The figure above shows the number of holoclones, meroclones and paraclones counted when 
the two sorted populations were plated out at clonal density and allowed to grow for five days. 
CD44high cells formed significantly more holoclones (17.67) and meroclones (19.33) per 1000 
cells as opposed to CD44low cells. CD44low cells formed the highest number of paraclones 
(20.33) per 1000 cells and this was significant. They formed the least number of holoclones 
(4.67). The total number of colonies formed by CD44high cells was also higher (48) than those 






Figure 2.26: Flowcytometric analysis of H357 cells. Representative FACS plots obtained for 
H357 cells. Doublets were excluded using a forward vs. side scatter profile (A) and suitable 
cells were gated. Cells were analysed as control without adding antibody to the sample (B) and 
after the addition of PhycoErythrin-conjugated anti-CD44 antibody (C). 4.4% of the cells 
expressing the highest levels of CD44 were collected as CD44high cells and 4.2% of cells 
showing the lowest or no expression were collected as CD44low cells. For this cell line the gate 
for CD44low cells was positioned further forward to ensure exclusion of cells expressing only 
background levels of fluorescence. Following collection, cells were cultured for 5 days and the 
colonies formed were counted.  
 
Figure 2.27: Growth of CD44high cells vs. CD44low H357 cells.Cultures of CD44high (a) and 
CD44low (b) H357 cells shown in phase contrast. CD44high cells show higher colony forming 
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efficiency and form more holoclones (H) and meroclones (M) thanCD44low cells (a). CD44low 
cells show poor colony forming efficiency and mainly form paraclones (P) that show little 









CD44high 28.67 2.96 17.11 1.64 15.33 1.15 
CD44low 8.67 0.67 11.33 2.03 23.33 1.86 
Table 2.7: Colony counts for the H357 cell line 
 
Figure 2.28: Comparison of colony counts obtained for CD44high vs. CD44low H357 cells. 
The figure above shows the number of holoclones, meroclones and paraclones formed when 
equal numbers of cells from the two sorted population were plated at clonal density and 
cultured for five days. CD44high cells formed significantly more holoclones (28.67) and 
meroclones (17.11) per 1000 cells as opposed to CD44low cells (8.67, 11.33). CD44low cells 
formed the highest number of paraclones (23.33) per 1000 cells and the least number of 
holoclones (8.67). The total number of colonies formed by CD44high cells was also higher (48) 





The potential role of CD44 as a stem cell marker in oral cancer cell lines was examined as it 
had been proposed as a marker for oral cancer stem cells by Prince (2007) who showed that 
CD44positive cells, but not other cells from the oral cancer samples were able to produce tumours 
when injected subcutaneously into nude mice at low numbers. As stated previously, work done 
in the Mackenzie Lab showed that the cells at the edge of a holoclone stain less strongly for 
CD44 than those in the center. Thus, the brighter cells at the center perhaps better represent the 
stem cell population and this differential pattern could be exploited using the cell sorter method 
to enrich reliably for stem cells. Cells were sorted on the basis of CD44 expression and the 4-
6% of the highest and lowest expressing cells wereselected as CD44high or CD44low. When 
plated out at clonal density, the CD44high population consistently produced more holoclones 
and meroclones and also formed a higher total number of colonies in comparison to the 
CD44low cells. This trend was also demonstrated in each of the three cell lines examined namely 
H357, Ca1 and UK1.It has been previously demonstrated that holoclones are composed of cells 
capable of extensive division, display self-renewal and restore cellular heterogeneity in the 
epidermis and in OSCC cell lines (Tudor et al, 2004; Potten et al, 1981). Although these 
observations encourage the acceptance of CD44 as a stem cell marker, it is still worthwhile to 
note that the overall number of clonogenic cells remains low as out of 2000 cells plated only 
48-60 colonies were counted on average for the CD44high population, which is less than 10% 
of the total cells plated. It could also be argued that the colony number is low owing to the fact 
that cells die during the sorting process as they are stressed. Laser capture sections of cells, 
taken from the centres and edges of holoclones, analyzed through qPCR for stem cell markers 
showed the central cells had high expression of stem cell signature genes (Biddle et al, 2001). 
Similar experiments performed on cultured murine keratinocytes showed that cells isolated 
from the centres of type 3 murine colonies showed high expression of stem cell genes compared 
to type 2 and type 1 cells (Tudor et al, 2007). These observations also suggest that CD44high 
cells within the center of holoclones are more clonogenic than the cells present at the edge, it 
also points out the fact that CD44 is not the only molecule related to clonogenicity and possibly 
interacts and functions synergistically with other molecules. Based on this, it was hypothesized 
that other markers, in combination with CD44 might play a role in better enriching for a stem 
cell population. CD24 is a small cell membrane protein comprising 27 amino acids and is a 
ligand for P-selectin (Aigner et al, 1998). The interesting fact about this protein is that it is 
usually not present in human adult tissues but has been found to be upregulated in human 
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carcinomas such as small cell carcinoma (Aigner et al, 1998). CD44highCD24low cells have been 
used to prospectively identify breast cancer stem cells in humans and injections of low numbers 
of these cells into mice gave rise to tumours (Al-hajj et al, 2005). This has been further 
reinforced by work published in a more recent paper (Mani, 2008). Thus experiments were 
undertaken to check the role of CD24 in OSCC and whether it could provide a better way to 




2.4 Detection of CD44 and CD24 at protein level using Fluorescent 
Activated Cell Sorting (FACS) 
 
2.4.1 Introduction: 
The initial FACS experiments demonstrated that CD44+ cells were different from CD44- cells, 
in being more clonogenic, i.e. formed more holoclones per number of cells seeded whereas 
CD44- cells formed more paraclones and meroclones. It was also demonstrated that CD44+ 
cells formed more colonies per number of cells seeded. Al-Hajj and Clarke (2003) had 
demonstrated that the combination of CD44 and CD24 and lineage markers could be used to 
sort out a population of stem-like cells from breast cancers that had a CD44highCD24low 
phenotype. To check whether CD24 plays a role in stemness  in OSCC, it was used in 
combination with CD44 to see if this could better enrich for stem-like cells in oral cancer lines. 
The protocol followed for cell selection was the same as discussed in section 2.2.2.1, shown in 
figure 2.21. 
2.4.2 Materials and Methods 
FACS was used to carry out these investigations and the principle has been discussed in the 
previous section. The cell lines used for this part of the study were CA1 and 5PTand were 
chosen to show that the trends seen were consistent over a range of OSCC lines. Cells from 
these lines were stained with FITC-conjugated anti-CD24 and PE-conjugated anti-CD44 
antibodies and the cells were first analyzed and then sorted into four quadrants. These were Q1 
(44+24-), Q2 (44+24+), Q3 (44-24-) and Q4 (44-24+) respectively. Cells were sorted into 
separate tubes and then seeded for cell culture at 1000 cells /flask in T25 culture flasks and 
cultured for 5 days. The type and number of colonies were counted under a microscope in 9 
(1cmX1cm) squares drawn on the bottom of each flask at 4X magnification. The following 
section deals with the results obtained. The gates were adjusted to include at least 5% of each 
population in order to have sufficient cells that recovered after the sorting process. Colonies 








1) FACS Analysis 
 
Figure 2.29: Flowcytometric analyses of CA1 cells stained with CD44 (PE) and CD24 
(FITC) antibodies. Representative Facsplots obtained for CA1 cells, stained with anti-CD44 
(PE) and anti-CD24 (FITC) antibodies. Doublets were excluded using a forward vs. side scatter 
profile (A) and suitable cells were gated. Control cells were analyzed without adding any 
antibody to the sample (B) and after the addition of PhycoErythrin-conjugated anti-CD44 and 
FITC-conjugated anti-CD24 antibody (C). As explained before, to improve the efficiency of 
the sort, the gates were positioned to include at least 5% of the total population studied with 
cells selected on either expression of the highest or the lowest levels. They were collected as 










2) Cell morphology 
 
 
Figure 2.30: Culture of sorted CA1 cells.Phase contrast images of CD44highCD24low (a), 
CD44highCD24high (b), CD44lowCD24low (c) and CD44lowCD24high (d).CD44highCD24low cells 
show good growth although they mostly formmeroclones and a few holoclones. 
CD44highCD24highcells form mostly holoclones but with a few dispersed paraclones. 
CD44lowCD24low cells show very poor growth and formed mostly small abortive paraclone 












3. Colony forming efficiency of sorted CA1 cells when plated at clonal density:  
Cells were plated for culture immediately after sorting (p0) and colonies were counted. 
Following, they were detached from the dish and plated again for colony counts to see if the 
trend seen could be repeated after the first passage (p1).  
(i) Cells plated immediately after sorting (p0): 
This section shows the type and number of colonies formed by plating the different cell 








       
Q1(44+24-) 31.50 4.82 82.70 7.13 46.33 6.43 
Q2(44+24+) 79.27 3.41 49.73 6.14 39.63 4.05 
Q3(44-24-) 15.10 2.35 43.80 7.23 86.23 7.60 
Q4(44-24+) 30.83 1.26 51.73 8.40 42.03 3.08 
Table 2.8: Colony counts for sorted CA1 cells (p0) 
 
 
Figure2.31: Colony forming efficiencies of sorted populations of CA1 cells immediately 
after plating (p0).Q2 (44+24+) double positive cells formed a significantly higher proportion 
of holoclones as opposed to the other populations (table 2.8). Q1 (44+24- ) cells formed the 
most number of meroclones and the next highest number of holoclones. Q3 (44-24- ) cells 
formed the highest number of paraclones and meroclones and the least number of holoclones. 
Q4 showed more holoclones and meroclones than Q3 but fewer paraclones. 
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(ii) Cells plated after first passage (p1): 
Following colony counts, cells were detached and replated at clonal density for further counts, 
also termed Passage 1 (p1). 
Quadrant Average Holo SEM Average Mero SEM Average Para SEM 
Q1(44+24-) 19.50 2.12 30.30 1.70 42.25 1.77 
Q2(44+24+) 40.00 3.54 24.15 6.86 31.55 4.17 
Q3(44-24-) 12.50 2.83 23.15 1.91 51.20 8.77 
Q4(44-24+) 16.05 2.76 31.95 2.05 36.63 1.59 
Table 2.9: Colony forming efficiency of sorted CA1 populations at first passage (p1) 
 
Figure 2.32: Colony forming efficiency of sorted CA1 cells after first passage 
This graph shows the numbers of the different types of colonies counted for each quadrant 
examined after the cells had been passaged once. The cells obtained from quadrant Q2 
(CD44highCD24high) still show a significantly higher number of holoclones than the other 
quadrants. Q3 still shows the highest number of paraclones counted. The overall numbers of 





4) Average total number of colonies formed immediately after sorting (p0) and at 
first passage (p1) 
Quadrant  CA1(p0) SEM  CA1(p1) SEM 
Q1(44+24-) 170.0 2.8 93.5 6.4 
Q2(44+24+) 175.5 13.4 106.0 5.6 
Q3(44-24-) 139.0 2.8 84.0 1.3 
Q4(44-24+) 136.5 16.3 84.0 7.1 
Table 2.10: Average total number of colonies formed by the sorted populations 
immediately after sorting (p0) and after first passage (p1).  
 
Figure 2.33: The average total number of colonies formed immediately after plating (p0) 
and after the first passage (p1).The overall number of colonies formed by all the four sorted 
populations after the first passage was also significantly less (Q1-93.5, Q2-106, Q3-84 and Q4-
84) as compared to the numbers formed immediately after plating (170, 175, 139, 136), and 
are listed in the order CD44highCD24low (Q1), CD44highCD24high (Q2), CD44lowCD24low (Q3) 







Quadrant % Holoclone %Meroclone %Paraclone Total Colonies 
Q1(44+24-) 19.7 50.3 30.0 170.0 
Q2(44+24+) 45.1 29.9 25.7 175.5 
Q3(44-24-) 12.6 29.8 57.5 139.1 
Q4(44-24+) 22.7 43.9 33.3 136.5 
Table 2.11: Colony forming efficiencies of sorted cells immediately after plating 
Quadrant %Holoclone %Meroclone %Paraclone Total Colonies 
Q1(44+24-) 22.5 33.7 43.8 93.5 
Q2(44+24+) 40.9 27.4 32.5 106.0 
Q3(44-24-) 17.3 29.2 53.5 84.0 
Q4(44-24+) 21.4 36.3 42.3 84.0 
Table 2.12: Colony forming efficiencies of sorted cells after first passage 
The tables above show the percentages of holoclones, meroclones and paraclones formed for 
each of the sorted quadrants immediately after plating (table 3.3f) and after the first passage 
(table 3.3g). The extreme right hand column shows the total numbers of colonies counted for 
each set of experimental runs.CD44highCD24high cells (Q2) consistently formed the highest 
percentage of holoclones, immediately after plating (45%) and also after the first passage 
(40.09%). The percentage of paraclones formed by these cells also increased after the first 
passage (25.07%, 32.55%). They also gave rise to the most number of colonies compared to 
all the other quadrants (175.5, 106). However the number of colony forming cells seemed to 
decrease after the first passage for all the 4 quadrants examined. The average number of 
paraclones increased after the cells were passaged. Meroclones formed by 
CD44highCD24lowdecreased significantly after the first passage (p0=50.29; p1=33.69) and they 
showed a significant increase in the percentage of paraclones formed. The highest percentages 
of paraclones were counted for CD44lowCD24low cells and this remained the case immediately 









B) 5 PT cell line 
1) FACS Analysis 
 
Figure 2.34: Flowcytometric analyses of 5PT cells stained with anti-CD44 (PE, y-axis)) 
and anti-CD24 (FITC, x-axis) antibodies.Representative Facsplots obtained when CA1 cells 
were stained with anti-CD44 (PE) and anti-CD24 (FITC) antibodies. Doublets were excluded 
using a forward vs. side scatter profile (A) and suitable cells were gated. Control cells were 
analyzed without adding any antibody to the sample (B) and after the addition of PhycoErythrin 
(PE)-conjugated anti-CD44 and FITC-conjugated anti-CD24 antibody (C). As explained, to 
improve the efficiency of the sort, the gates were positioned to include at least 5% of the total 
population studied with cells selected on either expression of the highest or the lowest levels. 
They were collected as CD44highCD24low (Q1), CD44highCD24high(Q2), CD44lowCD24low (Q3) 




2) Cell morphology: 
 
Figure 2.35: Culture of sorted 5PT cells.Phase contrast images of CD44highCD24low (a), 
CD44highCD24high (b), CD44lowCD24low (c) and CD44lowCD24high (d). CD44highCD24low cells 
showgood growth although they mostly formed meroclones and few holoclones. Panel (b) 
shows the colonies generated by CD44highCD24high cells that form mostly holoclones with a 
few scattered paraclones. CD44lowCD24low cells showed very poor growth and formed mostly 
small abortive colonies (c). CD44lowCD24high cells form few holoclones, forming mostly 




3) Colony forming efficiency of sorted 5PT cells when plated at clonal density:  
Cells were plated for culture immediately after sorting (p0) and colonies were counted. 
Following, they were detached from the dish and plated again for colony counts to see if the 
trend seen could be repeated after the first passage (p1).  
(i) Cells plated immediately after sorting (p0): 
This section shows the type and number of colonies formed by plating the different cell 
populations collected immediately after sorting, also termed Passage 0 (P0). 
Quadrant Average Holo SEM Average Mero SEM Average Para SEM 
Q1(44+24-) 24.50 2.12 65.75 4.60 39.00 0.71 
Q2(44+24+) 63.60 5.80 36.00 2.12 33.00 3.54 
Q3(44-24-) 16.75 5.30 38.25 15.91 82.50 10.61 
Q4(44-24+) 14.50 0.71 30.00 1.41 60.25 6.36 
Table 2.13:  Number of colonies of each type formed by sorted cell populations 
immediately after plating. 
Figure 2.36:  Colony forming efficiencies of sorted populations of 5PT cells 
(p0).CD44highCD24high cells (Q2) again formed a significantly higher proportion of holoclones 
as opposed to the other populations (table 3.3h). CD44highCD24low cells (Q1) were formed the 
most number of meroclones and the second highest number of holoclones. CD44lowCD24low 
cells (Q3) formed mostly paraclones and the second highest number of meroclones. They also 
formed low numbers of holoclones. CD44lowCD24highcells (Q4) formed the least number of 














Q1(44+24-) 14.75 3.182 34.2 2.2627 39.575 1.461 
Q2(44+24+) 38.2 2.2914 28.5 2.1213 27.5 3.5427 
Q3(44-24-) 10 2.8284 29.225 6.7529 50.3 3.8184 
Q4(44-24+) 14.75 2.4749 31.5 3.6078 32.5 3.5263 
Table 2.14: Colonies formed by sorted cells after the first passage (P1). 
 
Figure 2.37: The type and number of colonies formed by sorted 5PT cell populations 
after the first passage (P1).The numbers of the types of colonies counted for each quadrant 
examined, after the cells had been passaged once are shown. The cells obtained from quadrant 
Q2 (CD44highCD24high) still show a significantly higher number of holoclones than the other 
quadrants. Q3 formed a high proportion of paraclones but the highest numbers of paraclones 
were counted for CD44lowCD24high cells. The overall numbers of each type of colony formed 




4) Average total number of colonies formed immediately after sorting (p0) and at 
first passage (p1). 
Quadrant 5PT(po) SD  5PT(p1) SD 
Q1(44+24-) 134.5 9.2 95.0 1.4 
Q2(44+24+) 123.5 9.2 90.5 0.7 
Q3(44-24-) 157.5 10.6 87.0 12.7 
Q4(44-24+) 107.0 4.2 110.0 7.1 
Table 2.15: Average total number of colonies formed by the sorted populations 
immediately after sorting (p0) and after first passage (p1). 
 
Figure 2.38:  The average total number of colonies formed immediately after plating 
(p0) and after the first passage (p1).The total number of colonies formed after the first 
passage was lower for three of the sorted populations (Q1, Q2, and Q3), however this was only 
significant for Q3 cells (Q1-95,134; Q2-90.5, 123; and Q3-87, 157). Q4-cells showed a slight 





Quadrant %Holoclone %Meroclone %Paraclone Total Colonies 
Q1(44+24-) 19.3 51.3 29.4 134.5 
Q2(44+24+) 48.2 27.9 23.8 123.5 
Q3(44-24-) 13.1 31.4 55.6 157.5 
Q4(44-24+) 14.2 28.9 57.1 107.0 
Table 2.16: Colony forming efficiencies of sorted cells immediately after plating 
Quadrant %Holoclone %Meroclone %Paraclone Total Colonies 
Q1(44+24-) 16.8 39.5 43.6 95.0 
Q2(44+24+) 40.3 28.3 31.4 90.5 
Q3(44-24-) 11.4 29.3 59.2 87.0 
Q4(44-24+) 12.2 28.6 59.1 110.0 
Table 2.17: Colony forming efficiencies of sorted cells after first passage. 
The tables above show the percentages of holoclones, meroclones and paraclones formed for 
each of the sorted quadrants immediately after plating and after the first passage. The extreme 
right hand column shows the total numbers of colonies counted for each set of experimental 
runs.CD44highCD24high cells (Q2) consistently formed the highest percentage of holoclones, 
immediately after plating (48.2%) and also after the first passage (40.3%). The percentage of 
paraclones formed by these cells also increased after the first passage (23.89%, 31.49%). The 
number of colony forming cells seemed to decrease after the first passage for all the 4 quadrants 
examined. The average number of paraclones increased after the cells were passaged and this 
was seen in all four quadrants examined. Meroclones formed by CD44highCD24lowagain 
decreased after the first passage (p0=51.3; p1=39.47) and they showed an increase in the 
percentage of paraclones formed (29.37, 43.68). The highest percentages of paraclones were 
counted for CD44lowCD24lowand CD44lowCD24highcells and this remained the case immediately 





The 5PT cell line, generated from oral carcinoma by Tom Carey (Michigan Lab) was added to 
the study as cells from this line give rise to good colony morphologies and we wanted to 
demonstrate that the trends seen were consistent over a range of cell lines from different 
cancers. Cells were separated into quadrants and sorted into four distinct populations namely, 
CD44highCD24low (Q1), CD44highCD24high (Q2) CD44lowCD24low (Q3) and CD44lowCD24high 
(Q4) and plated out at clonal density in T25 flasks.CD44highCD24high (Q2) cells from both cell 
lines formed significantly higher proportions of holoclones (p<0.05) compared to those formed 
by all other quadrants.The number of holoclones formed by these cells remained significantly 
higher when cells were plated immediately after sorting and also after the first passage. The 
total colony counts for Q2 were also higher than those obtained for Q1, Q3 and Q4 but this 
difference was not statistically significant (p>0.05). These resultswere consistent for the cell 
lines examined,suggesting that these proteins are similarlyexpressed in both cell lines. Q1 cells 
were seen to form the most number of meroclones in both cell lines, 91.5±4.95 for CA1 and 
69±5.66 allowing us to deduce that CD44highCD24low cells probably enrich for transient 
amplifying cells. Q3 cells significantly formed the highest number of paraclones, i.e. 79±4.24 
for CA1 and 87.5±3.54 for 5PT. They also formed the least amount of holoclones, 32.5±3.54 
for CA1 and 26±5.66 for 5PT. The number of colonies generated by these cells were also more 
than the other populations, but this difference was not only insignificant (p>0.05), but it could 
also be argued that paraclones divide more frequently than holoclones which is why they give 
rise to a much larger colony number. Q4 showed more holoclones and meroclones than Q3 but 
less paraclones. These results suggest that the use of CD44 and CD24 together does give greater 
enrichment for stem cells as opposed to CD44 alone, and suggest that CD44 and CD24 are both 
expressed on stem cells in oral cell lines. Al Hajj and co-workers showed that CD44highCD24low 
cells were more clonogenic, reconstituted the entire tumour population when transplanted into 
mice, and were also more invasive than their CD44highCD24high counterpart (2003). Later it was 
shown that CD44highCD24high cells were also clonogenic, represent the epithelial component of 
the tumour, and gave rise to the invasive CD44highCD24low cells (Vonderhaar et al, 2009). The 
overall percentage of colony forming cells remainedbetween 8-10% for both cell lines 
immediately after sorting, but the number of holoclones formed by CD44highCD24high 
population of CA1 cells dropped to 42.5±4.95, and for the 5P% line to 36.5±2.32 after the first 
passage. Hence the percentage of clonogenic cells, taken as a measure of the number of stem 
cells remains very low, even after sorting for the marker combination. This also showed that 
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although CD44highCD24high cells were clonogenic, the number of holoclones formed by them 
dropped as cells seem to revert to parental levels after enrichment.  
The addition of further markers to the sorting process might help to sort a purer population of 
clonogenic cells. The sorting process itself stresses cells and some cells may lose clonogenicity 
because of this. It might also be feasible to let the cells recover overnight after the sorting 
process before harvesting them the next day to plate for colony counts. The purity of the isolates 
may even, after rigorous compensation controls,be influenced by instrument error with 
contamination by undesired cells from different quadrants. 
These results demonstrate heterogeneous patterns of cell surface expression of markers, and 
that they are related to the heterogeneous behavioural properties of cell sub-populations present 




2.5 Induction of EMT in cancer cell lines and the role of TGF- and 
external factors that may influence the extent of this process 
 
2.5.1 Introduction 
Examining the appearance of cultures plated at clonal densities indicates that when 
holoclones form by cell division: 
1. Cells remain tightly in contact with the surrounding cells.  
2. As colonies grow, some cells around the edges show tendency to break away from the 
colony.  
3. Thesecells appear more motile andhave a spindly morphology. 
 
Additionally, staining holoclones with stem cell markers reveals a pattern where cells in the 
center stain strongly for markers such as CD44, -Catenin and E-cadherin with cells at the edge 
showing weaker staining indicating their down regulation. Time lapse videos of cell lines show 
that when colonies form, cells making up the center of the colonies that are relatively stationary 
and maintain contact with neighbours whereasthose around the edge of the colony are more 
motile and show a spindle morphology when they leave. Thus, these spindly cells are generated 
from the colony itself and show scattering.If a holoclone colony is compared to a tumour then 
cells at the center represent the main bulk of the tumour. The cells at the edge of in 
vitrocolonies, mayin vivobe considered to represent the cells making up the tumour-host 
interface or “invasive front” of a tumour (Bankfalvi; Brabletz et al, 2005).In in vitro conditions 
there is an absence of connective tissue, but in vivo tumours are exposed to a multitude of 
growth factors and chemokines produced by both stromal and inflammatory cells in the 
extracellular environment. Reciprocally, tumour cells are able to influence stromal cells with 
tumour cells creating an environment that feeds back, as in wound healing, to promote EMT 
(Kalluri and Weinberg, 2009; Wu et al, 2009). Analysis of videos and staining patterns of in 
vitro cells suggest that the cells at the edge of holoclones are undergoing EMT. Cells present 
at the tumour-host interface have been shown to possess genes related to stemness and the latter 
have also been shown to possess EMT signature genes (Shinto et al, 2004). The lowering of 
markers such as -catenin and E-cadherin has been linked to EMT within a range of cancers 
including lung and pancreas (Debies, et al, 2008; Shah, et al, 2007) and therefore it is interesting 
to see a similar pattern in OSCC cell lines. In many cell types, TGF- is one of the potent 
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inducers and mediator of EMT (Zavadil and Bottinger, 2005). It was shown that TGF-β 
interferes with E-cadherin and β-catenin function in mammary epithelial cells, promoting 
motility and the acquisition of an EMT phenotype (Bakin et al, 2000). TGF-β has been linked 
to the progression of many cancers and in breast, it interacts with SMAD proteins that activate 
snail and slug, known repressors of E-cadherin and lead to increased invasiveness and 
metastatic potential (Massague, 2008). The effect of TGF- on OSCC cell lines was therefore 
investigated to see whether treatment could induce the formation of the motile cells similar to 
those seen at the edges of colonies. The effect of TGF- on the expression of EMT markers 
was also investigated using immunocytochemistry and FACS analysis.  
 
Aims: 
 To determine whether TGF-β induces EMT in oral cancer cell lines. 
 To investigate whether EMT generates cells with the properties of stem cells. 
 To assess the role of other extrinsic factors present in the tumour microenvironment 
that may contribute to this process. 
 To study the effect of EMT on known stem cell markers and their expression patterns 
in cancer cell lines. 
To investigate the changes associated with EMT, immunocytochemistry for CD44, ESA, E-
cadherin and β-catenin was carried out on control and treated cells. Sphere assays were also 
performed as sphere-forming ability is a hallmark of EMT and has also been linked to stemness 
(Mani et al, 2008). FACS analysis was also used to study the effect of treatments on different 
subpopulations present within OSCC cell lines stained for both CD44 and ESA. After initial 
experiments demonstrated that TGF-β induced EMT, whether the effect of TGF-β was 
permanent or was removed upon withdrawing TGF-β treatment was also examined. The effects 
of long term treatment with TGF-β were also investigated to see how this affected relative 




2.5.2 Materials and Methods (Part 1) 
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Cells were cultured as described before (2.2.2.1).  
TGF-β (R&D systems; TGFB1001B) was dissolved in PBS containing 0.001% HCL and was 
used at a concentration of 20 ng/ml. The inhibitor of TGF-, SB431542 (Sigma; S4317) was 
resuspended in 5% DMSO in distilled water and used at 5µg/ml.  
Fibroblast conditioned medium (FIBSCM) was prepared by growing sub-confluent cultures of 
fibroblasts that had been isolated from tumours by growth in RM+ culture medium for 5-6 
days. The medium was transferred to a 50ml falcon tube and spun down at 3000 revs/min to 
remove any cellular debris. After centrifugation, the supernatant was filtered into a clean tube 
through a 0.45um filter. This medium was then used to culture cells from CA1 and H357 cell 
lines for 5-6 days at the end of which they were photographed and compared to control cells 
and TGF-β treated cells. For immunocytochemistry protocols were followed as discussed 
before (2.2.1.2b). The procedure for selecting cells for FACS was the same as has been 
discussed (2.2.2.1, 2.2.2.2).For suspension cultures,0.75 cm2 tissue culture wells were coated 
overnight with polyhema (Sigma, Exeter, UK,12 mg⁄ml in 95% ethanol) to prevent cell 
attachment. The cells were then plated at a density of 1000 cells ⁄ well in 500 µl RM+ medium 
with addition of 1% methylcellulose (Sigma) to prevent cell aggregation. The cells were 
incubated (37_C, 5% CO2) and monitored for sphere growth for time periods ranging from 1-
2 weeks depending on the cell line studied. Following counting, spheres were reintroduced into 
adherent culture conditions and left for 24 hours. They were detached and again plated into 








2.5.3 Results (Part 1) 
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The effect of TGF-β and medium conditioned by the growth of tumour associated 
fibroblasts (FIBS CM) on OSCC cells. 
1) Cell culture 
 
Figure 2.38: The effect of TGF-β and fibroblast conditioned medium (FIBSCM) on 
OSCC cells (Scale=50µm).Cultures of CA1 (a-c) and H357 (d-f) cells under control conditions 
(a, d), with TGF-β (b, e) and with conditioned medium from tumour-associated fibroblasts (c, 
f) shown in phase-contrast. Control cells show the normal colony morphology patterns by 
forming holoclones (H), meroclones (M) and paraclones (P). Treatment with TGF-β results in 
the formation of spindle-shaped cells that show scattering and were seen to be motile in time-
lapse videos. Cells also lost the tendency to form colonies and developed elongated spindle-
like morphologies. Treatment with conditioned medium from tumour associated fibroblasts 
also resulted in similar changes and a spindle-like morphology (S) was acquired by both cell 







Immunocytochemistry carried out on the CA1 and H357 cell lines for EMT and stem cell 
markers (CD44, ESA, β-catenin and E-cadherin). 
I) CD44  
 
Figure 2.39: Expression of CD44 in OSCC cells under control conditions (Scale=50µm). 
Cultures of CA1 (a-c) and H357 (d-f) cells. Holoclones (H) formed by both lines are shown (a, 
d) in phase contrast, stained with DAPI nuclear stain (b, e) and with anti-CD44 FITC antibody 
(c, f) Cells showed good colony formation with a few scattered elongated cells present The 
patterns of CD44 expression were similar to those described earlier and strong expression of 
CD44 was seen at the cell surface and weak expression was seen in the cytoplasm. The 
elongated cells show strong expression of CD44 in the cytoplasm (c-inset), show peri-nuclear 








Figure 2.40: Expression of CD44 in OSCC cells treated with TGF-β 
(Scale=50µm).Cultures of CA1 (a-c) and H357 (d-f) cells treated with TGF-β and shown in 
phase contrast (a, d), stained with DAPI nuclear stain (b, e) and with anti-CD44 FITC antibody 
(d, f). Treated cells from both cell lines show a decreased tendency to form colonies, are 
scattered, and resemble fibroblasts. These cells also show strong localization of CD44 almost 
exclusively in the nucleus with very little being present in the cell peripheries. The nuclear 
localization is stronger in the CA1 cell line with all the cells showing nuclear expression of 
CD44 (insets-c) while H357 cells seem to show peri-nuclear (pn) accumulation and some show 
nuclear localization of the protein (n). A few H357 cells however show moderate expression 




Conditioned medium from tumour associated fibroblasts 
 
 
Figure 2.41: Expression of CD44 in OSCC cells after treatment with conditioned 
medium from tumour associated fibroblasts(Scale=50µm).Cultures of CA1 (a-c) and H357 
(d-f) cells treated with medium conditioned by the growth of tumour associated fibroblasts and 
viewed in phase-contrast (a, d), stained with DAPI nuclear stain (b, e) and with anti-CD44-
FITC antibody (c, f). Cells from each of the lines are scattered and display spindle-like 
morphology and dispersion on an individual level. CA1 cells show moderate to low expression 
at the cell surface whereas H357 cells generally show low expression at the cell surface with 







Figure 2.42: The expression of ESA in OSCC cells under control 
conditions(Scale=50µm).Cultures of CA1 (a-c) and H357 (d-f) cells cultured under control 
conditions and viewed in phase contrast (a, d), stained with DAPI nuclear stain (b, e) and with 
anti-ESA-FITC antibody (c, f). Cells from both cell lines form holoclones with spindle cells 
placed at the edge (d) or outside the colonies (a).Cells at the edges of the colonies show weaker 
expression of ESA than central cells that show strong expression at the cell surface. The spindle 
cells show weak expression at the surface with some cells showing nuclear localization of the 









Figure 2.43: Expression of ESA in OSCC cells treated with TGF-β 
(Scale=50µm).Cultures of CA1 (a-c) and H357 (d-f) cells treated with TGF-β and shown in 
phase contrast (a, d), stained with DAPI nuclear stain (b, e) and with anti-ESA-FITC antibody 
(c, f). Treated cells from both cell lines appear elongated and show poor colony formation. 
Weak expression of ESA is seen in both cell lines and is present in the cytoplasm. Most of the 
treated cells also show no expression at the cell surface, the pattern seen typically in control 








Figure 2.44: Expression of ESA in OSCC cells treated with conditioned medium from 
tumour associated fibroblasts (Scale=50µm). Cultures of CA1 (a-c) and H357 (d-f) cells 
treated with medium conditioned by the growth of tumour associated fibroblasts, viewed in 
phase contrast (a, c), stained with DAPI nuclear stain (b, e) and with anti-ESA-FITC antibody. 
Cultured cells show poor colony formation and an elongated spindle phenotype. Cells from 
both cells lines show very low expression of ESA at the cell surface and there are slight 
variations seen in patterns of expression in both cell lines. In CA1 cells, weak expression of 
ESA is seen in the nucleus of most cells, whereas H357 cells show peri-nuclear accumulation. 








Figure 2.45: Expression of β-Catenin under control conditions in OSCC cells 
(Scale=50µm).Cultures of CA1 (a-c) and H357 (d-f) cells grown under control conditions. 
Both cell lines form holoclones (H), shown in phase contrast (a, d) with cells at the edge 
showing spindle-like morphologies and scattering. Cells stained with DAPI nuclear stain (b, 
e), and with anti-β-Catenin-FITC antibody (c, f) show strong surface expression of β-Catenin 
in central holoclone cells but none in the nucleus. Cells around the edge of the colony show 









Figure 2.46:  Expression of β-catenin in OSCC cells treated with TGF-β 
(Scale=50µm).Cultures of CA1 (a-c) and H357 (d-f) cells treated with TGF-β and shown in 
phase contrast (a, d), stained with DAPI nuclear stain (b, e), and with anti β-catenin FITC 
antibody. Cells from both cell lines acquire spindle-like morphology, showing a decreased 
tendency to form colonies (a, d) and show dispersal. The expression of β-catenin at the cell 
surface is reduced and almost all cells show strong nuclear localization of the protein. (c-inset). 






Conditioned medium from tumour associated fibroblasts 
 
Figure 2.47: Expression of β-catenin in OSCC cells cultured with conditioned medium 
from tumour associated fibroblasts (Scale=50µm). Cultures of CA1 (a-c) and H357 (d-f) 
cells treated with medium conditioned by the growth of tumour associated fibroblasts shown 
in phase contrast (a, d), stained with DAPI nuclear stain (b, e) and anti-β-catenin-FITC antibody 
(c, f). Cultured cells show poor colony formation and acquire spindle morphology and appear 
scattered. Treated cells show no surface expression of β-catenin characteristic of control cells, 









Figure 2.48: Expression of E-cadherin in OSCC cells cultured under control conditions 
(Scale=50µm).Cultures of Ca1 (a-c) and H357 (d-f) grown under control conditions and shown 
in phase contrast (a, d), stained with DAPI nuclear stain and with anti-E-cadherin-FITC 
antibody. Holoclones are shown with spindle cells (S) at the edge and outside the colony. 
Strong E-cadherin expression is seen at the cell surface of central holoclone cells than those at 
the edge (E). For CA1 cells, some cells at the edge (E) show nuclear accumulation of E-
cadherin. Spindle cells lying outside the colony show weak expression at the cell surface and 














Figure 2.49: Expression of E-cadherin OSCC cells treated with TGF-β (Scale=50µm). 
Cultures of CA1 (a-c) and H357 (d-f) cells treated with TGF-β and shown in phase contrast (a, 
d), stained with DAPI nuclear stain (b, e) and with anti-E-cadherin FITC antibody (c, f). 
Treatment results in the formation of spindle cells and dispersal of cells. Strong nuclear 
localization (N) of E-cadherin is seen but none at the cell surface and this is more pronounced 






Conditioned medium from tumour associated fibroblasts 
 
 
Figure 2.50: Expression of E-cadherin in OSCC cells cultured with conditioned medium 
from tumour associated fibroblasts (Scale=50µm). Cultures of CA1 (a-c) and H357 (d-f) 
cells treated with medium conditioned by the growth of cancer associated fibroblasts shown in 
phase contrast (a, d), stained with DAPI nuclear stain (b, e) and with anti-E-cadherin-FITC 
antibody (c, f). Treated cells acquire spindle morphology and show weak surface expression of 
E-cadherin. Nuclear localization (N) of E-cadherin is seen in the spindle cells and some of 




3) FACS Analysis 
FACS analysis of the CA1 and H357 cell lines was undertaken to assay for changes within 
subpopulations of cells in these cell lines. To determine the effect of treatment, the cell lines 
were stained with CD44 and ESA antibodies and three sub-populations were compared and 
analyzed, the CD44highESAlow (a), the CD44high(b) and the ESAlow/- (c) populations. Staining of 
OSCC cells with CD44 and ESA antibodies and subsequent analysis through two dimensional 
facsplots consistently identified a population of cells that is CD44highESAlow and stands to the 
left of the main population (Figure 2.50d). The co-expression pattern of high CD44 expression, 
a stem cell marker, with low expression of the epithelial marker ESA, suggested a possible 
relationship between EMT and cancer stem cells (Biddle and Mackenzie, 2012). When isolated 
and cultured, CD44highESAlow cells form predominantly fibroblast-like cells whereas the 
CD44highESAhigh cells that form holoclones and represent the clonogenic population. 
CD44highESAlow cells also formed more spheres than CD44highESAhigh cells, a further indication 
that they enrich for sphere forming EMT cells. qPCR analysis of CD44highESAlow cells showed 
low message expression of E-cadherin and high expression of Vimentin and Twist, markers of 
EMT and both CD44highESAhigh and CD44highESAlow cells can be passaged indefinitely, that is 
indicative of self-renewal ability (Biddle et al, 2011). The CD44high population was studied in 
this experiment to assess the effect of TGF-β on the stem cell population within OSCC lines. 
The size of the ESAlow/- population was assayed as it was thought that a loss of epithelial 
markers would further strengthen the conclusion that cells were undergoing EMT.  
Positioning of gates:  
To set the gates for FACS analysis of different subpopulation within OSCC cell lines, cells 
without any added antibody were used to assess autofluorescence (Figure 2.50 a-c) Stained 
cells showed fluorescence several units higher on a log scale compared to a control sample that 







Figure 2.51: Characteristic FACS plots for CA1 cells. Analysis of CA1 cells for 
expression of CD44 and ESA and the positioning of the gates for the experiment. Panels (a-c) 
show the cells without any added antibody and corresponding cell populations with the 
antibodies added are shown above (d-f). Panel (d) shows the co-expression pattern of cells 
analyzed for CD44 and ESA and identifies a CD44highESAlow population (red). The gates were 
drawn arbitrarily to include as much of this population without including cells from the main 
bulk of the total population. For each sample, the gates were kept in the same position when 
comparing control samples with treated ones. Panel (e) shows the expression pattern for CD44 
that often shows an identifiably separate cluster of more highly expressing cells at the far right 
that assists in the positioning of the gate, but for some populations of stained cells clearly 
separated populations were not apparent and gates defining high expressing subpopulations 
were selected more arbitrarily according to the overall pattern of positive and negative staining. 
For both cell lines the 5% of cells expressing the highest levels of CD44 were selected and 
gated as CD44high. Panel (f) shows the expression pattern for ESA and 5% of cells expressing 






I) CA1:  
a) CD44highESAlow cells 
Figure 2.52: FACS analysis of CA1 cells stained with CD44 (y-axis) and ESA (x-axis) 
antibodies.FACS analysis of the CD44highESAlow population (red) within the CA1 cell line 
Doublets were excluded using forward and side scatter and dead cells were excluded using 
DAPI as discussed (2.2.2.1). Panel (a) shows the cells without any added antibody. Panel (b) 
shows the CD44highESAlow population in untreated control cells (gated). Panel (c) and Panel 
(d) show the changes of this population when cells were treated with TGF-β and conditioned 
fibroblast medium. 
CD44highESAlow 1 2 3 Average SEM 
Control 0.93 1.50 2.62 1.68 0.86 
TGF-Beta 6.33 7.23 7.57 7.04 0.64 
Fibs CM 1.87 1.95 3.63 2.48 1.00 
Table 2.18: Changes in the size of the CD44highESAlow population within the CA1 cell 
line. 
 
Figure 2.53: The percentage of CD44highESAlow cells in controls and the response to 
treatment.Changes in the CD44highESAlow population when controls were compared to 
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cellstreated with TGF- β and those treated with conditioned medium from fibroblasts. The size 
of  
the gated CD44highESAlow population is low in control cells (1.68±0.86%) and increases 
significantly when they are treated with TGF- (7.04±0.64%). Treatment with FIBSCM also 
resulted in an increase in the number of these cells (2.48±1.00) but this was low compared to 




Figure 2.54: FACS analysis of cells stained with CD44 antibody.FACS analysis of the 
CA1 cells for expression of CD44. Cells were analyzed first without antibody to assess 
autofluorescence (a) and stained with anti-CD44-PE antibody (b-d). 5-6% of the cells 
expressing the highest levels of CD44 were selected as CD44high and gated (red) in the controls 
(b). This was then compared to the percentage of CD44high cells seen after treatment with TGF-
β (c) or with FIBSCM (d). The percentage of CD44 high cells increased with both TGF-β and 
conditioned medium.  
 
CD44high 1 2 3 Average SEM 
Control 5.23 5.17 5.10 5.17 0.07 
TGF-Beta 11.37 10.63 8.67 10.22 1.40 
Fibs CM 7.89 6.97 7.50 7.45 0.46 






Figure 2.55: Changes in the CD44high population with treatment.The change in the 
percentage of cells that express high levels of CD44. In control samples 5% of cells expressed 
were selected as CD44high. When cells were treated with TGF-β this population increased 
highly significantly to 10.22±1.40%. Treatment with FIBSCM also resulted in a significant 
increase in CD44high cells (7.45±0.46%). 
 
c) ESAlow/- cells 
 
Figure 2.56: FACS analysis of cells stained with ESA (APC) antibody.FACS analysis of 
the CA1 cells for expression of ESA. Cells were analyzed first without antibody to assess 
autofluorescence. Cells were stained for anti-ESA antibody and 5-6% of the cells expressing 
the lowest levels of ESA were selected as ESAlow/- and gated (red) in the controls (b). This was 
then compared to the percentage of ESAlow/- cells seen with treatment with TGF-β (c) or with 





ESAlow 1 2 3 Average SEM 
Control 5.43 5.10 5.23 5.26 0.17 
TGF-Beta 33.11 29.43 29.23 30.59 2.18 
Fibs CM 8.52 10.03 8.52 9.03 0.87 
Table 2.20: Changes in the ESAlow/-population within the CA1 cell line. 
 
 
Figure 2.57: Changes in the ESAlow/- population with treatment.The effect of treatment 
on ESAlow/- cells. In control samples 5.43±0.15% of the cells expressed either low levels of 
ESA or no ESA at all (gated as ESAlow/-). This population increased to 33.11±3.02% with 
treatment with TGF-β which was highly significant (p<0.005). Conditioned medium from 




II) H357:  
a) CD44high ESAlow cells 
 
 
Figure 2.58: FACS analysis of H357 cells stained with CD44 (y-axis) and ESA (x-axis) 
antibodies.FACS analysis of the CD44highESAlow population (red) within the H357 cell line 
and changes in the size of this population after treatment with TGF-β and FIBSCM. Panel (a) 
shows the cells without any added antibody. Panel (b) shows the CD44highESAlow population 
in control cells (gated). Panel (c) and Panel (d) show the changes in the size of this population 
when cells were treated with TGF-β and conditioned fibroblast medium. 
 
 
CD44highESAlow 1 2 3 Average SEM 
Control 3.67 4.00 4.07 3.91 0.21 
TGF-Beta 32.57 30.81 26.90 30.09 2.90 
Fibs CM 15.93 14.10 13.27 14.43 1.36 






Figure 2.59: The percentage of CD44highESAlow cells in controls and the response to 
treatment.The changes in the size of the CD44highESAlow population when controls were 
compared to TGF-β treated cells and those treated with FIBSCM. The percentage of cells gated 
as the CD44highESAlow population is 3.91±0.21% for control cells. This increases significantly 
after treatment with TGF-β (30.09±2.9%). Treatment with FIBSCM also resulted in an increase 
in these cells (14.43±1.36) but was less than that seen for TGF-β. The response of this cell line 




Figure 2.60: FACS analysis of H357 cells stained with CD44 antibody.FACS analysis of 
H357 cells for expression of CD44. Cells were analyzed first without antibody to assess 
autofluorescence (a), stained with anti-CD44-PE antibody (b-d). 5-6% of the cells expressing 
the highest levels of CD44 were selected as CD44high and gated (red) in the controls (b). This 
was then compared to the percentage of CD44high cells seen after treatment with TGF-β (c) or 
with FIBSCM (d). The percentage of CD44high cells was seen to increase with both TGF-β and 




CD44high 1 2 3 Average SEM 
Control 5.47 5.13 5.23 5.28 0.17 
TGF-Beta 32.90 24.73 28.23 28.62 4.10 
Fibs CM 12.70 10.03 11.33 11.36 1.33 
Table 2.22: Changes in the CD44high population within the H357 cell line. 
 
Figure 2.61: Changes in the CD44high population with treatment. The change in the 
percentage of cells expressing the highest levels of CD44. In control samples 5.28±0.17% of 
cells were gated as CD44high. Treatment with TGF- results in a (28.62±4.1) increase in the 
size of this population which was significant. Treatment with conditioned medium from 
fibroblasts also resulted in an increase in CD44high cells (11.36±1.33%) but this was less than 




c) ESAlow/- cells 
 
Figure 2.62: FACS analysis of cells stained with ESA (APC) antibody.FACS analysis of 
H357 cells for expression of ESA. Cells were analyzed first without antibody to assess 
autofluorescence (a). Cells were stained with anti-ESA (APC) antibody (b-d) and 5-6% of the 
cells expressing the lowest levels of ESA were selected as ESAlow/- and gated (red) in the 
controls (b). This was compared to the percentage of ESAlow/- cells seen after treatment with 
TGF-β (c) or FIBSCM (d). The percentage of ESAlow/- cells increased with both TGF-β and 
FIBSCM but this was more significant in the TGF- β treated cells.  
 
ESAlow/- 1 2 3 Average SEM 
Control 5.43 5.37 5.12 5.31 0.17 
TGF-Beta 38.90 34.07 33.23 35.40 3.06 
Fibs CM 15.50 11.17 11.67 12.78 2.37 







Figure 2.63: Changes in the ESAlow/- population with treatment. The effect of treatment 
on ESAlow/- cells. In control samples 5.31±0.17% of the cells were gated as ESAlow/-. This 
population increased to 35.40±3.06% after treatment with TGF-β which was highly significant 
(p<0.005) and to 12.78±2.37% with FIBSCM. The response recorded overall for this cell line 
was also greater compared to that of CA1 cells. 
 
4) Sphere Assays 
This section shows the results when CA1 and H357 cells were cultured in non-adherent 
conditions as spheres. The design for the experimental setup has already been discussed (2.3.2). 
Sphere forming ability has been linked to both stemness and EMT (Biddle et al, 2011, Mani et 
al, 2008) and these experiments were designed to determine whether treatment with either 
TGF-β or conditioned medium from cancer associated fibroblasts (FIBSCM) affected sphere 
formation. The number of spheres formed by control cells were counted and compared to the 
number formed by cells that were treated with TGF-β and FIBSCM. After counts had been 
performed, the spheres were reintroduced into adherent conditions, left overnight, detached, 
and reintroduced into secondary sphere assays and monitored for sphere growth to assess for 





a) CA1 cell line:  
 
 
Figure 2.64: Sphere forming ability of Ca1 cells and the effect of treatment with TGF-β 
and FIBSCM.The formation of spheres by control CA1 cells (a), cells treated with TGF-β (b) 
and FIBSCM (c). Control cells form round compact spheres with clean edges that reach a larger 
size than those with either treatment. Treated cells form a larger number of spheres although 
they look to be less compact. Cells treated with conditioned medium from malignant fibroblasts 
form the most number of spheres. 
 
CA1 I II III IV V Average SD % 
Controls 92.0 84.0 78.0 86.0 80.0 84.0 5.5 8.4 
TGF-β 146.0 152.0 137.0 165.0 142.0 148.4 10.8 14.8 
FibsCM 150.0 165.0 169.0 139.0 158.0 156.2 12.1 15.6 
 








Figure 2.65 (i): The effect of treatment on sphere formation in CA1 cells.The number 
of spheres formed from CA1 cells per 1000 cells seeded and the effect of treatment with TGF-
β or FIBSCM. Control cells formed on average 84 ±5.48 (8.4%) spheres per 1000 cells seeded. 
Cells treated with TGF- formed 148.4±10.78 (14.8%) spheres while those treated with 
FIBSCM formed 156±12.03 (15.6%) spheres. Both treatments significantly increased sphere 






CA1 I II III IV V Average SD % 
Controls 110.00 115.00 124.00 95.00 121.00 113.00 11.42 11.3 
TGF-B 164.00 155.00 149.00 162.00 142.00 154.40 9.13 15.44 
FibsCM 161.00 186.00 179.00 183.00 188.00 179.40 10.83 17.94 
Table 2.25: The average number of spheres formed by CA1sphere-cells following 
introduction into adherent conditions. 
 
 
Figure 2.65 (ii): The effect of reintroduction into adherent conditions.The number of 
spheres formed by CA1 sphere cells reintroduced into adherent conditions for 24 hours and 
then seeded at 1000 cells per well. Control sphere-cells formed significantly more spheres on 
average than they had in the primary suspension cultures (113±11.42, 84±5.5). Sphere-cells 
treated with TGF-β (154.4±9.13) and conditioned fibroblast medium (179.4±10.83) formed 
more spheres than they did in primary cultures (148.4±10.8, 156.2±12.1) but the FIBSCM 





Figure 2.66: Re-introduction of CA1 spheres into adherent conditions. The morphology 
generated by CA1 spheres when reintroduced into adherent conditions. After about 4-6 hours 
cells have the appearance seen in (a). Left overnight, the cells start to spread out from the initial 
point of attachment (b). Within 48 hours the whole sphere flattens down to form an epithelial-
like colony with elongated spindle shaped cells around the edges (c). Panel (d) shows magnified 
insets of cells at the edges of the colonies, forming both cobblestone shaped epithelial cells and 




B) H357 cell line: 
 
 
Figure 2.67: Sphere forming ability of H357 cells and the effect of treatment with TGF-
β and FIBSCM.The formation of spheres by control H357 cells (a), cells treated with TGF- 
(b) and conditioned medium from fibroblasts (c), shown in phase contrast. Control cells form 
round compact spheres with clean edges. TGF-β treated cells form a larger number of spheres 
but seem less compact. Cells treated with conditioned medium from tumour associated 
fibroblasts form the highest number of spheres which are of varying sizes.  
H357 I II III IV V Average SD % 
Controls 146.00 132.00 119.00 126.00 88.00 122.20 21.55 12.22 
TGF-β 271.00 325.00 267.00 195.00 195.00 250.60 55.68 25.06 
FibsCM 336.00 321.00 360.00 420.00 348.00 357.00 38.07 35.7 
 








Figure 2.68 (i): The effect of treatment on sphere formation in H357 cells.The 
number of spheres formed by H357 cells per 1000 cells seeded and the effect of treatment with 
TGF-β or conditioned medium from tumour associated fibroblasts. Control cells formed on 
average 122 ±21.55 (12.2%) spheres per 1000 cells seeded. Cells treated with TGF-β formed 
250±55.68 (25%) spheres while those treated with conditioned medium formed 357±38.07 
(35.7%) spheres. Both treatments were seen to significantly increase sphere forming ability. 
Overall the H357 cell line formed a larger number of spheres under any of the conditions tested 




H357 I II III IV V Average Stdev % 
Controls 286.00 345.00 291.00 332.00 248.00 300.40 38.82 30.04 
TGF-B 325.00 401.00 420.00 365.00 380.00 378.20 36.31 37.82 
FibsCM 300.00 331.00 340.00 260.00 355.00 317.20 37.77 31.72 
Table 2.27: The average number of spheres formed by H357sphere-cells following 




Figure 2.68 (ii): The effect of reintroduction into adherent conditions. The number of 
spheres formed by H357 sphere cells reintroduced into adherent conditions for 24 hours and 
then detached and seeded at 1000 cells per well. Control sphere-cells, and those treated with 
TGF-β formed significantly more spheres in secondary cultures (300.4±38.82, 378.2±36.31) 
than they had in primary suspension cultures (122.2±21.55, 250.6±55.68) The number of 








Figure 2.69: Re-introduction of H357 spheres into adherent conditions.The morphology 
generated when H357 spheres are reintroduced into adherent conditions. After about 4-6 hours 
cells resemble the appearance seen in (a). Left overnight, the cells spread out from the initial 
point of attachment (b). Within 48 hours the whole sphere flattens to form an epithelial colony 
with elongated spindle shaped cells around the edges (c). Panel (d) shows magnified insets of 
cells forming at the edges of the spheres and settling down to form both cobblestone shaped 





5) Time Lapse Video of OSCC cells treated with TGF-β and FIBSCM: 
Time lapse video analysis of OSCC cells grown under control conditions shows that, in both 
cell lines, when holoclones form, there appear to be two populations of cells present. The 
central cells within the holoclone show characteristic cobblestone morphology, are cohesive 
being in tight contact with neighbouring cells, and appear relatively stationary. The cells 
present at the edges of colonies show a spindle morphology and try to break away from the 
main colony, being motile. There are also cells lying outside the colonies that are elongated 
with spindle morphology and resemble fibroblasts. They also appear to be generated from the 
edges of colonies. Cells treated with TGF-β and FIBSCM show scattering on an individual 
level, do not form cohesive colonies, remaining instead, as a loose group of cells that show 
high motility, and make and break cell-cell contacts with other cells. 
CA1Control.avi (Command Line)CA1TGF.avi (Command Line)CA1FIBSCM.avi (Command Line)
 
 
H357Control.avi (Command Line)H357TGF.avi (Command Line)H357FIBSCM.avi (Command Line)
 
 
Note: To play files  
1. use VLC media player (VideoLAN), the installation file for which has been 
provided in the SOFTWARE folder on the CD, 
or 
2. To view in Windows media player, kindly install K-lite codec pack, also provided 
in the SOFTWARE folder on the CD. 
(The files have been checked by Kaspersky Pure Antivirus [Kaspersky Labs™] and do not 




2.5.4  Discussion: 
The aim of this chapter was to ascertain whether EMT occurs in OSCC lines and whether this 
process could be influenced by TGF- and other factors present in the tumour 
microenvironment such as cancer associated fibroblasts. Cells from CA1 and H357 cell lines 
were cultured under control conditions, with TGF- and with conditioned medium from cancer 
associated fibroblasts (FIBSCM). Control cells formed characteristic colonies in the form of 
holoclones, meroclones, and paraclones as discussed. Populations of spindle shaped cells, 
resembling fibroblasts were seen at the edges of colonies or lying outside the colonies in both 
cell lines. Based on the results obtained in previous sections we hypothesized that the cells at 
the edges of holoclone colonies differed from those present in the center with regards to stem 
cell potential. The central cells were thought to represent clonogenic cells whereas those at the 
edge had probably begun some form of differentiation. We also hypothesized that some cells 
at the edge might be undergoing EMT to give rise to the spindle shaped cells seen routinely 
between colonies during cell culture. Cells treated with TGF-β tended not to form colonies but 
formed scattered cells that had elongated spindle morphology and looked similar to the cells 
formed at the edges of colonies. Time-lapse video showed that cells treated with TGF-β and 
FIBSCM show a high level of motility and scattering, and take on elongated spindle 
morphologies. The cells also showed decreased cohesiveness and did not form colonies as 
under control conditions (2.2.1.3 E). Thus both treatments enhanced the phenomenon occurring 
around the edges of colonies that resulted in the formation of elongated spindle cells just 
described.  
Cells grown under control conditions showed good expression of ESA at the cell surface with 
central cells within colonies expressing higher levels of ESA than those at the edges. Elongated 
spindle cells at the edge also displayed loss of membranous ESA and some of these cells 
showed accumulation of ESA around the nucleus. Down-regulation of ESA and nuclear 
localization of its intracellular domain occurs in colon cancers with ESA interaction with 
members of the Wnt signalling pathway, specifically β-catenin (Maetzel et al,  
2009). In the Ca1 cell line there was little evidence of nuclear localization of ESA under control 
conditions, while in the H357 cell line a majority of cells within colonies expressed nuclear as 
well as surface ESA. Treatment with both TGF-β and FIBSCM resulted in a lowering in cell 
surface ESA which occurs in EMT (Harrison, 2010). High expression of ESA has been linked 
to tumourigenicity and poor prognosis in breast cancer (Spizzo et al, 2004, 2011). Treated cells 
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also showed nuclear expression of ESA and this was associated with loss of the epithelial 
phenotype and the acquisition of a more mesenchymal, characterized by the elongated spindle 
cells. Further, Gires and colleagues (2009) showed that nuclear signalling by ESA increases 
tumourigenicity, promotes proliferation and invasion of pharyngeal and colon carcinoma cells 
and through interactions with members of the Wnt signalling pathway.  
When examined for E-cadherin, in both cell lines the expression was seen at the surface of cells 
in the center of colonies and was lower in the cells around the edge. Treatment with TGF- 
also resulted in loss of membranous E-cadherin. Strong expression of E-cadherin was seen in 
the nuclei of both types of treated cells but TGF- caused a greater effect than the fibroblast 
conditioned medium. These findings suggest that cells are undergoing EMT in response to 
treatment, associated with possible disruptions in the Wnt signalling pathway or pathways 
involved in cell-cell adhesion (Franz et al, 2009). Nuclear E-cadherin has also been implicated 
in gain of invasiveness of many tumours such as pharyngeal, esophageal, renal and colorectal 
carcinomas and has been used as a prognostic marker in the diagnosis of these tumours 
(Salahshor, 2008; Chetty, 2008). The precise mechanism by which E-cadherin translocates to 
the nucleus is not well understood but it is thought that the catenin-cadherin pathway is 
involved. As discussed earlier, -catenin was expressed at the surface of cells in the center of 
colonies (Fig 2.45-2.47), whereas edge cells show reduced membrane expression and often, 
translocation to the nucleus. This was also seen in the elongated spindle cells seen lying outside 
colonies. Treatment with both TGF-β and conditioned medium resulted in a loss of 
membranous -catenin and translocation to the nucleus. This has previously been linked to 
poor prognosis and gain of invasiveness of many cancers and again seems to implicate that 
these cells have undergone EMT and have acquired a motile, mesenchymal phenotype 
(Schmalhofer et al, 2009; Kim et al, 2001).  
The CA1 cell lines expressed strong cell surface CD44 within central colony cells with little 
evidence of nuclear accumulation. The motile cells differed in their CD44 expression patterns, 
with some staining brightly for CD44 in the cytoplasm, while others showed nuclear 
accumulation and moderate membrane expression. Nuclear CD44 has been linked to poor 
prognosis and the acquisition of stem cell potential (Lee et al, 2011). It also occurs in EMT and 
promotes tumour metastasis in colon cancer (Su et al, 2011). The staining patterns observed in 
our cell lines suggest that the cells around the colony edge acquire a mesenchymal phenotype 
by undergoing EMT. This is influenced by TGF- as treatment exaggerates these expression 
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patterns and also by the fibroblast conditioned medium. This suggests that factors within the 
tumour host interface or the invasive front also plays a role in influencing this differentiation 
programme. The tumour-host environment, better referred to as the invasive front, is made up 
of tumour cells, fibroblasts, inflammatory cells and endothelial cells. TGF-β is known to be 
secreted by immune cells (Kalluri and Weinberg, 2009) and this is enhanced by tissue 
inflammation at the wounding site (Wu et al, 2009). The stromal tissue surrounding the tumour 
is known to play a vital role in promoting and maintaining tumour development through the 
involvement of cancer associated fibroblasts (Olumi et al, 1999) and recent work with TGF-β 
has also strengthened this observation (Kojima et al, 2010). Cancer cells are also known to 
secrete cytokines that promote inflammation and lead to the production of TGF-β (Finger and 
Giaccia, 2010; Franz et al, 2009) and it could be possible that fibroblasts present in the stromal 
environment, alongwith inflammatory cells release cytokines that promote the activation of the 
TGF-β pathways, resulting in oral cancer cells undergoing EMT.  
FACS analysis using CD44 and ESA antibodies consistently identified a subpopulation of cells 
that was CD44highESAlow. This population also stood out from the main population of cells 
which generally stained high for both ESA and CD44 and represented the epithelial component 
of the cell lines. Analysis of CA1 cells showed that 2-3% of the total population were 
CD44highESAlow whereas in H357 cells this number was much higher (4%-5%). Further, this 
population increased significantly with TGF- treatment in both CA1 and H357 cell lines and 
shows a potential role for TGF- in initiating EMT in these cells. Treatment with conditioned 
medium from malignant fibroblast also resulted in an increase in the size of this population, 
and suggests an alternate mechanism for EMT. TGF-β caused the proportion of ESAlow/- cells 
to increase significantly (CA1 33.11±3.02%; H357) when compared to controls and this 
suggests that cells shed their epithelial phenotype in response to treatment. The number of cells 
expressing the highest levels of CD44 also increased with treatment with TGF- and 
conditioned fibroblast medium. TGF-β may this play a role in influencing stem cell potential 
as CD44high cells have been shown to be clonogenic in oral and breast cancers (Al-Hajj et al, 
2003; Prince et al, 2008). They have also been shown to more efficiently give rise to tumours 
in vivo (Biddle et al, 2011). CD44 is involved in contributing to the EMT process in breast 
cancers where CD44+CD24- cells were stem-like have characteristics of EMT cells (Mani et 
al, 2008). These cells reconstituted tumour heterogeneity in mice and also showed invasion and 
metastases to lymph nodes. Further Takahashi and co-workers (2010) demonstrated that CD44 
is upregulated in response to TNF-α and interacts under the influence of TGF-β with SMAD 
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proteins to initiate EMT and increase the motility and invasiveness of these cells. 
Correspondingly the invasiveness and motility of breast cancer cells is reduced by antibodies 
targeting CD44 (Uchino et al, 2010). Interestingly CD44 also interacts with the Wnt pathway 
and induce nuclear translocation of -catenin (Zoller, 2011). Conditioned medium from 
fibroblasts also caused an increase in the numbers of cells expressing high CD44 which was 
less marked than that caused by TGF-β but still suggests that factors in the tumour stroma 
interface can interact with CD44 and influence cancer stem cell behaviour and bring about 
EMT.  
The ability of cells to survive in anchorage independent conditions has been used to enrich for 
tumour initiating cells. In 1992, Reynolds and Weis showed that neural cells formed spheres 
called “neurospheres” and that the cells making up the spheres were clonogenic and had self-
renewal potential. They were further shown to reconstitute cellular heterogeneity and had the 
ability to divide into multiple lineages, a further defining hallmark for stem cells. When these 
cells were implanted back into the brain, they showed stem cell capabilities in vivo. Based on 
this model, breast cells were also shown to have the ability to form “mammospheres” 
containing cells that showed self-renewal and an ability to form multilineage colonies (Dontu 
and Wicha, 2005). Sphere forming capacity has been shown to be one of the hallmarks of EMT 
and recent evidence suggests that this process results in the generation of cells with stem cell 
properties (Mani et al, 2008; Morel et al, 2008). Our studies show that OSCC cell lines contain 
a population of cells which have the ability to form spheres (CA1=8.4%; H357=12%) under 
control conditions. Treatment with TGF- caused a significant increase in the number of 
spheres formed and interestingly, treatment with fibroblast conditioned medium produced an 
even greater increase in the number of spheres formed. Interestingly, when control spheres 
were reintroduced into adherent conditions, cells from the spheres attached and spread out to 
form epithelial looking cells and formed large colonies resembling holoclones. These colonies 
had a prominent halo of spindly motile cells around the edge. Once these cells were again 
plated into a sphere assay, they formed more spheres per 1000 cells than they had before. This 
suggests that sphere formation enriches for cells that have clonogenic ability, that the epithelial 
populations in spheres and holoclones are interchangeable and that they are able to switch 
between the epithelial and mesenchymal phenotypes.  
Part II 
2.6 The effect of short-term treatment with TGF-β and its inhibitor 
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(SB431542) on subpopulations of cells within OSCC cell lines and their 
effects of these on the expression of vimentin. 
2.6.1 Introduction 
Further experiments were carried out with TGF-to determine whether the effects of TGF- 
were reversible or permanent by following cell changes after TGF-β was withdrawn. An 
inhibitor of TGF- was applied to check the specificity of TGF- treatment. Vimentin is a 
marker that is upregulated in EMT and is associated with the acquisition of invasive properties 
by pancreatic cancer cells (Krantz et al, 2010; Kong et al, 2011). To investigate the long term 
effects of TGF treatment, cells were also treated with TGF-β for 10 and 20 days. Various 
published reports describe agents that inhibit or augment the effect of TGF-β. One such agent 
is TNF-α, which as a fibroblast product, might be responsible for the effects of fibroblast 
conditioned medium. Therefore, the effects of TNF-and NS-398 which acts through COX-II 
inhibition were investigated. 
2.6.2 Materials and Methods 
Cells were cultured as discussed (2.3.2). TGF-β (R&D systems; TGFB1001B) was dissolved 
in PBS containing 0.001% HCL and was used at a concentration of 20ng/ml. The inhibitor of 
TGF-, SB431542 (Sigma; S4317) was resuspended in 5% DMSO in distilled water and used 
at 5µg/ml. TNF-α (R&D systems) was dissolved in distilled water and used at a concentration 
of 10ng/ml. The protocol followed for FACS was the same as has already been discussed 








1) CA1 cell line 
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A) Cell morphology 
 
Figure 2.70: The effect of TGF-β and its inhibitor on CA1 cells.Culture of CA1 cells for 
5 days under control conditions (a), with an inhibitor of TGF-β (SB431542) (b), TGF-β 
20ng/ml (c) and with both TGF-β and SB431542 (d), shown in phase contrast. Control CA1 
cells show good colony formation with holoclones and scattered motile cells. With the 
inhibitor, the colony formation seems unaffected but there is a decrease in the number of 
scattered cells (b). Cells treated with TGF-β, show a markedly decreased tendency to form 
colonies, appear scattered and acquire spindle morphology (c). When both TGF-β and the 
inhibitor are added, the cell morphologies generated are similar to those when the inhibitor is 
added alone (b) and cells form holoclones meroclones and paraclones and no spindle shaped 
cells (d). 
 
B) FACS Analysis CA1 cells: 
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FACS analysis of the CA1 and H357 cell lines was used to assay for changes within 
subpopulations of treated cells. To examine the effects of treatments, cell lines were stained 
with CD44 and ESA antibodies and the CD44highESAlow, the CD44high and the ESAlow 
populations were analyzed. 
a) CD44high ESAlow cells 
 
Figure 2.71: FACS analysis of CA1 cells stained with CD44 (y-axis) and ESA (x-axis) 
antibodies.FACS analysis of the CD44high ESAlow population (red) within the CA1 cell line 
and indicative changes of this population when control samples (b) were compared to cells 
treated with TGF-β (c), Sb431542 (d) and TGF+SB431542 (e). Doublets were excluded using 
forward and side scatter (2.2.2.2) and autofluorescence was determined using no antibody (a). 
The gated cells (red) represent the CD44highESAlow cells corresponding to the EMT population. 
Treatment with TGF- causes an increase in the number of CD44highESAlow cells (c). Cells 
treated with the inhibitor alone resembled the control samples (d). When the inhibitor was 
added together with the TGF-β (e), the percentage of cells within this population remained the 




44highESAlow 1 2 3 Average SEM 
Control 3.13 3.19 3.42 3.25 0.15 
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TGF-Beta 9.20 9.17 9.33 9.23 0.09 
Inhibitor 2.50 2.57 3.15 2.74 0.36 
TGF+Inhibitor 2.00 2.61 3.00 2.54 0.50 
Table 2.28: The effect of treatment on CD44highESAlow cells 
 
 
Figure 2.72: The effect of TGF-β and its inhibitor on the CD44highESAlow population 
within CA1 cells.The changes seen in the CD44highESAlow population when controls were 
compared to TGF-β treated cells, cells treated with inhibitor alone, and cells treated with both 
TGF-β and inhibitor. The percentage of cells gated as the CD44highESAlow population is low in 
control cells (3.25±0.15%) and this rises significantly (x3) when they are treated with TGF-β 
(9.23±0.09%). Treatment with inhibitor alone produces the same effect as when TGF-β and the 












Figure 2.73: FACS analysis of CA1 cells stained with CD44 (x-axis) PE-antibody. FACS 
analysis of the CD44high population (red) within the CA1 cell line to examine changes of this 
population when control samples (b) were compared to cells treated with TGF-β (c), Sb431542 
(d) and TGF+SB431542 (e). Doublets were excluded using forward and side scatter and 
autofluorescence was determined using no antibody (a). The gated cells (red) represent the 
CD44high cells, the putative stem population. Treatment with TGF-β causes an increase in the 
percentage CD44highcells (c). Cells treated with the inhibitor resembled control samples (d). 
When the inhibitor was added together with the TGF-β, the percentage of gated cells remains 
the same and the effect produced by TGF-β alone was not seen (e). The increase in CD44 







44high 1 2 3 Average SEM 
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Control 5.13 5.06 5.08 5.09 0.04 
TGF-Beta 10.70 10.50 12.00 11.07 0.81 
Inhibitor 5.40 5.33 5.15 5.29 0.13 
TGF+Inhibitor 4.63 5.00 4.66 4.76 0.21 
Table 2.29: The effect of treatment on the percentage of CD44high cells 
 
 
Figure 2.74: The effect of TGF-β and its inhibitor on the CD44highpopulation within CA1 
cells.The changes in the CD44high population when controls were compared to TGF-β treated 
cells, cells treated with inhibitor alone and cells treated with both TGF-β and inhibitor. The 
percentage of cells gated as the CD44high population in control samples is 5.09±0.04% and 
increases significantly (x2) when they are treated with TGF-β (11.07±0.81%). Treatment with 
inhibitor alone produces the same effect as when TGF-β is added together with the inhibitor 





c) ESAlow/- cells 
 
 
Figure 2.75: FACS analysis of CA1 cells stained with ESA (x-axis) PE-antibody. The y-
axis denotes side scatter. FACS analysis of the ESAlow/- population (red) within the CA1 cell 
line and changes of this population when control samples (b) were compared to cells treated 
with TGF-β (c), Sb431542 (d) and TGF-β+SB431542 (e). Autofluorescence was determined 
using no antibody (a). The gated cells (red) represent the ESAlow/- population, representative of 
cells that are shedding the epithelial phenotype. Treatment with TGF- causes an increase in 
the size of ESAlow/-population (c) and cells treated with the inhibitor alone resemble control 
samples (d). When TGF-β was added together with the inhibitor, the percentage of gated cells 






ESAlow/- 1 2 3 Average SEM 
Control 5.13 5.08 5.03 5.08 0.05 
TGF-Beta 19.67 18.70 19.82 19.40 0.61 
Inhibitor 5.63 5.80 5.10 5.51 0.37 
TGF+Inhibitor 5.77 5.20 5.41 5.46 0.29 
Table 2.30: The effect of treatment on the percentage of ESAlow cells 
 
 
Figure 2.76: The effect of TGF-β and its inhibitor on the ESAlow/- population within CA1 
cells.The changes in the ESAlow/- population when controls were compared to TGF-treated 
cells, cells treated with inhibitor alone, and cells treated with both TGF-β and inhibitor. The 
percentage of cells gated as the ESAlow/- population in control samples was 5.08±0.05% and 
this increases significantly (x4) when they are treated with TGF-β (19.40±0.61%). Treatment 
with inhibitor alone produces the same effect as when TGF-β and the inhibitor are added 






2) H357 cell line 
A) Cell morphology 
 
Figure 2.77: The effect of TGF-β and its inhibitor on H357 cells.Cultures of H357 cells 
for 5 days under control conditions (a), with inhibitor of TGF-β (SB431542) (b), TGF-β 
20ng/ml (c) and with both TGF-β and SB431542 added (d), shown in phase contrast. Control 
CA1 cells show good colony formation with holoclones and scattered motile cells shown in 
(a). With the inhibitor, the colony formation seems unaffected but there is a decrease in the 
number of motile cells seen (b). Cells treated with TGF-β show a markedly decreased tendency 
to form colonies, appear scattered and take on a spindly morphology (c). The addition of TGF-
β and the inhibitor together (d), results in the generation of colony morphologies similar to 
when the inhibitor is added alone (b) and cells form holoclones meroclones and paraclones and 




B) FACS Analysis 
a) CD44high ESAlow cells 
 
 
Figure 2.78: FACS analysis of H357 cells stained with CD44 (y-axis) and ESA (x-axis) 
antibodies.FACS analysis of the CD44highESAlow population (red) within the H357 cell line 
and changes of this population when control samples (b) were compared to cells treated with 
TGF-β (c), Sb431542 (d) and TGF-β+SB431542 (e). Autofluorescence was determined using 
no antibody (a). The gated cells (red) represent the CD44highESAlow cells, representative of 
EMT cells. Treatment with TGF- causes an increase in the number of CD44highESAlow cells 
and the population shifts towards the CD44highESAlow quadrant. Cells treated with the inhibitor 
alone resembled the control samples (d). When the inhibitor was added together with the TGF-
β, the percentage of cells gated as this population remains the same and the effect produced by 






44highESAlow 1 2 3 Average SEM 
Control 4.30 4.88 4.82 4.67 0.32 
TGF-Beta 25.80 26.13 29.25 27.06 1.90 
Inhibitor 3.60 4.52 4.46 4.19 0.51 
TGF+Inhibitor 3.33 4.52 4.23 4.03 0.62 
Table 2.31: The effect of treatment on the percentage of CD44high ESAlow cells 
 
 
Figure 2.79: The effect of TGF-β and its inhibitor on the CD44high ESAlow population 
within H357 cells.The changes in the size of the CD44highESAlow population of H357 cells 
when controls were compared to TGF-β treated cells, cells treated with inhibitor, and cells 
treated with both TGF-β and inhibitor. The percentage of cells gated as the CD44highESAlow 
population in control cells is (4.67±0.32%) which is higher than the intrinsic proportion of 
these cells in the CA1 cell line. The size of this population increases significantly (x6) when 
they are treated with TGF-β (27.06±1.90%). Treatment with inhibitor alone produces the same 
effect as when TGF-β and the inhibitor are added together (4.19±0.51%, 4.03±0.62%). This 





b) CD44high cells 
 
 
Figure 2.80: FACS analysis of H357 cells stained with CD44 (x-axis) PE-antibody. The 
y-axis denotes side scatter. FACS analysis of the CD44high population (red) within the H357 
cell line and changes in the size of this population when control samples (b) were compared to 
cells treated with TGF-β (c), Sb431542 (d) and TGF-β+SB431542 (e). Autofluorescence was 
determined using no antibody (a). The gated cells (red) represent the CD44high cells which are 
the putative stem population. Treatment with TGF-β increases the number of CD44highcells (c). 
Cells treated with the inhibitor alone resembled the control samples (d). When the inhibitor 
was added together with the TGF-β, the percentage of gated cells remains the same and the 
effect produced by TGF-β alone is not seen. The increase in CD44 correlated with an increase 




44high 1 2 3 Average SEM 
Control 5.20 5.18 5.09 5.16 0.06 
TGF-Beta 19.76 19.89 19.94 19.86 0.09 
Inhibitor 5.00 5.10 6.00 5.37 0.55 
TGF+Inhibitor 5.17 5.21 4.92 5.10 0.16 
Table 2.32: The effect of treatment on the percentage of CD44high cells 
 
 
Figure 2.81: The effect of TGF-β and its inhibitor on the CD44highpopulation within 
H357 cells.The changes in the CD44high population when controls were compared to TGF-
treated cells, cells treated with inhibitor alone, and cells treated with TGF- together with 
inhibitor. The percentage of cells gated as the CD44high population in control samples is 
5.16±0.06% and increases significantly (x4) when cells are treated with TGF- (19.86±0.09%). 
Treatment with inhibitor alone produces the same effect as when TGF- and the inhibitor are 




c) ESAlow/- cells 
 
Figure 2.82: FACS analysis of H357 cells stained with ESA (x-axis) PE-antibody. The y-
axis denotes side scatter. FACS analysis of the ESAlow/- population (red) within the H357 cell 
line and changes of this population when control samples (b) were compared to cells treated 
with TGF- (c), Sb431542 (d) and TGF+SB431542 (e). Autofluorescence was determined 
using no antibody (a). The gated cells (red) represent the ESAlow/- cells that represent putative 
EMT cells. Treatment with TGF- causes an increase in the percentage ESAlow/-cells. Cells 
treated with the inhibitor alone also resembled the control samples. With the addition of 
inhibitor together with TGF-, the percentage of cells within this population remains the same 







ESAlow/- 1 2 3 Average SEM 
Control 5.23 5.60 5.13 5.32 0.25 
TGF-Beta 34.83 36.05 31.05 33.98 2.61 
Inhibitor 6.53 5.75 5.21 5.83 0.66 
TGF+Inhibitor 8.63 8.66 8.56 8.62 0.05 
Table 2.33: The effect of treatment on the percentage of ESAlow/- cells. 
 
 
Figure 2.83: The effect of TGF-β and its inhibitor on the size of the ESAlow population 
within H357 cells.The changes in the ESAlow/- population when controls were compared to 
TGF-treated cells, cells treated with inhibitor alone, and cells treated with both TGF- and 
inhibitor. The percentage of cells gated as the ESAlow/- population in control samples was 
5.32±0.25% and rises significantly (x7) when they are treated with TGF- (33.98±2.61%). 
Treatment with inhibitor alone causes no effect (5.83±0.66%).When TGF- is added together 
with the inhibitor, a slight increase in this population is observed (8.62±0.05%) but this was 





Cells were further studied using immunocytochemistry to detect vimentin as an assay of the 
effect of TGF- on the expression of this protein that acts as an EMT marker and has been 
associated with acquisition of invasive and motile potential.  
1) Vimentin 
a) Control cells 
 
Figure 2.84: Expression of Vimentin in OSCC cells cultured under control 
conditions.Cultures of CA1 (a-c) and H357 (d-f) cells cultured under control conditions and 
shown in phase contrast (a, c), stained with DAPI nuclear stain (b, e) and anti-vimentin FITC 
antibody (c, f). CA1 and H357 cells form colonies with spindle cells lying outside and at the 
edges (a). The cells within the colony show no expression of vimentin while the spindle-shaped 
cells (S) show very high expression restricted mainly to the cytoplasm. H357 cells within 
colonies also remain largely negative for vimentin with the exception of elongated spindle-








Figure 2.85: Expression of Vimentin in OSCC cells treated with TGF-β.Cultures of CA1 
(a-c), and H357 (d-f) cells treated with TGF- (a, c) shown in phase contrast, stained with 
DAPI nuclear stain (b, e) and anti-Vimentin-FITC antibody (c, f). Treated cells show elongated 
spindle morphology, resemble fibroblasts, remain scattered and in both cell lines, express high 




c) Cells treated with TGF added together with inhibitor. 
 
 
Figure 2.86: Expression of Vimentin in OSCC cells cultured with SB431542 and TGF-
β.Cultures of CA1 (a-c) and H357 (d-f) cells grown with SB431542 and TGF-β added together 
(a, d) shown in phase contrast, stained with DAPI (b, e) and anti-vimentin FITC antibody (c, 
f). Cells resemble those grown under control conditions with normal colony morphology. CA1 
cells making up the colony express very low Vimentin with the exception of one spindle  cell 
(inset), lying outside the colony that expresses a very high level (c). H357 cells are shown with 
spindle cells at the colony edge that show moderate expression of Vimentin within the 







To examine the effects of TGF-β and its inhibitor on OSCC cell lines, the CA1 and H357 cell 
lines were subjected to short-term treatment (5 days) with TGF- and its inhibitor, SB431542. 
Additionally the Fanconi OHSU cell line was also analyzed (not shown). Cells from both cell 
lines displayed an elongated spindle-like morphology and showed increased migratory capacity 
as seen on time lapse videos. Cells from both lines also showed a decreased propensity to form 
adherent colonies. Treatment with the inhibitor had no adverse effects on the growth of these 
cells and SB431542 was seen to effectively block TGF-β activity as when cells were grown 
with both the inhibitor and TGF-β added together, they resembled control cells. FACS analysis 
for CD44 and ESA showed an increase in the size of the CD44highESAlow and CD44high 
populations with treatment in both cell lines but it was the H357 cell line that was found to be 
more susceptible to TGF-β as seen by the greater responses to treatment.  
This investigation was undertaken primarily to see whether the intrinsic CD44highESAlow cells 
detected under control conditions with FACS analysis could be reduced or eliminated by 
removal of TGF-β to begin with. The inhibitor blocked the EMT induced with TGF-, however 
some motile elongated cells remained when both cell lines were grown with just the inhibitor. 
This suggests that the motile population seen in OSCC cell lines under control conditions is 
not dependant on TGF- to complete this process and this was also seen in Fanconi cells. The 
same result was seen when the Fanconi OHSU cell line was examined. These observations 
suggest that multiple signalling pathways may work synergistically to bring about EMT in 
cancer cell lines. Soluble factors and cytokines such as TNF-α and EGF have been implicated 
in working synergistically with TGF-β to cause EMT characterized by the acquisition of 
spindle morphology and invasiveness in breast and ovarian cancer cells. (Asiedu et al, 2011; 
Zhihua et al, 2010).In both, these changes were further characterized by the downregulation of 
surface E-cadherin and an increase in the expression of mesenchymal markers such as Snail, 
Slug and Twist. It could also mean that the EGF (2.2.2.1) supplement present in the culture 
medium could be responsible for the EMT cells observed routinely in OSCC cultures.The role 
of EGF in the progression of many cancers has been well documented (Mendelson et al, 2000). 
It is also known that tumour cells are capable of producing endogenous cytokines such as TGF-
β, TNF-α, and these feedback contextually with the surrounding microenvironment to augment 
and possibly maintain a mesenchymal state. Other cells in the tumour microenvironment 
include cancer associated fibroblasts and it has recently been shown that they produce 
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endogenous TGF-β that inturn induces and maintains feedback loops with tumour cells 
promoting a favourable environment for tumour invasion (Kojima et al, 2010). The role of 
cancer associating fibroblasts in tumour progression has been shown for many cancers 
including those of the colon and breast where they augmented and stimulated the growth of 
tumour cells in mouse models (De Wever et al, 2004; Orimo et al, 2005). They are also known 
to induce EMT in prostate cancer cells which also results in the generation of stem capabilities 
(Cirri and Chiarugi, 2011; Gianonni, 2010).  
The expression of Vimentin was assessed in OSCC cell lines and was seen to be high in spindle-
shaped lying outside colonies (CA1) or in some cells at the edge (H357). Other cells in the 
colonies showed no expression. Treated cells showed strong cytoplasmic expression of 
vimentin. These staining patterns support the suggestion that CD44highESAlow cells have 
undergone EMT (Biddle et al, 2011) and this is supported by qPCR analysis of these cells that 
shows high expression of EMT signature genes such as vimentin, snail and Twist. This 
population was also seen to increase with treatment and treated cells show strong expression 
and spindle morphology. Up-regulation of Vimentin has been associated with EMT in cancers, 
including pancreatic cancer (Krantz et al, 2012) and bladder cancers (Shorning et al, 2011). 
Further, this increase in Vimentin has specifically been associated with areas of tumours 
showing poor differentiation and is thus linked to poor prognosis of pancreatic cancers (Javle 
et al, 2007). Vimentin has been used as a diagnostic marker in many cancers including those 
of the cervix, bladder and breast (Dal-Vecchio et al, 2011). In head and neck cancers increased 
vimentin expression has been correlated with increased metastatic risk (Nijkamp et al, 2011), 
drug resistance to the anti-cancer drug, gefitinib (Frederick et al, 2007) and loss of anchorage 






2.7 The effect of long-term treatment with TGF- and treatment 





Short term treatment caused an increase in the overall percentage of CD44highESAlow cells. This 
switching of cells into the CD44highESAlow phenotype was interesting as it implies that there 
are cells within the main bulk of the tumour that have the ability to switch into the EMT 
phenotype, but how longer term treatment would continue to expand this population was 
uncertain. It was also uncertain whether these cells were able to switch back into the epithelial 
phenotype. To investigate this, cell were treated with TGF-β for a further 10 and 20 days to 
determine the effect of long term treatment.  
2.7.2 Materials and Methods 
The methods are the same as have been discussed previously (2.5.2) 
2.7.3 Results 
I) Long-term treatment with TGF- and its effect on OSCC lines 
i) CA1 cell line 
A) CD44highESAlow:
Figure 2.87: FACS analysis of CA1 cells stained with CD44 (y-axis) and ESA (x-axis) 
PE-antibody. FACS analysis of the CD44high ESAlow population (red) within the CA1 cell line 
and indicative changes in the size of this population when control samples (a-c) were compared 
to cells treated with TGF- for 5 days (d), 10 days (e) and 20 days (f). The gated cells (red) 
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represent the CD44highESAlow cells which are the hypothesized EMT population. Treatment 
with TGF- for 5 days results in an increase in this population as seen before. Treatment with 
this for 10 and 20 days causes a progressive rise in the number of CD44highESAlow cells.  
Condition I II III % CD44highESAlow SEM 
5 days Control 1.23 1.53 1.41 1.39 0.15 
10 days Control 1.47 1.50 1.56 1.51 0.05 
20 days Control 0.53 0.76 0.70 0.66 0.12 
5 days TGFβ 10.03 8.20 9.92 9.38 1.03 
10 days TGFβ 13.00 12.66 12.89 12.85 0.17 
20 days TGFβ 15.60 15.04 14.68 15.11 0.46 
Table 2.34: The effect of long-term treatment with TGF- on CA1 cells. 
 
 
Figure 2.88: Long-term treatment with TGF-β and its effect on CD44highESAlow cells.The 
changes in the CD44highESAlow population when controls were compared with cells treated 
with TGF-β for 5, 10 and 20 days. The size of the CD44highESAlow population gated in control 
cells is low (1.39±0.15%) and increases significantly when they are treated with TGF-for 5 




B) CD44high cells: 
 
Figure 2.89: FACS analysis of CA1 cells stained with CD44 (x-axis). FACS analysis of 
the CD44high population (red) within the CA1 cell line and the changes in this population when 
control cells (a-c) were compared to those treated with TGF- for 5 days (d), for 10 days (e) 
and for 20 days (f). The gated cells (red) represent the CD44high cells which are the putative 





Condition I II III % CD44high SEM 
5 days Control 5.17 5.30 5.37 5.28 0.10 
10 days Control 3.42 3.28 3.27 3.32 0.08 
20 days Control 1.93 2.06 2.45 2.15 0.27 
5 days TGFβ 12.53 13.10 13.68 13.10 0.58 
10 days TGFβ 14.37 13.79 14.87 14.34 0.54 
20 days TGFβ 14.33 14.06 14.38 14.26 0.17 
Table 2.35: The effect of long-term treatment with TGF- on CD44highCA1 cells. 
 
 
Figure 2.90: Long-term treatment with TGF-β and its effect on CD44high cells.The 
changes in the CD44high population in CA1 cells when controls were compared with cells 
treated with TGF-β (red) for 5, 10 and 20 days. The percentage of CD44high cells was 
5.28±0.10% at day 5 rose significantly with TGF- for 5 days (13.1±0.58%), 10 days 
(14.34±0.54%) and 20 days (14.38±0.17%) respectively. The percentage of CD44high cells 
increases till day 10 and then seems to remain the same at day 20. And this increase also 
correlates with the increase in the CD44highESAlow population indicating that most of the CD44 




C) ESAlow/- cells: 
 
 
Figure 2.91: FACS analysis of CA1 cells stained with ESA (x-axis). The y-axis denotes 
side-scatter.FACS analysis of the ESAlow population (red) within the CA1 cell line and 
changes in the size of this population when control cells (a-c) were compared to those treated 
with TGF- for 5 days (d), 10 days (e) and TGF-β for 20 days (f). The gated cells (red) represent 
the ESAlow/-population thatrepresents cells shedding their epithelial state and becoming more 






Condition I II III % ESAlow SEM 
5 days Control 5.20 5.22 5.29 5.24 0.05 
10 days Control 8.17 6.23 6.93 7.11 0.98 
20 days Control 3.97 4.38 5.06 4.47 0.55 
5 days TGFβ 36.70 35.89 36.66 36.42 0.46 
10 days TGFβ 47.60 45.99 46.62 46.74 0.81 
20 days TGFβ 69.97 67.56 66.38 67.97 1.83 
Table 2.36: The effect of long-term treatment with TGF- on ESAlow/- CA1 cells 
 
 
Figure 2.92: Long-term treatment with TGF-β and its effect on ESAlow/- cells. The figure 
above shows the changes in the ESAlow/- population in CA1 cells when controls were compared 
to cells treated with TGF-β for 5, 10 and 20 days. The percentage of ESAlow/- cells gated in the 
controls was 5.24±0.05%. This rose significantly when treated with TGF- for 5 
(36.42±0.46%), 10 (46.74±0.81%) and 20 (67.97±1.83%) days. The percentage of ESAlow/- 





ii) H357 cell line 
a) CD44highESAlow 
 
Figure 2.93: FACS analysis of H357 cells stained with CD44 (y-axis) and ESA (x-axis) 
PE-antibody. FACS analysis of the CD44high ESAlow population (red) within the H357 cell 
line and changes in the size of this population when control samples (a-c) were compared to 
cells treated with TGF- for 5 days (d), 10 days (e) and 20 days (f). The gated cells (red) 
represent the CD44highESAlow cells which are the EMT population. Treatment with TGF- for 
5 days results in an increase in this population as seen before. Treatment with TGF-β for 10 






Condition I II III % CD44highESAlow SEM 
Control 5 days 4.91 5.07 5.33 5.10 0.21 
Control 10 days 5.35 5.25 5.67 5.42 0.22 
Control 20 days 4.63 5.17 5.33 5.04 0.37 
TGF 5-day 26.93 27.70 26.95 27.19 0.44 
TGF 10-day 45.00 42.79 41.03 42.94 1.99 
TGF 20-day 48.30 50.50 53.53 50.78 2.63 
Table 2.37: The effect of long-term treatment with TGF- on H357 cells. 
 
 
Figure 2.94: Long-term treatment with TGF-β and its effect on CD44highESAlow 
cells.Changes in the CD44highESAlow population when control cells were compared to those 
treated with TGF-β for 5, 10 and 20 days. The percentage of cells gated as the CD44highESAlow 
population is 5.1±0.21% in control cells. This rises highly significantly after treatment with 
TGF- for 5 (27.19±0.44%), 10 (42.94±1.99%) and 20 (50.78±2.63) days. Overall, there is a 







Figure 2.95: FACS analysis of H357 cells stained with CD44 (x-axis). The y-axis denotes 
side-scatter.FACS analysis of the CD44high population (red) within the H357 cell line and 
changes in the size of this population when control samples (a-c) were compared to those 
treated with TGF- for 5 days (d), 10 days (e) and for 20 days (f). The gated cells (red) represent 
the CD44high cells, the putative stem cell population. Treatment with TGF- for 5 and 10 days 
causes a rise in this population but the effect of treatment with 20 days is the same as that seen 






Condition I II III % CD44high SEM 
5 days Control 5.40 5.17 5.18 5.25 0.13 
10 days Control 5.07 4.53 5.10 4.90 0.32 
20 days Control 4.07 3.80 3.97 3.95 0.14 
5 days TGFβ 22.50 26.47 28.65 25.87 3.12 
10 days TGFβ 35.28 38.33 36.83 36.81 1.53 
20 days TGFβ 39.50 40.13 40.97 40.20 0.74 
Table 2.38: The effect of long-term treatment with TGF- on CD44highH357 cells. 
 
 
Figure 2.96: Long-term treatment with TGF- and its effect on CD44high cells. Changes 
in the CD44high population in H357 cells when control cells were compared to those treated 
with TGF- for 5, 10 and 20 days. The percentage of CD44high cells gated in the controls was 
5.25±0.13%, and rises significantly after treatment with TGF- for 5 (25.87±3.12%), 10 
(36.81±1.53%) and 20 (40.2±0.74%) days. This increase correlates with the increase in the 






Figure 2.97: FACS analysis of H357 cells stained with ESA (x-axis). The y-axis denotes 
side-scatter.FACS analysis of the ESAlow/- population (red) within the CA1 cell line and 
changes in the size of this population when control cells (a-c) were compared to those treated 
with TGF- for 5 days (d), 10 days (e), and for 20 days (f). The gated cells (red) represent the 
ESAlow/-cells that are shedding their epithelial state and becoming more mesenchymal. The 





Condition I II III % ESAlow/- SEM 
5 days Control 5.23 5.10 5.12 5.15 0.07 
10 days Control 6.87 6.27 6.41 6.51 0.31 
20 days Control 5.80 6.17 6.12 6.03 0.20 
5 days TGFβ 33.00 30.00 31.02 31.34 1.53 
10 days TGFβ 57.23 50.00 50.99 52.74 3.92 
20 days TGFβ 70.33 68.50 70.04 69.62 0.98 
Table 2.39: The effect of long-term treatment with TGF- on ESAlow H357 cells 
 
 
Figure 2.98: Long-term treatment with TGF- and its effect on ESAlow/- cells. The figure 
above shows the changes in the ESAlow/- population in CA1 cells when controls were compared 
to cells treated with TGF-β for 5, 10 and 20 days. The percentage of ESAlow/- cells gated in the 
controls was 5.15±0.07%. This rose significantly when treated with TGF- for 5 
(31.34±1.53%), 10 (52.74±3.92%) and 20 (69.62±0.98%) days. The percentage of ESAlow/- 




II) The effect of TGF-withdrawal on OSCC cell lines 
i) CA1 cell line: 
(a) CD44highESAlow 
Condition I II III % CD44highESAlow STDEV 
Control 1.23 1.56 2.32 1.70 0.56 
5 days TGFβ 10.03 9.52 10.47 10.01 0.48 
5 days TGFβ, 5 days withdrawal 8.10 8.65 9.60 8.78 0.76 
5 days TGFβ, 15 days withdrawal 4.73 4.63 3.81 4.39 0.50 
Table 2.40: The effect of TGF-withdrawal on CD44highESAlow CA1 cells 
 
Figure 2.99: Withdrawal of TGF- and its effect on CD44highESAlow cells.The effect of 
withdrawing TGF-β treatment on the proportion of CD44highESAlow cells within the CA1 cell 
line. Control samples were compared to samples treated with TGF- for 5 days, and those that 
had been treated with TGF- and further grown under control conditions for a further 5 and 15 
days. Withdrawal of TGF- causes a reduction in the percentage of CD44highESAlow cells and 
indicates that the effect of TGF treatment is reversible. However the proportion of these cells 







Condition I II III % CD44high SEM 
5 days Control 5.17 5.17 5.27 5.20 0.06 
5 days TGFβ 12.53 12.43 11.78 12.25 0.41 
5 days TGFβ, 5 days withdrawal 11.05 10.10 11.30 10.82 0.63 
5 days TGFβ, 15 days withdrawal 7.13 7.43 6.63 7.06 0.40 
Table 2.41: The effect of TGF-withdrawal on CD44high CA1 cells 
 
 
Figure 2.100: Withdrawal of TGF-β and its effect on CD44high cells.The effect of 
withdrawing TGF treatment on the proportion of CD44high cells within the CA1 cell line. 
Control samples were compared to those treated with TGF- for 5 days, and those that had 
been treated with TGF- and grown under control conditions for a further 5 and 15 days. 
Withdrawal of TGF- causes a significant lowering in the percentage of CD44high cells 
indicating that the effect of TGF-β treatment is reversible and by day 15 they almost resemble 






Condition I II III % ESAlow/- SEM 
5 days Control 5.20 5.40 5.28 5.29 0.10 
5 days TGFβ 36.70 34.77 30.91 34.13 2.95 
5 days TGFβ, 5 days withdrawal 36.47 33.45 29.28 33.07 3.61 
5 days TGFβ, 15 days withdrawal 10.50 10.24 11.43 10.72 0.63 
Table 2.42: The effect of TGF-withdrawal on ESAlow CA1 cells 
 
Figure 2.101: Withdrawal of TGF-β and its effect on ESAlow/- cells.The effect of 
withdrawing TGF-β treatment on the proportion of ESAlow/- cells within the CA1 cell line. 
Control samples were compared to samples treated with TGF- for 5 days and those that had 
been treated with TGF- and grown under control conditions for a further 5 and 15 days. 
Withdrawl of TGF- for 5 days did not cause a significant reduction in the proportion of 
ESAlow/- cells (33.07±3.61%). However, after 15 days of withdrawl, the percentage of ESAlow/- 
cells reduced significantly (10.72±0.63%), indicating that the effect of TGF-β on ESA in OSCC 




ii) H357 cell line 
(a) CD44highESAlow 
Condition I II III 
% 
CD44highESAlow SEM 
Control 1.23 2.43 2.82 2.16 0.83 
5 days TGFβ 10.03 9.93 10.30 10.09 0.19 
5 days TGFβ, 5 days withdrawal 7.73 8.30 9.03 8.36 0.65 
5 days TGFβ, 15 days withdrawal 4.80 5.90 6.20 5.63 0.74 
Table 2.43: The effect of TGF-withdrawal on CD44highESAlow CA1 cells 
 
 
Figure 2.102: Withdrawl of TGF-β and its effect on CD44highESAlow cells.The effect of 
withdrawing TGF-β treatment on the proportion of CD44highESAlow cells within the H357 cell 
line. Control samples were compared to samples treated with TGF- for 5 days, and those that 
had been treated with TGF- and grown under control conditions for a further 5 and 15 days. 
Withdrawal of TGF- causes a reduction in the percentage of CD44highESAlow cells and 
indicates that the effect of TGF-β treatment is reversible. However the proportion of these cells 
still remains higher than the controls indicating that some EMT cells have not switched back 






Condition I II III % CD44high SEM 
5 days Control 5.17 5.33 5.25 5.25 0.08 
5 days TGFβ 12.53 13.10 14.00 13.21 0.74 
5 days TGFβ, 5 days withdrawal 9.13 11.50 12.10 10.91 1.57 
5 days TGFβ, 15 days withdrawal 7.13 7.40 8.10 7.54 0.50 
Table 2.44: The effect of TGF-withdrawal on CD44high H357 cells 
 
 
Figure 2.103: Withdrawal of TGF-β and its effect on CD44high cells.The effect of 
withdrawing TGF treatment on the proportion of CD44high cells within the H357 cell line. 
Control samples were compared to those treated with TGF- for 5 days, and those that had 
been treated with TGF- and grown under control conditions for a further 5 and 15 days. 
Withdrawal of TGF- causes a significant lowering in the percentage of CD44high cells 







Condition I II III % ESAlow/- SEM 
5 days Control 5.20 5.23 5.23 5.22 0.02 
5 days TGFβ 36.70 33.00 33.00 34.23 2.14 
5 days TGFβ, 5 days withdrawal 36.47 26.63 31.63 31.58 4.92 
5 days TGFβ, 15 days withdrawal 14.83 19.53 19.53 17.97 2.71 
Table 2.45: The effect of TGF-withdrawal on ESAlow/- H357 cells 
 
 
Figure 2.104: Withdrawal of TGF-β and its effect on ESAlow/- cells.The effect of 
withdrawing TGF-β treatment on the behaviour of ESAlow/- cells within the H357 cell line is 
demonstrated above. Control samples were compared to samples treated with TGF- for 5 days 
and those that had been treated with TGF- and grown under control conditions for a further 5 
and 15 days. Withdrawl of TGF- causes a significant reduction in the proportion of ESAlow/- 
cells after withdrawl for 5 (31.58±4.92%) and 15 (17.97±2.71%) days. A large proportion of 







Treatment with TGF- for 5 days caused an increase in the relative proportion of 
CD44highESAlow, CD44high and ESAlow/- cells within the bulk of the population. Treatment with 
TGF-β for longer indicated that this further increased the size of these populations. At the end 
of twenty days, very few cohesive cells remained. The response of the two cell lines studied 
varied with the H357 cells showing more susceptibility to TGF-β treatment compared to the 
CA1 cell line. The number of cells expressing high levels of CD44 increased in both lines 
examined and this correlated with the increase in the CD44highESAlow population. TGF-β also 
caused a decrease in the expression of ESA and the response shown by the H357 cell line was 
greater than that for CA1 cells.  
For both lines, withdrawing TGF-β treatment caused a decrease in the CD44highESAlow 
population. By day 15, after withdrawal of TGF-β, the proportion of CD44highESAlow cells 
declined in both cell lines but remained higher than the controls, suggesting that the effect of 
TGF- is largely but slowly reversible. That some of the cell remained CD44highESAlow even 
after 15 days of withdrawal, suggests that there may be a small proportion of CD44highESAlow 
cells that does not revert back.  
The next questions asked were: 
Do these cells (CD44highESAlow) have the ability for self-renewal and do they possess stem 
potential? 














This chapter will deal with the questions raised from the previous experiments about the 
CD44highESAlow population of cells within the cell lines. Mani and co-workers suggested that 
EMT generates cells with the properties of stem cells. As TGF- seems to more or less 
exclusively affect this CD44highESAlow population and these represents the cells that have 
undergone EMT, we were interested to find out whether these cells have self-renewal and 
clonogenic potential. Further, invasiveness and migratory tendencies are also properties 
possessed by stem-like cells. For this experiment, cells from both the cell lines examined 
previously, CA1 and H357 were sorted into three quadrants that were CD44highESAlow, 
CD44highESAhigh and CD44low(ESAhigh). It has already been shown in the previous sections that 
CD44 enriches for cells with the stem cell property of clonogenicity and self-renewal. In breast 
cancer a stem like proportion of cells was isolated which was CD44highESAlow and CD24low. 
The rationale behind this study is that if cells have stem cell ability, then they should be able 
to reconstitute the cellular heterogeneity or hierarchy of cells detected with FACS analysis. 
Hence cells from these three quadrants were sorted into collecting tubes and plated out at clonal 
density. They were allowed to grow/recover for five days and then detached from the dish and 
analyzed using the FACS Canto (BD) machine and BDFACSDiva software to check whether 
cellular heterogeneity had been restored.  
 
 
2.8.2 Materials and Methods 








a) Sorting  
 
 
Figure 2.105: Sorting of CA1 and H357 cells. Representative FACS plots for CA1 (a) and 
H357 (b) cells co-stained with CD44 (y-axis) and ESA (x-axis) antibody. The gated 
populations are CD44highESAlow (yellow), CD44highESAhigh (red) and CD44lowESAhigh (green). 
Cells from the three populations were simultaneously sorted and plated at clonal density and 
cultured. After 5-7 days, cells were detached and analyzed for co-expression of CD44 and ESA 
to check whether cellular heterogeneity was restored. For controls, cell were passed through 





(b) OSCC re-plate Analysis 
(i) CD44highESAhighre-plate 
 
Figure 2.106: FACS analysis of sorted CD44highESAhigh OSCC cells. The FACS plots 
obtained for control CA1 (a) and H357 (c) cells, compared to those generated by culture of 
sorted CD44highESAhigh cells (b, d), stained CD44 (PE, y-axis) and ESA (APC, x-axis) 
antibodies. 
The sorted CD44highESAhigh population seems to fully restore cellular heterogeneity of CA1 (b) 
and H357 (d) cells, and generate characteristic FACS plots normally seen for these cell lines. 
The main bulk of the cells stain high for CD44 and ESA forming the main bulk of the 






Figure 2.107: FACS analysis of sorted CD44highESAlow OSCC cells. The FACS plots 
obtained for control cells CA1 (a) and H357 (c) cells, compared to those generated by culture 
of sorted CD44highESAlow cells (b, c), stained with CD44 (PE, y-axis) and ESA (APC, x-axis) 
antibodies. 
The sorted CD44highESAlow population also restores cellular heterogeneity for CA1 (b) and 
H357 (d) cells generating similar FACS plots normally seen for these cell lines. For both lines 







Figure 2.108: FACS analysis of sorted CD44low OSCC cells. The FACS plots for control 
CA1 (a) and H357 (c) cells, compared to those from cultures of sorted CD44lowESAhigh cells, 
stained with CD44 (PE, y-axis) and ESA (APC, x-axis) antibodies. The sorted CD44lowESAhigh 
population does not reconstitute the characteristic facsplots seen for CA1 (b) and H357 (d) cell 




(2) Cell morphology generated by sorted CD44highESAlow and CD44highESAhighOSCC 
cells 
(i) CA1 cell line 
 
Figure 2.109: Colony morphology shown by sorted CA1 cell populations when 
replated.The colony morphologies generated when CD44highESAlow cells (a, b) and 
CD44highESAhigh (c, d) cells were sorted out of the main population and replated at clonal 
density. CD44highESAlow cells give rise to two different types of cells. There were cells among 
these that form large scattered holoclone-like colonies (a) and show characteristic cobblestone 
morphology with a pronounced ring of spindle cells that look like fibroblasts and circled the 
colony. The other type formed clusters of elongated cells that were ovoid and spindle- like in 
appearance. CD44highESAhigh cells when plated out retain their epithelial morphology and form 
mostly holoclones among meroclones and paraclones (c), made up of cobblestone cells. These 
grow up to a large size and there are also moderate numbers of spindle shaped and ovoid motile 




(ii) H357 cell line 
 
 
Figure 2.110: Colony morphology shown by sorted H357 cell populations when 
replated.The colony morphologies generated when CD44highESAlow cells (a, b) and 
CD44highESAhigh (c, d) cells were sorted out of the main population and replated at clonal 
density. CD44highESAlow cells give rise to two different types of cells. There were cells among 
these that form large holoclone-like colonies (a) and show characteristic cobblestone 
morphology with a pronounced ring of spindle cells that look like fibroblasts and circled the 
colony. The other type formed clusters of elongated cells that were ovoid and spindle- like in 
appearance. CD44highESAhigh cells when plated out retain their epithelial morphology and form 
mostly holoclones among meroclones and paraclones, made up of cobblestone cells. There are 





The aim of this experiment was to ascertain whether the EMT fraction within OSCC, the 
CD44highESAlow cells, had stem cell potential and whether they could restore cellular 
heterogeneity seen in OSCC lines. To check this, FACS sorted CD44highESAlow cells were 
compared to CD44highESAhigh cells, the known stem fraction within OSCC lines and CD44low 
cells that are thought to be differentiated cells with no stem potential. Sorted cells were grown 
from clonal density and then analyzed for differences in morphology and for co-expression of 
CD44 and ESA. CD44highESAhigh cells grew, predominantly as holoclones and showed 
characteristic morphology seen in OSCC lines and spindle cells could be identified at the edges 
of the colonies or lying outside them. In comparison to these cells, CD44highESAlow cells grew 
predominantly as elongated spindle cells with few scattered holoclone colonies that grow to a 
large size. In contrast, CD44low cells showed poor growth and formed paraclones. This 
suggested that the CD44highESAhigh cells were the non-EMT stem cell fraction while the 
CD44highESAlow cells were EMT cells that contained some cells that could switch back to the 
non-EMT through the process of MET and collectively show that each can regenerate the other. 
It has now been shown that the majority of cells in the CD44highESAhigh subpopulation are 
bipotent by their ability to give rise to both non-EMT and EMT fractions seen within OSCC 
lines (Biddle et al, 2011) when sorted cells were allowed to recover and analyzed for CD44 
and ESA co-expression. Collaborative work done in the lab has also shown that the 
CD44highESAlow/+ (nearer to the main population) have high ALDH1 activity and represent 
EMT cells that have stem potential as shown by their ability to fully restore cellular 
heterogeneity. This shows that there are cells present within OSCC lines that could undergo 
EMT, become migratory, and then switch back through the process of MET, and is also in 
support of the migrating stem cell hypothesis proposed by Brabletz and co-workers (2005) that 
states that malignant stem cells acquire two phenotypes, one that favours growth and 
proliferation and the other that favours migration and invasion involving transient expression 
of mesenchymal markers by cells (EMT) that could be reversed by mesenchymal to epithelial 




2.9 The effect of TNF-α on EMT in OSCC cell lines and the combined 
effect of TNF- and TGF- on these lines. 
 
2.9.1 Introduction 
This section deals with the effect of TNF- on OSCC cell lines and the possible involvement 
of TGF- in this interaction. Recent studies on breast cancer cell lines have implicated TNF- 
in augmenting or positively reinforcing TGF-β-induced EMT in these lines. Asiedu and co-
workers found that TNF used in conjunction with TGF- generated breast cancer cells with 
EMT characteristics that showed lowered surface expression of E-Cadherin and increased 
expression of Vimentin. They were also able to show that these cells showed high self-renewal 
and clonogenicity judged by their ability to form spheres in culture. These cells also readily 
initiated tumours in mice and reconstituted tumour heterogeneity. Further the cells generated 
by treatment were also more resistant to anti-cancer drugs such as paclitaxel (Asiedu et al, 
2011). Results discussed in the previous sections suggest that TGF- causes EMT in OSCC 
cell lines and we were interested to see whether this effect could be enhanced by using both 
TNF-α and TGF-β together. The CA1 and H357 cell lines were again used for this as they 
express a readily identifiable population of EMT cells which stand out from other cells by being 
CD44highESAlow. 
 
2.9.2 Materials and methods 
The methods for FACS analysis have been previously discussed. (2.3.2, 2.4.2). TNF-α (R&D 
Systems) was resuspended in PBS and used at a concentration of 10ng/ml and added once to 






1) CA1 cells: 
A) Cell Morphology 
 
Figure 2.111: The effect of TNF-α on growth of CA1 cells. Cultures of CA1 cells grown 
under control conditions (a), with TGF-β (b), TNF-α and TGF-β (c), TNF-α (d), TNF-α + 
inhibitor (e), TGF-β + inhibitor. Control cells (a) show normal colony morphology and form 
holoclones (H), meroclones (M) and paraclones (P). Cells treated with TGF-β form spindle 
shaped cells with decreased colony formation. Cells with both TGF-β and TNF-α formed only 
elongated spindle cells resembling fibroblasts without any colony formation (c). Cells treated 
with TNF-β alone and TNF-α + inhibitor also displayed spindle morpholody with reduced 




B) FACS Analysis 
a) CD44highESAlow 
 
Figure 2.112: FACS analysis of CA1 cells stained with CD44 (y-axis) and ESA (x-axis) 
fluorescent antibodies 
The FACS plots obtained when CA1 cells were stained with CD44 and ESA antibodies and 
analyzed for the effect of treatment with TGF-β and TNF-α on specifically the CD44highESAlow 
population (gated, red). Panel (a) shows the analysis without any added antibody to adjust for 
background noise. Cells were analyzed as controls (b), cell treated with TGF- (c), TNF- (d), 
both TGF-β and TNF-α (e) and TNF-α added together with SB431542 (f).  
Treatment with TGF-β and TNF-α alone causes the percentage of CD44highESAlow cells to rise 
when they are added separately and both individually cause about the same increase. When 
both TGF-β and TNF-α are added together the percentage of CD44highESAlow cells rises much 
more significantly as when they are added alone and the whole epithelial population shifts into 
the 44/ESA gate. When TNF-α and SB431542 are added together the gated population stays 





CD44highESAlow 1 2 3 Average SEM 
Control 3.83 3.67 3.93 3.81 0.13 
TGF 11.00 9.40 9.47 9.96 0.91 
TNF 9.73 11.00 9.80 10.18 0.71 
TGF+TNF 35.00 33.83 34.73 34.52 0.61 
TNF+SB 8.27 7.73 6.47 7.49 0.92 
Table 2.46: Change in the percentage of CD44highESAlow cells with treatment. 
 
Figure 2.113: Changes in the CD44highESAlow population in the CA1 cell line with TNF-
α. 
The figure above shows the changes in the CD44highESAlow subpopulation of cells detected as 
a separate population when Ca1 cells were grown under control conditions, with TGF- 
(20ng/ml), TNF- (10ng/ml), both TGF-β and TNF-α, and TNF-α with SB431542 which is an 
inhibitor of TGF- discussed earlier. Cells treated only with TGF- showed a higher 
percentage of cells which were CD44highESAlow/- compared to controls. The same effect was 
achieved when cells were treated with TNF- alone. When both TGF-β and TNF-α were added 
together, it caused a major rise in this population and 34.52±0.61% of the cells were 
CD44highESAlow/- showing that both work synergistically. Inhibition with SB431542 caused a 







Figure 2.114: FACS analysis of CA1 cells stained with CD44 (x-axis) antibody and the 
effect of treatment on the CD44high cell population within the cell line. The figure above 
shows the facsplots obtained when CA1 cells (a) were stained with CD44 antibody (b-e) and 
analyzed to detect changes in the population of CD44high (gated, red). Cells were grown under 
control conditions (b), with TGF- (c), with TNF- (d), TGF-β and TNF-α together (e) and 
TNF-α with SB431542 (f). The top 5% of the cells expressing the highest levels of CD44 were 
selected as CD44high and gated. The effects of the treatments were analyzed by keeping the 
gates unchanged between experimental samples. The highest increase in this population was 
seen when TGF-β and TNF-α were added together. TNF-α on its own did increase the 
percentage of cells that were CD44high but this increase was insignificant compared to controls. 
TGF- caused CD44high cells to increase but this was insignificant as to the increase detected 




CD44high 1 2 3 Average SEM 
Control 4.80 5.23 5.47 5.17 0.34 
TGF 9.63 8.90 10.43 9.66 0.77 
TNF 6.90 8.20 7.33 7.48 0.66 
TGF+TNF 37.43 37.50 37.10 37.34 0.21 
TNF+SB 8.00 6.00 5.87 6.62 1.20 
Table 2.47: Changes in the percentage of CD44high cells with TNF-α. 
 
 
Figure 2.115: Changes in the CD44high population with treatment.The figure above 
shows the changes in the CD44high subpopulation when the CA1 cell line were grown under 
control conditions, with TGF- (20ng/ml), TNF- (10ng/ml), both TGF and TNF, and TNF 
with SB431542 which is an inhibitor of TGF- discussed earlier. Cells treated only with TGF-
 showed a higher percentage of cells which were CD44high (9.66±0.77%) compared to 
controls. The same effect was achieved when cells were treated with TNF- (7.48±0.66%) 
alone although this was insignificant. When both TGF-β and TNF-α were added together, it 
caused a major rise in this population and 37.34±0.21% of the cells were CD44high showing 
that both work synergistically. This also correlated with the increase in the CD44highESAlow 
cells. Inhibition with SB431542 caused a decrease in TNF-α activity but did not completely 






Figure 2.116: FACS analysis of CA1 cells stained with ESA(apc) antibody (x-axis) and 
the effect of treatment on the ESAlow/- cell population within the cell line.The figure above 
shows the FACSPLOTS obtained when CA1 cells (a) were stained with ESA antibody (b-e) 
and analyzed to detect changes in the ESAlow population (gated red). Cells were grown under 
control conditions (b), with TGF- (c), with TNF- (d), TGF-β and TNF-α together (e) and 
TNF-α with SB431542 (f). The 5% of the cells expressing the lowest levels of ESA were 
selected as ESAlow/- and gated. The effects of the treatments were analyzed by keeping the gates 
unchanged between experimental samples. The highest increase in this population was seen 
when TGF-β and TNF-α were added together. TNF-α on its own did increase the percentage 
of cells which were CD44high but this increase was insignificant compared to controls. TGF-
 caused CD44high cells to increase but this was insignificant as to the increase detected when 





ESAlow 1 2 3 Average SEM 
Control 5.20 5.17 5.17 5.18 0.02 
TGF 9.10 10.53 9.83 9.82 0.72 
TNF 6.20 6.70 5.40 6.10 0.66 
TGF+TNF 27.00 25.43 26.17 26.20 0.78 
TNF+SB 6.97 5.73 5.80 6.17 0.69 
Table 2.48: Changes in the percentage of ESAlow/- cells with treatment. 
 
Figure 2.117: The effect of treatment on the ESAlow/- population of CA1 cells.The changes 
in the ESAlow/- subpopulation when the CA1 cell line were grown under control conditions, 
with TGF- (20ng/ml), TNF- (10ng/ml), both TGF-β and TNF-α, and TNF-α with SB431542, 
an inhibitor of TGF- discussed earlier. Cells treated with TGF- showed a significantly 
higher percentage of cells that were ESAlow/- (9.82±0.72%) compared to controls. The same 
effect was achieved when cells were treated with TNF- (6.10±0.66%) alone although this was 
less, but still significant. When both TGF-β and TNF-α were added together, it caused a major 
rise in this population and 26.20±0.78% of the cells were CD44high showing that both work 
synergistically, and this was highly significant. This also correlated with the increase in the 
CD44highESAlow cells. Inhibition with SB431542 caused a decrease in TNF-α activity but did 




2) H357 cells: 
A) Cell morphology 
 
Figure 2.118: The effect of TNF-α on growth of H357 cells. Cultures of H357 cells grown 
under control conditions (a), with TGF-β (b), TNF-α and TGF-β (c), TNF-α (d), TNF-α + 
SB431542 (e), TGF-β + inhibitor. Control cells (a) show normal colony morphology and form 
holoclones (H), meroclones (M) and paraclones (P). Cells treated with TGF-β form spindle 
shaped cells with decreased colony formation. Cells with both TGF-β and TNF-α formed only 
elongated spindle cells resembling fibroblasts without any visibly adhesive cells. Cells treated 
with TNF-α alone and TNF-α + inhibitor also displayed spindle morpholody with reduced 




B) FACS Analysis 
a) CD44highESAlow 
 
Figure 2.119: FACS analysis of H357 cells stained with CD44 (y-axis) and ESA (x-axis) 
fluorescent antibodies. The FACS plots obtained when H357 cells were stained with CD44 
and ESA antibodies and analyzed for the effect of treatment with TGF-β and TNF-α on 
specifically the CD44highESAlow population (gated, red). Panel (a) shows the analysis without 
any added antibody to adjust for background noise. Cells were then analyzed as controls (a), 
cell treated with TGF- (c), TNF- (d), both TGF-β and TNF-α (e) and TNF-α added together 
with SB431542 (f).  
Treatment with TGF-β alone causes the percentage of CD44highESAlow cells to rise more when 
compared to treatment with TNF alone which causes a rise in this population but this effect is 
less marked than with TGF-. This is in contrast to the CA1 cell line where both TGF-β and 
TNF-α produce almost the same effect when they are added on their own. When both TGF-β 
and TNF-α are added together the percentage of CD44highESAlowcells rise to much higher levels 
than when TGF- is added on its own. When TNF-α and SB431542 are added together the 





CD44highESAlow 1 2 3 Average SEM 
Control 5.70 5.80 5.80 5.77 0.06 
TGF 34.37 28.97 28.97 30.77 3.12 
TNF 11.40 10.40 9.00 10.27 1.21 
TGF+TNF 61.10 47.33 47.33 51.92 7.95 
TNF+SB 7.33 5.47 5.47 6.09 1.08 
Table 2.49: Changes in the percentage of CD44highESAlow cells with treatment. 
 
Figure 2.120: Changes in the CD44highESAlow population in the H357 cell line with or 
without treatment.The changes in the CD44highESAlow subpopulation of cells detected as a 
separate population when H357 cells were grown under control conditions, with TGF- 
(20ng/ml), TNF- (10ng/ml), both TGF-β and TNF-α, and TNF-α with SB431542 which is an 
inhibitor of TGF- discussed earlier. Cells treated only with TGF- showed a higher 
percentage of cells which were CD44highESAlow/- compared to controls. The same effect was 
achieved when cells were treated with TNF- alone. When both TGF-β and TNF-α were added 
together, it caused a major rise in this population and 51.92% of the cells were CD44highESAlow/- 
showing that both work synergistically. Inhibition with SB431542 caused a decrease in TNF-






Figure 2.121: FACS analysis of H357 cells stained with CD44 (x-axis) antibody and the 
effect of treatment on the CD44high cell population within the cell line.The FACSPLOTS 
obtained when H357 cells (a) were stained with CD44 antibody (b-e) and analyzed to detect 
changes in the population of CD44high (gated, red). Cells were grown under control conditions 
(b), with TGF- (c), with TNF- (d), TGF-β and TNF-α together (e) and TNF-α with 
SB431542 (f). The top 5% of the cells expressing the highest levels of CD44 were selected as 
CD44high and gated. The effects of the treatments were analyzed by keeping the gates 
unchanged between experimental samples. The highest increase in this population was seen 
when TGF-β and TNF-α were added together. TNF-α on its own did increase the percentage 
of cells which were CD44high but this increase was insignificant compared to controls. TGF- 
caused CD44high cells to increase but this was insignificant as to the increase detected when the 





CD44high 1 2 3 Average SEM 
Control 5.47 5.27 5.23 5.32 0.13 
TGF 31.33 27.40 26.90 28.54 2.43 
TNF 17.37 12.83 16.83 15.68 2.48 
TGF+TNF 66.23 55.00 55.00 58.74 6.49 
TNF+SB 6.87 6.00 5.20 6.02 0.83 
Table 2.50: Changes in the percentage of CD44high cells with treatment. 
 
Figure 2.122: Changes in the CD44high population with treatment.The changes in the size 
of the CD44high subpopulation of cells within the H357 cell line. Cells were grown under 
control conditions, with TGF- (20ng/ml), TNF- (10ng/ml), both TGF-β and TNF-α, and 
TNF-α with SB431542 which is an inhibitor of TGF- discussed earlier. Cells treated only with 
TGF- showed a significantly higher percentage of cells that were CD44high (28.54±2.43%) 
compared to controls. The same effect was achieved when cells were treated with TNF- 
(15.68±2.48%) alone although to a lesser extent. When both TGF-β and TNF-α were added 
together, it caused a major rise in this population and 58.74±6.49% of the cells were CD44high 
showing that both work synergistically. This also correlated with the increase in the 
CD44highESAlow cells. Inhibition with SB431542 caused a decrease in TNF-α activity but did 




c) ESAlow/- cells 
 
Figure 2.123: FACS analysis of H357 cells stained with ESA (APC) antibody (x-axis) and 
the effect of treatment on the ESAlow/- cell population within the cell line.The facsplots 
obtained when H357 cells (a) were stained with ESA antibody (b-e) and analyzed to detect 
changes in the ESAlow/- population (gated, red). Cells were grown under control conditions (b), 
with TGF- (c), with TNF- (d), TGF-β and TNF-α together (e) and TNF-α with SB431542 
(f). The 5% of cells expressing the lowest levels of ESA were selected as ESAlow and gated. 
The effects of the treatments were analyzed by keeping the gates unchanged between 
experimental samples. The highest increase in this population was seen when TGF-β and TNF-
α were added together. TNF-α also increases this ESAlow population as is evident by the 
increased number of cells within the gate. TGF- also increases the percentage of cells which 
were ESAlow/- as was discussed in the last chapter but this was insignificant as to the increase 





ESAlow/- 1 2 3 Average SEM 
Control 5.27 5.00 5.17 5.14 0.13 
TGF 41.40 40.13 40.62 40.72 0.64 
TNF 12.30 7.63 9.53 9.82 2.35 
TGF+TNF 72.10 66.70 65.60 68.13 3.48 
TNF+SB 11.13 6.40 7.15 8.23 2.54 
Table 2.51:  Changes in the percentage of ESAlow/- cells with TNF-α. 
 
Figure 2.124: The effect of treatment on the ESAlow/- population of H357 cells.The changes 
in the ESAlow/- subpopulation when H357 cells were grown under control conditions, with 
TGF- (20ng/ml), TNF- (10ng/ml), both TGF-β and TNF-α, and TNF-α with SB431542 
which is an inhibitor of TGF- discussed earlier. Cells treated only with TGF- showed a 
higher percentage of cells which were ESAlow/- (40.72±0.64%) compared to controls. TNF-α 
on its own caused a lesser effect that it did when used on the CA1 cell line. However, when 
both TGF-β and TNF-α were added together, it caused a major rise in this population and 
68.13±3.48% of the cells were ESAlow/- showing that both work synergistically. This also 
correlated with the increase in the CD44highESAlow cells. Inhibition with SB431542 caused a 
decrease in TNF-α activity but did not completely block it as there was still a significant 





The aim of this chapter was primarily to ascertain the effect of TNF-α on OSCC cells and also 
the combined effect of TGF-β and TNF-α on these cell lines. FACS analysis was used to assess 
the changes in the size of the CD44highESAlow, CD44high and ESAlow/- populations. The tumour 
environment has been described as a wound that never heals (Biddle and Mackenzie, 2012) 
and epithelial tissues are subjected to a variety of EMT-inducing stromal factors upon 
wounding. These include TGF-β and TNF-α, known to be secreted by immune cells (Kalluri 
and Weinberg, 2009) and to be enhanced by tissue inflammation at the wounding site (Wu et 
al, 2009). The stromal tissue surrounding the tumour to plays a vital role in promoting and 
maintaining tumour development as shown by the involvement of cancer associated fibroblasts 
(Olumi et al, 1999). Recent work with TGF-β has strengthened this observation (Kojima et al, 
2010). TNF-α is a pro-inflammatory cytokine that has been associated with the progression of 
many cancers including osteosarcoma where it was shown to mediate the activation of pro-
inflammatory genes (Cvoro et al, 2011). In breast cancer, TNF-α has been shown to interact 
synergistically with TGF-β to generate EMT cancer cells that also possess the hallmark 
CD44highCD24low/- signature for breast cancer stem cells (Asiedu et al, 2011). Our results 
support this finding and show that the effect of TNF-α on OSCC cells is similar to that of TGF-
β in causing an increase in the EMT population (CD44highESAlow) and an increase in the size 
of both the CD44high and ESAlow/- populations. Further to this we found that the addition of 
TNF-α and TGF-β together greatly enhances the effect seen indicating that they work together 
synergistically to promote EMT in OSCC cells. The response of cell lines varied butwhen TGF-
β and TNF-α were added together there was a significant increase in the size of the 
CD44highESAlow population in both CA1 (x10) and H357 (x12) cells. Further, there was an 
increase in the size of both, the CD44high and ESAlow/- populations. On microscopic 
examination, cells from both lines were seen to possess a spindle-shaped morphology and a 








The previous chapters have primarily dealt with the effect of TGF- on cellular morphology 
and the relative change in the proportion of intrinsic CD44highESAlow, the CD44high, and 
ESAlow/-populations present in OSCC cell lines. To address the question of whether TGF- 
directly increases cell migration (a) the effect of TGF- on cellular migration was determine 
and (b) the effect on this process of other compounds potentially affecting EMT was 
examined.Elevated COX-2 expression has also been documented for many cancers including 
OSCCs (Minter et al, 2003). Nonsteroidal anti-inflammatory drugs (NSAIDS) have marked 
antitumour activity affected through inhibition of COX-2 regulated pathways and these have 
been shown to be chemopreventive in animal models of colon, bladder and breast cancers 
(Williams et al, 1999). Epidemiological studies indicate that NSAIDs reduce breast and 
oesophageal cancer mortality (Zha et al, 2004). In OSCCs, it has been shown that NS-398, a 
selective COX-2 inhibitor, suppressed the invasion of OSCC cells and it would found that this 
was dependant on the integrin αvβ6, that is known to be a receptor for TGF-β (Munger et al, 
1999). The role of NS-398 was this evaluated to determine its effect on the migration of OSCC 
cells.  
 
2.9.2 Materials and Methods 
Cells were grown to confluence in 6-well plates. A p1000 pipette tip was used to make a 
scratch across the center of each wellafter which the cells were washed and refreshed with 
complete media. Pictures were takenevery 24 hrs on an inverted microscope (Nikon) to 
evaluate migration across the scratch. ImageJ software (Zeiss) was used to measure the area 
each scratch for each of the time points examined. For each experiment, 3 fields along the 
scratch in each well were analyzed in triplicate for each sample. The area uncovered with 
cells was converted to the area covered by subtracting from the total area available for 






A) CA1 cell line 
 
Figure 2.125: Scratch/migration assay for the CA1 cell line (part1).Cultures of control 
CA1 cells (top row; a-c) and those treated by TGF- treated cells (bottom row; d-f) subjected 
to a scratch assay. Control cells and TGF- treated cells were scratched and photographed at 
T0 (a, d) and the migration of cells across the wound was assessed at T-24hours (b, e) and T-
48 hours. The relative area remaining at the end of the time periods was assessed to calculate 
the area covered and control cells were compared to those treated with TGF-for all the time 
points. Cells treated with TGF-β migrate across the scratch faster and within 48 hours the gap 





CA1 cell line % Area covered 24hrs 
SD 
n=3 % Area covered 48hrs 
SD 
n=3 
Control 28.70 2.36 74.60 4.45 
TGF-β 84.90 3.17 94.93 3.70 
Table 2.52: Area that was covered by control and TGF-β treated CA1 cells. 
 
 
Figure 2.126: Migration of control CA1 cells compared to TGF-β treated cells.A 
comparison of the relative area covered in control cells compared to the area covered by TGF-
 treated cells. TGF- treated cells migrate quicker and cover 84.9±3.17% of the scratched area 
in 24 hours and 94.9±3.7% in 48 hours. In comparison, control cells migrate slower and cover 





Figure 2.127: Scratch/migration assay for the CA1 cell line (part2).The results of a scratch 
assay of CA1 cells treated with Inhibitor of TGF- (a-c), TGF- and Inhibitor added together 
(d-f) and NS-398 (g-i). Cells for all three treatments were photographed at T0 (a, d, g), T24 
hours (b, e, h) and T48 hours (c, f, i). The relative area remaining at the end of the time periods 
was assessed to calculate the area covered and cells were compared to controls discussed earlier 
(Figure 3.9b). Cells treated with inhibitor alone, and TGF- added with the inhibitor, migrate 
over the same relative areas at all time periods. NS-398 slowed down the migration of cells as 




CA1 cell line % Area covered 24hrs SD % Area covered 48hrs SD 
Inhibitor 19.71 1.66 65.33 5.04 
TGF-β+Inhibitor 22.68 3.60 70.32 1.98 
NS-398 15.51 2.32 58.88 3.11 
Table 2.53: Area covered by cells treated with SB431542 (±TGF) and NS-398 
 
 
Figure 2.128: The effect of SB431542, with or without TGF-β and NS398 on 
migration.The effect of SB431542 (TGF-inhibitor) alone, SB431542 together with TGF- 
and NS-398 (a COX-II inhibitor) on the migration of CA1 cells across the scratch. Cells treated 
with SB431542, and SB431542 added with TGF-showed the similar rates of migration at 24 
hours (19.71±1.66%, 22.68±3.60%) and 48 hours (65.33±5.04, 70.32±1.98) to controls. Cells 
treated with NS-398 showed slower migration and covered less area in 24 hours (15.51±2.32) 
and 48 hours (58.88±3.11%) as is evident by the gaps remaining at the end of treatment. There 




B) Fanconi cells line 
 
Figure 2.129: Scratch/migration assay for the OHSU Fanconi cell line (part1).The figure 
above shows control OHSU Fanconi cells (top row; a-c) and TGF- treated cells (bottom row; 
d-f) subjected to a scratch assay. Control and TGF- treated cells were scratched and 
photographed at Time 0 (a, d) and the migration of cells across the wound was assessed at 24 
hours (b, e) and 48 hours. Cells treated with TGF-β migrated across the scratch the faster and 
within 48 hours the gap is almost covered. As discussed later, spindle shaped cells resembling 




OHSU cell line % Area covered 24hrs 
SD 
n=3 % Area covered 48hrs 
SD 
n=3 
Control 27.71 3.84 61.27 2.56 
TGF-β 64.45 4.60 87.41 2.18 
Table 2.54: Area that was covered by control and TGF-β treated OHSU cells. 
 
 
Figure 2.130: Migration of control OHSU cells compared to TGF-β treated cells.The 
figure above compares the relative area covered by control cells compared to the area covered 
by TGF- treated cells. Again, TGF- treated cells close the gap quicker and cover 66.45±4.6% 
of the scratched area in 24 hours and 87.41±2.18% in 48 hours. Control cells migrate slower 





Figure 2.131: Scratch/migration assay for the OHSU cell line (part2). The figure above 
shows the results of a scratch assay CA1 cells treated with Inhibitor of TGF- (a-c), TGF- 
and Inhibitor added together (d-f) and NS-398 (g-i). Cells for all three treatments were 
photographed at T0 (a, d, g), T24 hours (b, e, h) and T48 hours (c, f, i). Cells treated with 
Inhibitor alone and TGF- added with the inhibitor, migrate over similar relative areas each 
time period. NS-398 seems to slow down the migration of cells as is evident by the uncovered 





OHSU cell line 
% Area covered 
24hrs SD 
% Area covered 
48hrs SD 
Inhibitor 19.90 1.75 52.70 3.10 
TGF-β+Inhibitor 25.39 1.60 43.25 3.23 
NS-398 28.67 2.70 46.83 1.81 
Table 2.55: Area covered by cells treated with SB431542 (±TGF) and NS-398 
 
 
Figure 2.132: The effect of SB431542 with or without TGF-β and NS398 on migration. 
The figure above shows the effect of SB431542 (inhibitor) added alone, with TGF- and NS-
398 (COX-II inhibitor) on the migration of OHSU Fanconi cells across the scratch. Cells 
treated with SB431542 and SB431542 added with TGF- showed roughly the same rates of 
migration in 24 hours (19.90±1.75%, 25.39±1.60%). In 48 hours cells with both the inhibitor 
and TGF added together had covered slightly less area (43.25±3.23%) compared to those with 
inhibitor alone (52.70±3.10%). Cells treated with NS-398 showed slower migration and 
covered less area in 24 hours (28.67±2.70) and 48 hours (46.83±1.81%) as is evident by the 
gaps remaining at the end of treatment. There were also fewer motile cells seen migrating 





The aim if this experiment was to determine the effect of TGF- and its inhibitor (SB431542) 
on the migration of OSCC cells. The secondary aim was to see the effect of a known COX-II 
inhibitor (NS-398) on these lines as it has been shown to inhibit invasion in OSCC cells through 
interactionswith the integrin αvβ6,also a receptor for TGF-β.It was found that TGF- enhances 
cell migration and this effect was seen with boththe CA1 and Fanconi cell lines. Treated cells 
migrate faster than controls and covered 94% and 84% (CA1, OHSU) of the scratch area by 48 
hours with control cells covering only 74% and 61% respectively. Photographedunder high 
magnification, the scratch area shows cells resembling fibroblasts migrating across the scratch. 
The cells at the edge of the scratch also seemed to have undergone EMT as is apparent by their 
spindly morphology. The figure below shows Ca1 cells photographed at 24 (a) and 48 hours 
(b) with regions withininsets further magnified to show the elongated cells.  
 
Figure 2.133: CA1 cells migrating across the scratch.The migration of CA1 cells across the 
scratch at 24 hours (a) and 48 hours (b) shown in phase contrast. Cells at the edge of the scratch 





Figure 2.134: OHSU cells at 24 (a) and 48 (b) hours migrating across the scratch.The 
migration of OHSU cells across the scratch at 24 hours (a) and 48 hours (b) shown in phase 
contrast. Cells at the edge of the scratch have a spindle morphology, are elongated and detach 




2.10 Main Discussion and Summary 
At the start of this PhD, the main focus was to try to find reliable markers for stem cells that 
could be used for consistent identification and isolation of these cells from cell lines generated 
from OSCCs. The previous view that all cells in cancer tissue have equal growth potential was 
becoming replaced by the view that, like self-renewing adult tissues, cancers are maintained 
by special cells,stem cells, capable of sustained growth and replication. As previously 
discussed, normal keratinocytes, when cultured, consistently give rise to 3 main colony 
morphologies; holoclones, meroclones and paraclones. Holoclones are round colonies formed 
by cells tightly packed together and they show robust growth, can be extensively passaged, and 
hence are thought to contain stem cells (Barrandon, 1987). Meroclones are formed of larger 
cells, show less growth potential, and are thought to be formed from amplifying cells that are 
lower in the clonogenic hierarchy and are committed to differentiation. Paraclones consist of 
cells that show very little growth, cannot be cultured extensively, and are made up of 
cellsfurther down the differentiation pathway. Firm evidence that cancers have a hierarchical 
stem cell structure was first demonstrated in haematological malignancies by Bonnet and Dick 
(1997). They showed that patterns of cell surface protein expression can be used to predict cell 
behaviour and that only CD38+/CD34-cells are able to regenerate leukemia in mice. 
Subsequently, tumour initiating cells, corresponding to stem cells, have been demonstrated in 
most solid tumours including breast, prostate, gut, head and neck, and oral cancers (Al Hajj et 
al, 2003; Tang et al, 2007; Li and Tang, 2011; Todaro et al, 2010; Prince et al, 2007; Mackenzie 
et al, 2005; Gammon et al, 2011).  
Work by Locke and co-workers (2004), through microarray analysis of oral cancer cell lines, 
showed a number of markers that are expressed by holoclone cells but not by paraclone cells. 
From amongst these markers a list of most likely candidates was chosen for in situ 
hybridization to determine whether they could be used to isolate stem cell zones in oral cancers. 
The strategy was to useinsitu hybridization to look for stem cell zones or “hot spots” in wax 
embedded sections of a variety of control tissues including lung, heart musculature, and adult 
skin. Foetal skin was also chosen as usually it generally expresses high levels of most markers. 
It was hoped that similar examination of sections of oral cancers would identify zones with 
high expression of putative stem cell markers. Probes for insitu hybridization were designed 
for 13 markers andspecificity of the markers to regions in the tissue where they would normally 
be expressed was demonstrated. However, although the technique appeared to work well, areas 
corresponding to stem cell zones failed to be localized. Three of the markers examined, 
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Vimentin, notch and Dkk3 seemed to show slightly higher generalized expression in oral 
cancer compared to normal tissues but results were largely inconclusive. 
The next series of studies assessed whether a range of cell lines that had been generated from 
OSCC can provide in vitro models for theexamination of cancer stem cells. OSCC cell lines 
were confirmed to show heterogeneity similar to that of cultures of normal epithelial cells and 
to form holoclone, meroclone and paraclone colonies. Holoclones were found to stain brighter 
for putative stem cell markers than meroclones and paraclones (Mackenzie et al, 2006). Initially 
monoclonal antibodies against CD44, -catenin and E-cadherin were obtained to stain cell lines 
in the lab and to analyze the expression patterns they generate. CD44 localized to the membrane 
of colony forming cells with little or no expression in the cytoplasm. Expression was higher in 
holoclones than paraclones for all of the cell lines studied. Interestingly, expression was 
stronger in the central cells of the colony than at the edge. Some cells at the edge of colonies 
also showed nuclear staining for CD44, butat that time it was unclear what this signified. E-
cadherin was similarly localized almost exclusively to the cell membrane of adherent cells and 
the pattern of high expression in the center of the colony and weaker expression in the edge 
was again seen. -catenin showed a similar pattern of staining found moststrongly in the 
membrane region of cells in the center of the colonies but cells at the edge showing staining 
either around the nucleus in a peri-nuclear pattern or within the nucleus (Fodde and Brabletz, 
2007).These patterns were further demonstrated in cell lines established from HNSCC in 
Fanconi anemia patients (Gammon et al, 2011). 
Locke and colleagues (2005) demonstrated that holoclones contain highly clonogenic cells that 
can be grown indefinitely and are able to restore cellular heterogeneity. Cells FACS sorted on 
the basis of CD44 expression, which is high in holoclones, showed differential growth patterns 
with the CD44high cells a) forming more holoclones than meroclones and paraclones, b) forming 
more colonies overall and c) ability to restore all three colony types with cellular heterogeneity. 
CD44low cells showed poor growth and formed only abortive paraclone colonies. These results 
generally support the hypothesis of a role for CD44 as a molecule more strongly expressed on 
cells with stem cell properties that can act as a stem cell marker. However, although sorting for 
CD44 isolated stem cell enriched fractions, the specificity of CD44 alone was limited. 
Subsequent experiments demonstrated that stem cells could be more efficiently isolated using 
a combination of markers, a technique that had been used to enrich successfully for tumorigenic 
breast cancer cells by Al-Hajj and colleagues (2003). When OSCC cells were stained for CD44 
219 
 
and CD24 and cells sorted into four quadrants and used for clonogenicity assays,  
CD44highCD24high cells were found to be the most clonogenic and consistently formed more 
holoclones than cells from other quadrants. They could also be passaged with greater 
efficiency. These findings were interesting and showed an increase in purification. However, 
they still indicated that the overall enrichment efficiencies were relatively low and that, 
although cells with differential growth patterns and morphologies could be isolated, better 
markers are required if stem cell populations are to be isolated to greater purity.  
Early in the thesis work, it was observed that when populations of cells are plated at low 
densities, individual cells behave in very different ways.Time-lapse videos showed that some 
cells tend to be stationary and divide to form cohesive holoclone colonies, whereas other cells 
are highly motile, move around the dish and, although they were seen to divide, remained 
spaced and did not form cohesive colonies. If a cell went on to form a holoclone, all cells of 
the first few divisions initially remained tightly packed. Later, although the cells in the center 
remained tightly packed, the cells at the edge tended to become slightly larger and to spread 
out away from the colony. A few of these edge cells tended to show an elongated spindle-like 
morphology and appeared to be trying to move away from the colony.In videos, some cells 
were seen to detach and move away from the main colony. Sometimes they then returned and 
adhered to the colony again but some cells wandered away out of the field of vision. This 
suggested that cells at the colony edge were undergoing a process similar to EMT, in which 
they lost their characteristic cobblestone appearance, become more spindle-like, resembled 
fibroblasts,and became motile.  
If a holoclone colony is taken as a miniature equivalent of a tumour, the cells in the central 
region can be considered representative of the main bulk of the tumour, with the cells at the 
colony edge perhaps corresponding in some ways to cells at the invasive tumour front. Altered 
behaviour of cells at the invasive front of tumours has recently generated a lot of interest and 
there is increasing evidence for EMT occurring in this region (Bankfalvi and Piffko, 2000; 
Finger and Giaccia, 2010). If the cells at the colony margin undergo EMT, they possibly share 
some features of the cells that are present at the invasive front of the tumour-host interface and  
are responsible for causing tumour recurrence. Studies were therefore undertaken to examine 
how the in vitro properties and behaviour of these cells corresponded to known patterns of 
behaviour of cells undergoingEMT in other circumstances. TGF-βis a strong inducer of EMT 
for many cell types (Thiery et al, 2009; Zavadil and Bottinger, 2005) and dysregulated TGFβ 
activity has been linked to tumour progression and invasiveness in cancers (Moustakas and 
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Heldin, 2007). Hence TGF-β was selected for use on OSCC cell lines and was seen to induce 
EMT and to generate more cells with spindle morphologies at the edges of colonies. Activated 
fibroblasts, or myofibroblasts, present in the tumour microenvironment have been shown to 
play an important role in tumour invasion in pancreatic, breast, ovarian and bladder cancers 
(Bretnall et al, 2012; Micke and Ostman, 2004; Chaffer et al, 2007). To ascertain whether 
stromal factors present at the tumour-host interface could similarly bring about changes in 
OSCC cells, they were treated with medium conditioned by the growth of fibroblasts 
(FIBSCM) generated from specimens of oral cancers. Treatment with FIBSCM caused obvious 
morphological changes of OSCC cells, greater motility and a decreased tendency to form 
cohesive colonies. Instead of the characteristic cobblestone appearance normally displayed by 
epithelial cells, treated cells showed elongated spindle-like morphology. Time-lapse videos of 
these cells showed that they were highly motile and scattered actively about the culture. 
Immunocytochemistry indicated that FIBSCM treatment produced a marked loss of the normal 
cell surface expression of E-cadherin and β-catenin, with the latter seen to translocate to the 
nucleus.  
Downregulation of ESA (Epcam) has been associated with the EMT process (Hollieret al, 
2009) and various reports indicate that nuclear signalling by this molecule is associated with 
“stemness” and the progression of colon tumours (O’Brian et al, 2007; Went et al, 2006). Gires 
and colleagues (2009) have shown that increased nuclear signalling by ESA facilitates the 
translocation of β-catenin to the nucleus. Compared to control cells, cells from OSCC cell lines 
treated with either TGF-β or FIBSCM showed a marked reduction in the cell surface expression 
of ESA and also its translocation to the nucleus.  
CD44 was shown to be expressed strongly by holoclone cellsand to locate mainly to the cell 
surface. Although CD44 expression by the central cells of holoclones was typically stronger 
than for cells at the colony edges, occasional cells at the colony edge were high for CD44. The 
scattered spindle-shaped cells around holoclones showed a range of CD44 expression levels. 
Some showed high levels of localization to the cell surface but others clearly showed 
expression of CD44 within the nucleus. Nuclear localization of CD44 to the nucleus has been 
associated with the acquisition of increased invasiveness by colon carcinoma cells (Ying-Jhen 
Su, 2011) and it is required for the clonal formation invitro and tumorigenicity invivo 
(Bourguignon, 2008). Lee and co-workers (2009) found that translocation of CD44 to the 
nucleus modulates the cadherin-catenin pathways and also modulates members of the SMAD 
family proteins that are closely involved with cellular growth. This suggests a possible link 
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with TGF-β as it functions in close association with the SMAD family of proteins. 
Interestingly, as can be seen in many of the illustrations, cells that are dividing (D) apparently 
show very high levels of staining for CD44. This was also seen for other markers examinedas 
shown in the figure below. 
 
Figure 2.135: High surface expression of markers in dividing cells. CA1 cells are shown 
stained with DAPI nuclear stain (a, c) and anti-e-cadherin antibody (b) and anti-CD44 antibody 
(d). Cells that are dividing are designated ‘D’.  
Cell rounding-up and shrinkage during the division process might possibly result in an 
increased concentration of CD44 at the surface butit appears that this effect is largely an 
artefactas a similar pattern is seen with most antibodies and is perhaps associated with altered 
cell density resulting in non-specific binding of antibody. 
Sphere formation is mainly a property associated with cells that have undergone EMT (Biddle 
2011) and both TGF-β and FIBSCM increased the proportion of cells forming tumour spheres 
in suspension cultures, with the highest number of spheres formed by cells treated with 
conditioned medium. Reintroduction of spheres into adherent culture conditions indicated that 
222 
 
they readily attached and formed colonies of cells that expanded away from the adherent 
sphere, with a large proportion of these cells being motile elongated cells. Sphere assays have 
previously been used to isolate stem cells from breast cancers that have undergone EMT (Mani 
et al, 2008) and the ability of cells in spheres to revert back to form adherent colonies suggested 
that there are cells present in spheres that possess the phenotypic plasticity to switch between 
the epithelial and mesenchymal states, i.e. undergo EMT and MET (mesenchymal to epithelial 
transition). This also supports the notion that there may be two types of stem cells present 
within OSCC lines. Collaborative work done in the Mackenzie lab (Biddle et al, 2011) has 
recently confirmed the presence of two types of cells in OSCC lines, those that are proliferative 
and retain epithelial characteristics and those that are migratory and show an elongated spindle 
appearance and were the CD44highESAhigh and CD44highESAlow populations discussed earlier. 
In the lab, these cells have also been demonstrated in cultures of cells from lines generated 
from OSCCs of Fanconi anaemia patients (Gammon et al, 2011). Studies of these sub-
populations, using FACS, showed that the CD44highESAhigh cells represented the stem cell 
fraction within OSCC lines as they formed the most holoclones after isolation and culture. 
CD44highESAlow cellspredominantly formed clusters of spindle-shaped cells with few 
holoclones, and showed characteristics of EMT cells. It was also seen that the CD44highESAlow 
cells formed 10 times more spheres than the CD44highESAhigh cells, suggesting that a portion 
of CD44highESAlow cells are clonogenic as this property has previously been associated with 
stem cells (Dontu et al, 2003). Analysis of gene expression patterns in these two subpopulations 
within OSCC liens showed that CD44highESAlow cells expressed higher levels of Vimentin, 
Twist and Snail, all markers of EMT, and lower expression of E-cadherin, which is also a 
signature of EMT cells. To assay whether this EMT population exists in OSCC tumours in 
vivo, populations of cells were generated from fresh specimens of tumours and FACS sorted 
on the basis of CD44 and ESA expression and it was seen that this population also existed in 
cells extracted from OSCC specimens. It was further revealed that the size of the EMT 
CD44highESAlow population correlated with the progressive stage of the tumour. Cell lines from 
dysplastic skin did not contain a detectable C44highESAlow population but cells derived from 
primary and metastatic tumours showed high proportions of these cells (Biddle et al, 2011).In 
vivo tumorigenicity assays showed that both CD44highESAhigh and CD44highESAlow cells formed 
tumours within mice, but it was only the tumours generated from CD44highESAlow cells that 
showed evidence of lymphatic spread and contain cells that may have invasive potential. The 
fact that both populations of cells can form holoclone colonies suggested that there are cells 
present within the EMT (CD44highESAlow) population that have the ability to revert back to 
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form the non-EMT fraction within OSCC lines and vice versa. To verify this, single cells from 
both populations were plated and it was seen that the majority of CD44highESAhigh cells 
generated both EMT and non-EMT cell populations, but only a few CD44highESAlow cells 
demonstrated this property. This suggested that not all of the CD44highESAlow cells were 
bipotent and suggested that differences in the levels of ESA expression within the EMT fraction 
might distinguish bipotent cells from unipotent EMT cells.This link was further studied using 
ALDH1 and it was seen that CD44highESAlow/+ cells that are present nearer to the main 
population on FACS possessed the property of bipotency and also showed increased activity 
of ALDH1, whereas CD44highESAlow/- cells represented differentiated EMT cells that could not 
revert back and did not reconstitute cellular heterogeneity. 
FACS analysis of OSCC lines was used to examine further thebehaviour of the cell sub-
populations identifiable in growing cultures. FACS consistently identified a population of cells 
with high expression of CD44 and low expression of ESA. TheseCD44highESAlow cells 
localised as a distinct population, typically separated from the bulk of the cells which occupied 
the CD44highESAhigh and CD44low region of the plots. The CD44highESAlow population primarily 
represents the EMT component present within OSCC cell lines and formed tumour spheres 
(Biddle et al, 2011). Although whenplated out at clonal density,they initially form scattered 
cells with spindle-shaped fibroblast-like morphologies, with time they begin to generate 
holoclone-like colonies. The reverse is seen with CD44highESAhigh cells which, when plated out 
at clonal density, initially give rise predominantly to epithelial-like holoclone colonies but with 
time also generate an EMT-like population. These observations support the concept that cells 
that can switch between the epithelial CD44highESAhigh phenotype and the spindle-shaped 
CD44highESAlow EMT phenotype and also indicate that both populations of cells can self-
renew. Division of both cell types was observed in videos and there is now experimental data 
(Biddle et al, 2011) and showing that certain cells within each population have the ability to 
restore the population heterogeneity.  
The percentage of cells within OSCC lines that are CD44highESAlow varies from cell line to cell 
line. For example, in the Ca1 cell line, 1-3% of the cells show the CD44highESAlow phenotype 
while in the H357 cell line, the fraction is usual higher, being about 5-6%. Some other cell lines 
recently isolated by co-workers in the Mackenzie lab have shown very high levels of EMT 
(data not shown, Mackenzie lab).The susceptibility of cell lines to the effects of TGF-β also 
varies.For example, when exposed to TGF-β for 5 days, this population in CA1 cells increases 
to 8-9% and but forH357 cells increases to 25%. 
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When examined separately, the percentage of each of the CD44high and of ESAlow/- cell 
populations was also seen to increase with short term treatment with TGF-β. The increase in 
the percentage of ESAlow/- cells was greater than the overall increase in the CD44highESAlow 
population, indicating that not all the cells that reduced their ESA levels were high for CD44. 
To assess whether TGF-β is responsible for the presence of the apparently innate population of 
CD44highESAlow cells within cell lines, they were treated with an inhibitor of TGF that has been 
shown successfully to block TGF-β activity in various cellular systems. This inhibitor 
successfully abolished the effect seen with the addition of TGF-β,but failed to eradicate or 
reduce the inherentpopulation of CD44highESAlow cells routinely seen on FACS analysis of 
OSCC lines that suggested that the EMT process in OSCC lines occurs in a TGF-β independent 
manner.It is thought that this EMT may be bought about by EGF present in the RM+ medium 
as switching cells to basal media results in the loss of these cells in OSCC lines in the lab. 
Further experiments are needed to confirm this hypothesis. Experiments were also undertaken 
to assess the interaction of TGF-β with other mediators of inflammatory processes as 
inflammatory cytokines have been shown to play a role in the aggressiveness of tumours. TNF-
α when added on its ownfor 5 days produced changes similar to those caused by TGF-β in that 
cells took on a spindle-like morphology and increased the proportion of CD44highESAlow cells. 
However, TNF-α worked synergistically with TGF-β to greatly enhancethe effect seen 
compared to that seen with either cytokine alone, with the levels of EMT rising to 35% for Ca1 
cells and 60% for H357 cells.  
Cells were also stained with an anti-Vimentin antibody as Vimentin is known to be a signature 
protein acquired during EMT. Vimentin expression has been linked to the invasiveness of 
breast cancer cells (Kokkinos et al, 2011) and has been shown to regulate the EMT process 
through interaction with the slug and AXL family of proteins (Vuoriluoto et al, 2007). 
Holoclone cells generally show no expression of vimentin but there werescattered elongated 
cells that showed strong expression of vimentin with some cells at the edges of holoclones also 
being Vimentin positive. Cells treated with TGF-β showed very high expression of vimentin 
in almost all the cells. 
CD44highESAhigh, CD44highESAlow and CD44lowESAhigh cells were also sorted and cultured 
from clonal density for 5-6 days. Following this, these cells were detached from the dish, again 
stained with anti-CD44 and anti-ESA antibodies and analyzed using FACS. It was found that 
both CD44highESAlow and CD44highESAhigh cells reconstitute the native FACS plots generated 
and restore cellular heterogeneity seen in OSCC lines. This means that both population contain 
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self-renewing cells that are able to maintain themselves within the total population and also 
supports the concept of the mobile cancer stem cell. 
Experimental data also show that TGF-β enhances the motility and migration of OSCC cells. 
To check the effect of TGF-β on the migration and motility of cells, scratch assays were 
conducted and migration of treated cells was compared to controls over a period of 48 hours. 
It was found that TGF-β treated cells migrate across the gap the fastest and cover more than 
80% of the scratched area within 24 hours whereas control cells cover about 50-60% of the 
scratch area. Further the effect of NS-398 which is a COX-II inhibitor was also checked and it 
was found that it slowed the migration of cells across the gap. We had previously analyzed the 
effect of NS-398 using FACS and were able to show that it does not completely eradicate the 
innate EMT population present within OSCC lines but does decrease it, although this decrease 














Summary and Conclusions 
 
2.1 Analysis of the distribution of putative stem-cell-related molecules in wax-
embedded sections of OSCC using in situ hybridization. 
1.  Control tissues indicated that both the probe and the vector functioned well to give a 
good signal in both the cancer blocks and the control tissues.  
2.  Out of nine probes examined, only CEBP-α, Notch3 and Vimentin showed a good 
differential hybridization signal in cancer sections compared to normal adult skin, and although 
the probes for these molecules showed a higher signal in cancer blocks, they failed to localize 
stem cell zones/hot spots.  
3.  The rest of the probes examined, namely Hurpin, Pirin, RDHL and Erb-b3, were 
similarly selected on the basis of their differential expression in holoclones and paraclones 
(Locke et al, 2005) and suggestions in the literature of their potential differential expression in 
stem cells. However these probes failed to elicit any interesting patterns of probe localization. 
Thus, although it was hoped that patterns of stem cell localization within oral mucosa and oral 
tumours might be revealed with these probes, the observed distribution of label did not provide 
such information.  
4.  Insitu hybridization was also performed on cells cultured from OSCC cell lines, but 
they were either lost owing to technical failure, or showed poor specificity. 
2.2 Identification and isolation of stem/stem-like cells in OSCC cell lines 
a) Cell culture 
1.  The cell lines examined, consistently showed the generation of three types of colony 
morphologies, classified as holoclones meroclones and paraclones after cells were plated at 
clonal densities.  
2.  It also appeared that the cells forming holoclones are heterogeneous. The center of the 
holoclone is made up of tightly packed cobblestone shaped cells and slightly larger cells at the 





1.  When stained for CD44, holoclones show the brightest staining, with meroclones being 
the next in intensity and the weakest signal being detected in paraclones. The CD44 in 
holoclones seems to be predominantly present in the cell surface in all the cell lines examined.  
There was also nuclear localization of CD44 seen, present in mostly all the cells making up the 
meroclones and paraclones and only weak nuclear staining of CD44 could be detected within 
the central cells of the holoclone and it seems to be more pronounced in the cells making up 
the edge. 
Also seen consistently was the pattern of strong CD44 expression in the central cells of the 
holoclones and weak expression in cells making up the edges of these colonies.  
2.  E-cadherin was shown to be expressed at the protein level in all the cell lines examined. 
In holoclone colonies E-cadherin was shown to be present at the cell periphery with little or no 
expression in the cytoplasm. Central cells of the holoclone were shown to express higher levels 
than those making up the edge of the colonies. The scattered fibroblast-like cells showed 
reduced expression in the membrane and very weak levels within cytoplasm. A few cells also 
showed nuclear accumulation of the protein.  
 -Catenin was expressed in all three cell lines examined however the patterns observed 
differed. CA1 and H357 cells showed strong expression of the protein almost exclusively at 
the cell periphery with very little being present in the cytoplasm. Cells at the edge showed 
reduced levels. In the Fanconi 1131 cell line, -catenin was expressed in the cell membrane 
and in the nucleus of all the cells in the colonies but nuclear accumulation was more marked in 
cells present at the edge. 
c) Time Lapse Video 
1.  On video it can be seen that when holoclones form, 2 types of cells exist, the ones 
forming the central zone and the other the colony periphery. The central cells appear relatively 
stationary and adhere tightly to other cells and have characteristic cobblestone morphology. 
These cells are also seen to divide to maintain the central region of the holoclone. Cells at the 
edge of colonies are spindle-shaped in appearance and appear to break away from the colony. 
There are also spindle-shaped cells lying outside the edges of the colonies that are highly motile 
and make contact with other cells and they appear to be generated from the colony itself. 
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2.3 Detection of CD44 at protein level using Fluorescent Activated Cell Sorting 
(FACS) 
1.  Cells were sorted on the basis of CD44 expression and the 4-6% of the highest and 
lowest expressing cells wereselected as CD44high or CD44low. When plated out at clonal 
density, the CD44high population consistently produced more holoclones and meroclones and 
also formed a higher total number of colonies in comparison to the CD44low cells. This trend 
was also demonstrated in each of the three cell lines examined namely H357, Ca1 and UK1. 
 
2.4 Detection of CD44 and CD24 at protein level using Fluorescent Activated Cell 
Sorting (FACS) 
1.  CD44highCD24high (Q2) cells from both cell lines formed significantly higher 
proportions of holoclones (p<0.05).The number of holoclones formed by these cells remained 
significantly higher when cells were plated immediately after sorting and also after the first 
passage.  
2.  The total colony counts for CD44highCD24high were also higher than those obtained for 
CD44highCD24low, CD44lowCD24low and CD44lowCD24high but this difference was not 
statistically significant (p>0.05). These resultswere consistent for all the cell lines 
examined,suggesting that these proteins are similarlyexpressed in both cell lines. 
3.  CD44lowCD24low cells significantly formed the highest number of paraclones. They 
also formed the least amount of holoclones, 32.5±3.54 for CA1 and 26±5.66 for 5PT. The 
number of colonies generated by these cells were also more than the other populations, but this 
difference was not only insignificant (p>0.05), but it could also be argued that paraclones 
divide more frequently than holoclones which is why they give rise to a much larger colony 
number. 
4.  These results suggest that the use of CD44 and CD24 together does give greater 
enrichment for stem cells as opposed to CD44 alone, and suggest that CD44 and CD24 are both 
expressed on stem cells in oral cell lines. 
5.  These results also demonstrate heterogeneous patterns of cell surface expression of 
markers, and indicate that they are related to the heterogeneous behavioural properties of cell 
sub-populations present in cell lines. 
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2.5 Induction of EMT in cancer cell lines and the role of TGF-β and external factors 
that may influence the extent of this process 
a) Cell culture: 
1.  Control cells formed characteristic colonies in the form of holoclones, meroclones, and 
paraclones and populations of spindle shaped cells, resembling fibroblasts were seen at the 
edges of colonies or lying outside the colonies in both cell lines. Cells treated with TGF-β 
tended not to form colonies but formed scattered cells that had elongated spindle morphology 
and looked similar to the cells formed at the edges of colonies.  
2.  Time-lapse video showed that cells treated with TGF-β and FIBSCM show a high level 
of motility and scattering, and take on elongated spindle morphologies. The cells also showed 
decreased cohesiveness and did not form colonies as under control conditions (2.2.1.3 E). Thus 
both treatments enhanced the phenomenon occurring around the edges of colonies that resulted 
in the formation of elongated spindle cells just described. 
b) Immunocytochemistry 
1.  Cells grown under control conditions showed good expression of ESA at the cell 
surface with central cells within colonies expressing higher levels of ESA than those at the 
edges. Elongated spindle cells at the edge also displayed loss of membranous ESA and some 
of these cells showed accumulation of ESA around the nucleus. Treated cells also showed 
nuclear expression of ESA and this was associated with loss of the epithelial phenotype and 
the acquisition of a more mesenchymal, characterized by the elongated spindle cells. 
2.  In both cell lines, E-cadherin expression was seen at the surface of cells in the center of 
colonies and was lower in the cells around the edge. Treatment with TGF- also resulted in 
loss of membranous E-cadherin. Strong expression of E-cadherin was seen in the nuclei of both 
types of treated cells but TGF- caused a greater effect than the fibroblast conditioned medium. 
3.  CD44 was expressed in both cell lines examined. There was strong cell surface CD44 
expression within central colony cells with little evidence of nuclear accumulation. The motile 
cells differed in their CD44 expression patterns, with some staining brightly for CD44 in the 
cytoplasm, while others showed nuclear accumulation and moderate membrane expression. 
Treated cells showed decreased CD44 at the cell surface with increased accumulation evident 
within the nucleus of spindle cells. 
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c) FACS analysis: 
1.  FACS analysis using CD44 and ESA antibodies consistently identified a subpopulation 
of cells that was CD44highESAlow. 
2.  This population increased significantly when cells were treated with TGF-β in both cell 
lines, with the H357 showing the greater response to treatment. 
3.  Both treatments caused an increase in the number of cells that were CD44high and this 
was statistically significant with TGF-β.  
4.  Both treatments also resulted in an increase in the number of cells that were ESAlow/- 
and this was statistically significant with TGF-β. 
d) Sphere Assay 
1.  Our studies show that OSCC cell lines contain a population of cells which have the 
ability to form spheres (CA1=8.4%; H357=12%) under control conditions.  
2.  Treatment with TGF- caused a significant increase in the number of spheres formed 
and interestingly, treatment with fibroblast conditioned medium produced an even greater 
increase in the number of spheres formed.  
3.  When control spheres were reintroduced into adherent conditions, cells from the 
spheres attached and spread out to form epithelial looking cells and formed large colonies 
resembling holoclones. These colonies had a prominent halo of spindly motile cells around the 
edge.  
4.  Once these cells were again plated into a sphere assay, they formed more spheres per 




2.6 The effect of short-term treatment with TGF-β and its inhibitor (SB431542) on 
subpopulations of cells within OSCC cell lines and their effects of these on the expression 
of vimentin. 
a) Cell culture 
1.  Cells from both cell lines displayed an elongated spindle-like morphology and showed 
increased migratory capacity as seen on time lapse videos. Cells from both lines also showed 
a decreased propensity to form adherent colonies. Treatment with the inhibitor had no adverse 
effects on the growth of these cells and SB431542 was seen to effectively block TGF-β activity 
as when cells were grown with both the inhibitor and TGF-β added together, they resembled 
control cells.  
b) FACS analysis 
1.  FACS analysis for CD44 and ESA showed an increase in the size of the CD44highESAlow 
and CD44high and the ESAlow/- populations with TGF-β treatment in both cell lines but it was 
the H357 cell line that was found to be more susceptible to TGF-β as seen by the greater 
responses to treatment.  
c) Immunocytochemistry:  
1.  The expression of Vimentin was assessed in OSCC cell lines and was seen to be high 
in spindle-shaped lying outside colonies (CA1) or in some cells at the edge (H357). Other cells 
in the colonies showed no expression. Treated cells showed strong cytoplasmic expression of 
vimentin. These staining patterns support the suggestion that CD44highESAlow cells have 
undergone EMT 
2.7 The effect of long-term treatment with TGF-  and treatment withdrawl on OSCC 
cells 
1.  Treatment with TGF- for 5 days caused an increase in the relative proportion of 
CD44highESAlow, CD44high and ESAlow/- cells within the bulk of the population.  
2.  Treatment with TGF-β for longer indicated that this further increased the size of these 
populations. At the end of twenty days, very few cohesive cells remained. The response of the 
two cell lines studied varied with the H357 cells showing more susceptibility to TGF-β 
treatment compared to the CA1 cell line. The number of cells expressing high levels of CD44 
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increased in both lines examined and this correlated with the increase in the CD44highESAlow 
population. TGF-β also caused a decrease in the expression of ESA and the response shown by 
the H357 cell line was greater than that for CA1 cells.  
3.  Withdrawing TGF-β treatment caused a decrease in the CD44highESAlow population in 
both cell lines and by day 15, after withdrawal of TGF-β, the proportion of CD44highESAlow 
cells declined in both cell lines. but remained higher than the controls, suggesting that the effect 
of TGF- is largely reversible.  
4.  Some of the cell remained CD44highESAlow even after 15 days of withdrawal, suggests 
that there may be a small proportion of CD44highESAlow cells that does not revert back. 
 
2.8 The self-renewal potential of intrinsic populations within OSCC cell lines 
1.  CD44highESAhigh cells grew, predominantly as holoclones and showed characteristic 
morphology seen in OSCC lines and spindle cells could be identified at the edges of the 
colonies or lying outside them.  
2.  In comparison to these cells, CD44highESAlow cells grew as elongated spindle cells with 
few scattered holoclone colonies that grow to a large size.  
3.  In contrast, CD44low cells showed poor growth and formed paraclones.  
4.  This suggested that the CD44highESAhigh cells were the non-EMT stem cell fraction 
while the CD44highESAlow cells were EMT cells and both populations contain cells with 
regenerative potential that can switch back and forth from the epithelial phenotype to the 




2.9 The effect of TNF-α on EMT in OSCC cell lines and the combined effect of TNF-
α and TGF-β on these lines. 
1.  Our results show that the effect of TNF-α on OSCC cells is similar to that of TGF-β in 
causing an increase in the EMT population (CD44highESAlow) and an increase in the size of 
both the CD44high and ESAlow/- populations.  
2.  Further to this we found that the addition of TNF-α and TGF-β together greatly 
enhances the effect seen indicating that they work together synergistically to promote EMT in 
OSCC cells. The response of cell lines varied butwhen TGF-β and TNF-α were added together 
there was a significant increase in the size of the CD44highESAlow population in both CA1 (x10) 
and H357 (x12) cells.  
3.  Further, there was an increase in the size of both, the CD44high and ESAlow/- populations.  
4.  On microscopic examination, cells from both lines were seen to possess a spindle-
shaped morphology and a decreased tendency to form cohesive colonies.   
 
2.10 The effect of TGF-β, SB431542 and NS-398 on migration in OSCC cell lines. 
1.  It was found that TGF- enhances cell migration and this effect was seen with boththe 
CA1 and Fanconi cell lines. Treated cells migrate faster than controls and covered 94% and 
84% (CA1, OHSU) of the scratch area by 48 hours with control cells covering only 74% and 
61% respectively.  
2.  High magnification pictures of the scratch area show cells resembling fibroblasts 
migrating across the scratch. The cells at the edge of the scratch also seemed to have undergone 
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